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Summary 
My study is focused on understanding the mechanisms underlying the modulation of NK 
cell responsiveness and plasticity induced by tumor targeting therapeutic anti-CD20 
monoclonal antibodies (mAbs) nowadays routinely used in the treatment of B-cell 
malignancies and autoimmune disorders. Anti-CD20 mAbs are grouped into type I and II 
subtypes. Type I mAbs induce CD20 redistribution into lipid rafts and display a 
remarkable ability to activate complement-dependent cytotoxicity (CDC). On the other 
hand, type II mAbs, which are not able to localize CD20 complexes into lipid rafts and 
induce weak or no CDC, evoke more homotypic adhesion and direct killing of target cells. 
Both type I and II mAbs demonstrate efficient phagocytosis and antibody-dependent 
cytotoxicity (ADCC). Natural Killer (NK) cell-mediated ADCC, based on the recognition 
of IgG-opsonized targets by the low affinity Fc receptor for IgG FcgRIIIA/CD16, 
represents one of the main mechanisms by which anti-CD20 mAbs mediate their anti-
tumor effects. Besides ADCC, CD16 ligation also results in the production of cytokines 
such as IFN-g that plays a key role in the shaping of adaptive immune responses. 
Rituximab is a chimeric type I anti-CD20 mAb of 1st generation and is considered the 
reference molecule for the comparison with new generation anti-CD20 mAbs, designed 
to optimize clinical efficacy. Among them, obinutuzumab is a humanized Fc-
glycoengineered type II anti-CD20 mAb of 3rd generation designed to increase the affinity 
for CD16 receptor and consequently the killing of mAb-opsonized targets. However, the 
impact of CD16 ligation in optimized affinity conditions on NK functional program is not 
completely understood. Herein, I demonstrated that CD16 affinity ligation conditions may 
dictate both the amplitude of NK responsiveness (cytotoxicity and IFN-g production) as 
well as the ability to shift the NK functional program. Indeed, I observed that the 
interaction of NK cells with obinutuzumab-opsonized targets results in enhanced 
cytotoxicity and IFN-g production as compared with the parental non-glycoengineered 
mAb or the reference molecule rituximab, independently from the CD16-158V/F allotype. 
The affinity ligation conditions also strictly correlate with the ability to induce CD16 
surface down-modulation and lysosomal targeting of receptor-coupled signaling elements. 
Indeed, a preferential degradation of FceRIg chain and Syk tyrosine kinase was observed 
upon obinutuzumab stimulation independently from the CD16-158V/F allotype. Notably, 
although the down-regulation of FceRIg/Syk module hesitates in the impairment of 
cytotoxic function induced by CD16, NKp46 and NKp30 activating receptors, 
obinutuzumab-experienced NK cells exhibit an increased ability to produce IFN-g in 
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response to cytokines and target stimulation as well as to obinutuzumab-mediated CD16 
re-stimulation.  
Relying on the observation that obinutuzumab-experienced NK cells, under molecular and 
functional profile, resemble the distinctive features of the long-lived and highly functional 
“memory” NK cells, a population recently identified in HCMV seropositive individuals, I 
assessed the capability of anti-CD20 mAbs to affect the expansion as well as the 
phenotypic and functional properties of the “memory” NK subset. My data show that the 
majority of the analysed healthy donors is HCMV seropositive and exhibits a detectable 
population of “memory” NK cells (CD3- CD56+ FceRIg- CD16+) accounting for 3 to 50% 
of peripheral blood NK cells. I observed that “memory” NK cells selectively undergo 2- 
to 12-fold expansion upon co-culturing with anti-CD20-opsonized targets; on the 
opposite, the proliferation of “conventional” NK cells (CD3-  CD56+ FceRIg+ CD16+) is 
not affected by CD16 stimulation. I also noted that anti-CD20 mAb in vitro expanded 
“memory” NK cells show the molecular and functional hallmarks of their freshly isolated 
counterpart, including the increased expression of NKG2C receptor, the reduced 
expression of NKp46 receptor associated to an enhanced functional activity in response 
to CD16 re-stimulation, particularly in terms of IFN-g production.  
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Introduction 
1. Natural Killer cells  
1.1 Morphology and general characteristics 
Natural Killer (NK) cells belong to the innate branch of the immune system. They are 
defined as “natural killer” based on their ability to recognize and kill infected or 
transformed cells without prior immunization (Whiteside & Heberman, 1994; Lanier, 
2005). Besides immune surveillance against infections and tumors, NK cells may play a 
role in autoimmunity and hypersensitivity by contributing to the shaping of adaptive 
immune responses through their ability to secrete cytokines and chemokines and to 
cooperate with other components of the immune system such as dendritic cells (DCs), 
macrophages and B or T lymphocytes (Trinchieri, 1989; Moretta et al., 1994; Raulet, 
2004; Newman and Riley, 2007; Caligiuri, 2008; Vivier et al., 2008; Flodstrom-Tullberg 
et al., 2009; von Bubnoff et al., 2010; Bryceson et al., 2011).  NK cells were identified on 
purely functional basis and classified as lymphocytes for their origin from a progenitor 
shared with B and T lymphocytes and for the expression of several lymphoid line markers 
(Herbernan et al., 1975; Kiessling et al., 1975; Vivier et al., 2011). Unlike B and T 
lymphocytes, NK cells do not express somatically recombined and clonally distributed 
antigen receptors and interact with target cells by means of a limited pattern of activating 
and inhibitory germline-encoded receptors (see below) (Lanier, 2005; Long et al., 2013), 
thus representing a distinct lymphocyte subset (Cerwenka and Lanier, 2001). They 
account for the 10-15% of circulating lymphocytes in human peripheral blood and are 
resident in both lymphoid organs and several non-lymphoid tissues including liver, lungs, 
gut and uterus (Trinchieri, 1989; Cerwenka & Lanier, 2001; Colucci et al., 2003; Ferlazzo 
et al., 2004; Freud et al, 2005; Chinen et al., 2007). NK cells develop and become mature 
in the bone marrow and, through the action of chemotactic factors, reach lymphoid organs, 
peripheral tissues as well as sites of inflammation (Colucci et al., 2003; Carrega & 
Ferlazzo, 2012). Although the majority of NK cells is quiescent, they rapidly respond to 
exogenous stimuli. This makes them efficient in mediating the first line defense against 
pathogens and tumors and explains the definition of "ready to go cells” (Whiteside & 
Heberman, 1994; Lanier, 2005). About morphology, NK cells are characterized by a large 
cytoplasm enriched in azurophilic granules containing cytolytic mediators (Fig.1).  
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Figure 1. Natural Killer cell examined with Transmission electron microscopy (TEM). 
Arrows indicate the cytoplasmatic lytic granules containing cytotoxic molecules. 
 
NK cells comprise phenotypically and functionally heterogeneous populations (Cooper et 
al., 2001; Caligiuri, 2008; Fauriat et al., 2010; Bryceson et al., 2011; Long et al., 2013). 
In humans, they are phenotypically characterized by the absence of CD3, a T-cell co-
receptor, by the expression of CD56 (N-CAM-1), a neuronal cell adhesion molecule that 
participates in homotypic interactions, which may be co-expressed with FcgRIIIA/CD16, 
the low affinity receptor for the Fc fragment of immunoglobulin (Ig) G. In particular, the 
90% of peripheral blood human NK cells expresses low-intermediate CD56 and high 
CD16 (CD56dim CD16bright) while only the 10% of NK cells expresses high CD56 and low 
or no CD16 (CD56bright CD16dim/-) (Robertson and Ritz, 1990; Cooper et al., 2001; Mavilio 
et al., 2005; Caligiuri, 2008; Di Santo, 2008; Poli et al., 2009). The CD56dim CD16bright 
subset, classified as mature NK cells, are potent cytolytic effectors. On the contrary, less 
mature CD56bright CD16dim/- NK cells have relatively poor cytotoxic activity and 
predominantly produce inflammatory cytokines and chemokines in response to cytokine 
stimulation (Cooper et al., 2001; Caligiuri, 2008; Korbel et al., 2009; Fauriat et al., 2010; 
De Maria et al., 2011; Long et al., 2013).  
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1.2 Functional activity  
NK cells serve important functions in immune regulation, in tumor surveillance and in 
resistance against intracellular pathogens and viruses. Such responses are mediated 
through two major effector functions: the secretion of several pro-inflammatory and 
immunoregulatory cytokines and chemokines as well as the killing of sensitive target 
cells, which can be triggered without requiring any priming, transcription, translation or 
expansion (Robertson and Ritz, 1990; Cerwenka & Lanier, 2001; Lanier, 2005; Caligiuri, 
2008). It is well-known that NK cell survival, proliferation, migration and effector 
functions are influenced by several soluble factors. In response to interleukin (IL)-2, IL-
12, IL-15 or IL-18, released by phagocytes and DCs, NK cells produce interferon (IFN)-
g (Bryceson et al., 2006; Caligiuri, 2008). IFN-g, endowed with well-known anti-
bacterial/viral effects, promotes the differentiation of T helper (Th) cells in Th1 subset, 
activates macrophages and stimulates the microbicide activity of phagocytes, thus 
promoting the killing of phagocytosed microorganisms as well as causes the up-
modulation of the major histocompatibility complex (MHC) class I and II and the 
costimulatory molecules on antigen-presenting cells (APC) (Mocikat et al., 2003; 
Bryceson et al., 2006; Filipe Santos et al., 2006; Maher et al., 2007; Fauriat et al., 2010). 
By modulating the responses of DCs and T cells, IFN-g stands as a well-recognized key 
immunoregulatory factor in the shaping of adaptive immune responses (Martin-Fontecha 
et al., 2004; Walzer et al., 2005; Crouse et al., 2015).  Furthermore, in response to IL-2 
and IL-12, NK cells produce pro-inflammatory and immunoregulatory cytokines as the 
tumor necrosis factor (TNF)-α, IL-3 and IL-18, growth factors as the granulocyte 
macrophage colony-stimulating factor (GM-CSF) and chemokines as the macrophage 
inflammatory protein (MIP)-1α, MIP-1b and RANTES which in turn recruit other effector 
cells in the sites of inflammation (Cerwenka & Lanier, 2001; Raulet, 2004; Bryceson et 
al., 2006; Caligiuri, 2008; Cerboni et al., 2009; Fauriat et al., 2010; Bryceson et al., 
2011). Besides being an important source of soluble factors, NK cells recognize and kill 
sensitive target cells (Bryceson et al., 2009). The target cell killing may be due to the 
activation of death domain-containing receptors. Indeed, the TNF family members Fas 
ligand (FasL) and TNF-related apoptosis-inducing ligand (TRAIL), expressed on NK 
cells, may recognize the death domain-containing receptors Fas and TRAIL-R expressed 
on target cells, thus leading to their apoptosis (Zamai et al., 1998; Screpanti et al., 2005).  
However, the primary mechanism by which NK cells mediate target cell killing is the 
polarized release of the lytic granule content at the effector/target contact area, a highly 
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specialized structure defined cytolytic synapse. Cytotoxic granules are specialized 
secretory lysosomes containing lytic mediators such as the Ca2+-dependent pore-forming 
protein perforin and the apoptosis-inducing serine proteases granzymes, such as granzyme 
B. To ensure that NK cells do not indiscriminately kill the target cells, the cytotoxic event 
is a tightly regulated and highly ordered multistep process (Fig.2) (Rosen et al., 2000; 
Lieberman, 2003; Stinchcombe & Griffiths, 2007; Orange 2008; Griffiths, 2010; 
Galandrini et al., 2013).  During the early stages, the NK cell-mediated recognition of a 
sensitive target leads to the formation of a stable cell conjugate: the effector/target cell 
contact area undergoes a profound rearrangement leading to the generation of the cytolytic 
synapse (Vyas et al., 2002; MacFarlane & Campbell, 2006). With reference to the effector 
cell side, the central region of the cytotoxic synapse forms the central supramolecular 
activation cluster (c-SMAC) which comprises both engaged receptors and signaling 
molecules. Around c-SMAC structure, it is observed the peripheral SMAC (p-SMAC) in 
which NK adhesion molecules are recruited (Vyas et al., 2002). The assembly of p-SMAC 
structure both stabilizes the cell-cell adhesion and triggers a localized cytoskeletal 
remodeling (Davis, 2002; Vyas et al., 2002; Riteau et al., 2003; MacFarlane & Campbell, 
2006; Krzewski & Strominger, 2008). The polarization step of cytotoxic event includes 
the reorientation of the microtubule-organizing center (MTOC) that polarizes towards the 
cytolytic synapse the preformed lytic granules (Peters et al., 1991). This process is co-
ordinated by effector molecules responsible for actin cytoskeletal changes and for the 
mobilization of MTOC at cytolytic synapse (Krzewski et al., 2006; Krzewski et al., 2008). 
Later steps include the maturation and Ca+2-dependent exocytosis of lytic granules. 
During the maturation process, lytic granules are docked to the plasma membrane 
containing secretory domains (docking step) and gain the competence to fuse with them 
(priming step) (Mènager et al., 2007) thus leading to the release of their content: perforin 
and granzymes. Perforin is a homologue of the C9 fraction of complement system and is 
able to form plasma membrane pores thus altering the osmotic balance and allowing 
granzyme delivery into cytosol of target cells. Granzymes are enzymes with serine 
protease activity that cleave proteins at aspartate residues and activate caspases, the 
cysteine proteases responsible for the programmed cell death or apoptosis (Davis, 2002; 
Lieberman, 2003; Krzewski & Strominger, 2008). Among others, granzyme B plays a role 
in both the activation of caspase 3 and the cleavage of either cytoplasmic pro-apoptotic 
BH3-only family members or inhibitors of Caspase-Activated DNase (ICAD) thus 
promoting apoptosis (Thomas et al., 2000; Clark and Griffiths, 2003; Lieberman, 2003; 
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Bossi and Griffiths, 2005; Waterhouse et al., 2005). Several models have been proposed 
about the mechanism of synergy by which perforin and granzymes induce target cell 
death. In the “plasma membrane pore” model, perforin undergoes Ca+2-dependent 
polymerization and, by forming pores in target cell plasma membrane, allows both target 
cell osmotic lysis and granzymes delivery into the target cell cytosol (Lowin et al., 1995; 
Lieberman, 2003; Pipkin & Lieberman, 2007). The alternative “endosomolysis” model 
instead predicts that, upon binding with the target cell plasma membrane via electrostatic 
interactions or specific receptors, both perforin and granzymes are internalized into the 
endosomal compartment and that perforin induces granzyme release into the target cell 
cytosol by disrupting endosomal structures (Froelich et al., 1996; Lettau et al., 2007; 
Pipkin & Lieberman, 2007). Recently, it has been proposed a hybrid model for which, 
upon membrane permeabilization, it may occur a Ca2+-mediated membrane repair 
response, by means of membrane-vesicles patching to the formed pores, or a rapid 
internalization into endosomes of both perforin and granzymes, followed by perforin-
mediated release of granzymes into the target cell cytosol (Pipkin & Lieberman, 2007). 
Other granule-associated molecules take part to the “lethal hit” including calreticulin and 
serglycin as well as the lysosome-associated membrane proteins LAMP1 (CD107a) and 
LAMP2 (CD107b), cathepsins and CD63 (Pipkin & Lieberman, 2007). The cytotoxic 
event terms with a phase of NK cell inactivity which is characterized by activating 
receptor down-modulation followed by NK cell detachment from the apoptotic targets. 
NK cells restore their cytolytic capacity by forming new lytic granules and re-expressing 
activating receptors (Orange, 2008). Due to the recovery of cytolytic potential, NK cells 
are able to generate a second cytolytic synapse, immediately after dissipation of the first 
one, through a process defined “serial killing” by which an individual NK cell can make 
serial contacts with multiple targets and several cycles of killing (Bhat & Watzl, 2007).  
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Figure 2. Discrete steps in the activation of NK cytolytic machinery. The activation of cytolytic 
machinery is a finely regulated multistep process that involves several discrete steps resulting into 
the secretion of cytotoxic mediators. Target cell recognition is followed by the assembly of a 
cytotoxic synapse which coordinates granule polarization toward effector/target cell contact area 
and polarized exocytosis of lytic granule contents (degranulation) at specialized secretory domains 
within the cytotoxic synapse. Termination step includes the NK cell detachment from the apoptotic 
target and the recycling of cytolytic activity (modified from Orange, Nat Rev Immunol 2008). 
 
1.3 NK-mediated target cell recognition: activating and inhibitory receptors.    
The NK-mediated recognition of target cells is characterized by a complex interplay of 
opposite signals, delivered by inhibitory and activating receptors simultaneously 
expressed on NK cells and engaged by ligand-bearing targets, and the balance of such 
opposite signals calibrates NK cell responses toward functional inactivity or activation. In 
physiological conditions, the signals transduced by activating receptors are balanced by 
those transduced by inhibitory receptors, which recognize MHC class I molecules 
expressed by target cells, thus preventing their lysis. By contrast, in non-physiological or 
stress conditions associated with the down-modulation of MHC class I molecules, the 
stimulatory signals become unopposed by inhibitory receptors, thus resulting in NK 
activation and target cell killing (missing-self recognition). However, in this scenario the 
up-regulation of specific molecules which act as ligands for activating receptors generally 
occurs thus overcoming the action of inhibitory receptors (induced-self recognition) (Fig. 
3) (Karre et al., 2002; Natarajan et al., 2002; Lanier, 2005; Raulet & Vance, 2006). 
receptor down-regulation
detachment
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Figure 3. A complex interplay of inhibitory and stimulatory signals calibrates NK cell 
responses toward functional inactivity or activation. Healthy cells are protected from NK-
mediated killing by NK cells. In this scenario the signals transduced by activating receptors are 
balanced by those transduced by inhibitory receptors which recognize the target-associated MHC 
class I molecules. The lack of MHC class I molecules results in NK cell activation and target cell 
killing (missing-self recognition). Stress conditions may also up-regulate ligands for activating 
receptors thus overcoming the action of inhibitory receptors (induced-self recognition) (form 
Raulet & Vance, Nature Reviews 2006). 
 
NK-mediated recognition of sensitive target cells may lead to Antibody-Dependent 
Cellular Cytotoxicity (ADCC) or natural/spontaneous cytotoxicity (natural killing).  
ADCC is a key function of NK cells and leads to the lysis of IgG-opsonized targets upon 
interaction with the low affinity receptor for IgG FcgRIIIA/CD16 (Trinchieri, 1989; 
Trinchieri & Valiante, 1993; Perussia, 1998; Cerwenka & Lanier, 2001; Moretta et al., 
2001; Bryceson et al., 2009). FcgRIIIA/CD16 belongs to Fc receptor (FcR) family which 
include 1. Fc-alpha receptors (FcaRs) that bind IgA 2. Fc-epsilon receptors (FceRs) that 
bind IgE 3. Fc-gamma receptors (FcgRs) that bind to IgG isotypes with different affinities 
and include both activating or inhibitory receptors such as FcgRI (CD64) FcgRIIA 
(CD32A) FcgRIIB (CD32B) FcgRIIC (CD32C) FcgRIIIA (CD16A) or FcgRIIIB (CD16B) 
(Fig. 4).  
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Regarding the receptor affinity for IgG, it has been described that the FCGR3A gene, 
which enconds for the FcgRIIIA/CD16 receptor, exhibits a single nucleotide dimorphism 
(c. 599 G > T p.Phe158Val) that, in turn, encodes for FcgRIIIA/CD16 with either a 
phenylalanine (F) or a valine (V) at amino acid position 158, thus generating receptor 
variants with lower (FcgRIIIA -158F) or higher (FcgRIIIA-158V) binding affinity for IgG 
(Koene et al., 1997; Rascu et al., 1997; Wu et al., 1997) (Fig. 5). 
 
 
Fig. 5. FCGR3A-V158F polimorphism (modified from Gillis et al., Front Immunol 2014).  
	
 
In some individuals, in addition to FcgRIIIA/CD16 receptor, a second FcgR 
(FcgRIIC/CD32C) has been identified on the surface of NK cells (Metes et al., 1994; 
Metes et al., 1998; Metes et al., 1999; Morel et al., 1999; Ernst et al., 2002). This 
molecule, which preferentially binds polymeric IgG and has only a low affinity for 
monomeric IgG (Ravetch & Kinet, 1991; Van de Winkel & Capel, 1993; Hulett & 
Hogarth, 1994; Morel et al., 1999) is an activatory receptor capable of inducing both 
ADCC and cytokine (IFN-g, IL-1 and TNF-a) production (Metes et al., 1994; Metes et 
al., 1998; Metes et al., 1999; Morel et al., 1999; Ernst et al., 2002).  
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In addition to ADCC, NK cells also carry out an antibody-independent cytotoxic response, 
the so called “natural killing” which leads to the lysis of infected and tumor cells. Natural 
killing is regulated by a balance of signals derived from the aggregation of multiple 
inhibitory and activating receptors and requires the simultaneous co-engagement of 
different activating receptors by means of individual receptor ligands expressed by target 
cells (Long and Rajagopalan, 2002; Bryceson et al., 2006; Lodoen, 2006; Bryceson & 
Ljunggren, 2008; Lanier, 2008; Vivier et al, 2008; Long et al., 2013). The ligands of 
activating receptors include both pathogen-derived and induced-self molecules which are 
not or poorly expressed by healthy cells and selectively induced or up-regulated in 
response to multiple cellular stress conditions, such as heat shock, DNA damage, viral 
infection or neoplastic transformation (Long and Rajagopalan, 2002; Bryceson et al., 
2006). Natural killing is mediated by several activating receptor families such as the 
Natural Cytotoxicity Receptors (NCRs) which are Ig-like and type I transmembrane 
glycoproteins. NCRs include NKp46, which is selectively expressed on NK cells, NKp30 
and NKp44, which are expressed also on T cells (Moretta et al., 2001; Lanier, 2005; Watzl 
& Long, 2010). Although the ligands of NCRs are not fully characterized (Arnon et al., 
2001; Mandelboim et al., 2001; Moretta et al., 2001; Arnon et al., 2004; Bryceson & 
Ljunggren, 2008; Bryceson & Long, 2008; Lanier, 2008) several studies showed that the 
ligation of NKp46 by influenza virus-encoded hemagglutinin proteins or by not yet 
defined tumor-induced molecules leads to the killing of infected or neoplastic cells 
(Mandelboim et al., 2001; Jarahian et al., 2011; Tassi et al., 2006; Lanier, 2008). Ligands 
of NKp30 have been also identified, such as hemagglutinin proteins, BAT3 protein, BAF3 
protein which is implicated in the induction of apoptosis following DNA damage, pp65 
protein which is produced by human cytomegalovirus (HCMV) and B7–H6 protein which 
is a B7 receptor family member expressed on tumor cells (Tassi et al., 2006; Bryceson & 
Ljunggren, 2008; Lanier, 2008; Brandt et al., 2009; Watzl & Long, 2010). Finally, it has 
been demonstrated that NKp44 binds to hemagglutinin proteins and to the proliferating 
cell nuclear antigen (PCNA) which is generally expressed by tumor cells (Rosental et al., 
2011). Other activating receptors involved in natural killing are the Ig-like and type I 
transmembrane glycoproteins 2B4 (CD244) and leukocyte adhesion molecule DNAX 
accessory molecule-1 (DNAM-1 or CD226) as well as the C-type lectin-like and type II 
transmembrane glycoprotein Natural-killer group 2 member D (NKG2D or CD314). 2B4, 
whose expression is not restricted to NK cells, binds to CD48 ligand, a glycoprotein 
widely expressed on hematopoietic cells and induced by Epstein-Barr virus (EBV) 
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(Lanier, 2008; Watzl & Long, 2010). DNAM-1, which is expressed on NK cells, T cells 
and monocytes, binds to poliovirus receptor (PVR or CD155) or nectin cell adhesion 
molecule-2 (Nectin2 or CD112) that are expressed on epithelial and endothelial cells and 
are up-regulated on certain tumors (Bottino et al., 2003; Watzl & Long, 2010). NKG2D, 
which is expressed on NK cells, γδ T cells and CD8+ T cells, binds to several MHC class 
I-homologous ligands such as the MHC class I-chain related molecules (MIC)-A and -B 
and the UL16-binding family proteins (ULBPs) up-regulated on stressed cells (Cerwenka 
& Lanier, 2001; Long & Rajagopalan, 2002; Raulet, 2003; Gasser & Raulet, 2006; Watzl 
& Long, 2010).  
 
1.4 Molecular signals mediating NK cell activation: ITAM-dependent or 
independent signaling pathways.   
After recognition of IgG-opsonized targets, the low-affinity receptor for IgG 
FcγRIIIA/CD16 stimulates several NK responses including ADCC, the transcription of 
genes encoding cytokines and chemokines as well as the surface expression of activation 
molecules (Trinchieri, 1989; Trinchieri and Valiante, 1993; Perussia, 1998). Notably, 
FcγRIIIA/CD16 crosslinking is able, on its own, to induce degranulation/cytotoxicity as 
well as production of pro-inflammatory cytokines and chemokines (IFN-g, TNF-a, IL-6, 
GM-CSF and CCL5). Based on this feature, FcγRIIIA/CD16 is referred as the prototype 
of NK activating receptors (Trinchieri, 1989; Trinchieri & Valiante, 1993; Perussia, 
1998; Bryceson et al., 2005; Bryceson et al., 2011; Long et al., 2013). FcγRIIIA/CD16, 
in addition to NK cells, is also expressed by monocytes/macrophages (Pincetic et al., 
2014) and, along with T cell antigen receptor (TCR) as well as B cell antigen receptor 
(BCR) and other FcRs, belongs to the family of multi-chain immune recognition receptors 
(MIRRs), which are composed by Ig-like subunits and signal transducing adaptors 
(Langlet et., 2000). In humans, FcγRIIIA/CD16 is expressed as an oligomeric complex 
consisting of a Fc-binding a chain non-covalently associated with disulfide-linked 
homodimers or heterodimers of CD3z and FceRIg signal trasducing adaptors (Lanier et 
al., 1991; Perussia, 1998; Bryceson et al., 2009; Bryceson et al., 2011). In NK cells, 
FcγRIIIA/CD16 exhibits two extracellular Ig domains, a very short cytoplasmic tail and a 
transmembrane domain that promotes its association with CD3z and FceRIg adaptor 
chains (Lanier, 1991; Letourneur et al., 1991; Hibbs et al., 1994; Tamm & Schmidt, 
1996). The membrane-proximal Ig domain of FcγRIIIA/CD16 is recognized by the 
monoclonal antibody (mAb) 3G8 while the distal one is recognized by mAb B73.1 
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(Perussia et al., 1984; Perussia & Trinchieri, 1984; Tamm & Schmidt,1996; Grier et al., 
2012). The signaling adaptors CD3z and FceRIg contain in their cytoplasmic domains the 
immunoreceptor tyrosine-based activation motifs (ITAMs) defined by the sequence 
(D/E)XXYXX(L/I)X6–8YXX(L/I): FceRIg has a single ITAM domain, whereas CD3ζ 
has three ITAMs (Reth, 1989; Raulet, 2004; Tassi et al., 2006; Bryceson and Long, 2008; 
Lanier, 2008). Upon receptor engagement, the ITAM sequences of CD3z and FceRIg 
subunits undergo tyrosine phosphorylation by the Src family member lymphocyte-specific 
protein kinase Lck, whose catalytic activity increases in response to receptor crosslinking. 
Phosphorylated ITAMs act as docking sites for SH2 domains of spleen tyrosine kinase 
(Syk) and ζ-chain-associated protein kinase of 70 kDa (ZAP-70) which, upon recruitment 
and activation, act on several downstream signaling molecules, thus controlling the signal 
propagation and the development of functional responses (Leibson, 1997; Brumbaugh et 
al., 1998). Subsequent signaling events include the activation of phosphatidyl-inositol-3-
OH kinase (PI3K) which in turn mediates the phosphorylation of phosphatidylinositol 4,5-
bisphosphate to phosphatidylinositol 3,4,5-trisphosphate (PIP3), thus promoting the 
plasma membrane recruitment of several pleckstrin homology (PH) domain containing 
molecules, such as phospholipase C (PLC)-g1, PLC- g2 and Vav1. PLC-g exerts its 
function by hydrolyzing membrane PIP2 into inositol 1,4,5-trisphosphate (IP3) and 1,2-
diacylglycerol (DAG), thus mediating the mobilization of intracellular Ca+2and the 
activation of protein kinase C (PKC). Vav proteins are guanine nucleotide exchange 
factors (GEFs) for the Rho family GTPases critically involved in both actin cytoskeleton 
reorganization and polarization of the MTOC-associated lytic granules toward cytolytic 
synapse (Azzoni et al., 1992; Ting et al., 1992; Leibson, 1997; Lou et al., 2001; Jiang et 
al., 2000/2002; MacFarlane & Campbell, 2006; Bryceson & Long, 2008; Lanier, 2008; 
Bryceson et al., 2009; Long et al., 2013; Watzl & Long, 2010).  
As previously described, NK cells express other activating receptors which recognize a 
multitude of ligands expressed on infected and tumor cells including pathogen-derived 
and stress/self-induced molecules (Long & Rajagopalan, 2002; Long et al., 2013). As 
opposed to FcγRIIIA/CD16, these activating receptors, better classified as “co-activating” 
or “co-stimulating”, are unable on their own to induce NK activation, but can act 
synergistically leading to signal complementation and triggering functional responses, 
such as degranulation and cytokine production (Fig. 6) (Long & Rajagopalan, 2002; 
Bryceson et al., 2005; Bryceson et al., 2006; Lodoen, 2006; Bryceson & Ljunggren, 2008; 
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Lanier, 2008; Vivier et al., 2008; Bryceson et al., 2009; Kim et al., 2010; Kim & Long, 
2012; Long et al., 2013).  
 
Figure 6. Synergies among co-activating receptors in NK cells. Specific pairwise combinations 
between NKG2D, 2B4, DNAM-1, NKp46 and CD2 synergize to induce functional responses such 
as degranulation and cytokine secretion (from Bryceson et al., Blood 2006) 
 
Many co-activating NK receptors are multimeric and induce a common signaling 
pathway, similar to the one triggered by FcγRIIIA/CD16 stimulation, through non-
covalently-coupled small adaptor subunits including CD3ζ, FcεRIγ and DNAX activating 
protein 12 (DAP12) which contain ITAM sequences and act as molecular chaperones 
essential for the surface expression of their cognate receptors (Reth, 1989; Bryceson & 
Long, 2008; Lanier, 2008). These ITAM-dependent receptors include the activating 
counterparts of KIRs and KLRs as well as NCRs (NKp30, NKp44 and NKp46) (Kruse et 
al., 2014). NCRs are expressed as monomers and contain a positively charged amino acid 
in their transmembrane domain which, in turn, facilitates the receptor association with the 
signaling adaptors carrying a negative charge in their transmembrane region as well as 
extracellular regions consisting of only a few cysteine residues responsible for 
dimerization (Bryceson & Long, 2008; Lanier, 2008; Watzl & Long, 2010). NKp30 and 
NKp46 are coupled with CD3ζ and FcεRIγ chain homodimers or heterodimers, whereas 
NKp44 associates with the DAP12 homodimer (Moretta et al., 2001; Lanier, 2003; 
Bottino et al., 2004; Bryceson et al.,2005; Watzl & Long, 2010). As described for 
FcγRIIIA/CD16, NCR engagement results in Src-family kinase-mediated tyrosine 
phosphorylation of the ITAM sequences. This promotes the recruitment of Syk and ZAP-
70 tyrosine kinases which, in turn, act on transmembrane adapter molecules including 
LAT and NTAL leading to the recruitment, phosphorylation and activation of further 
downstream signaling complexes such as PI3K, PLC-g1, PLC- g 2 and Vav-1,2,3 
(Bryceson & Long, 2008; Lanier, 2008; Watzl & Long, 2010).   
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Other co-activating NK receptors induce functional responses through ITAM-independent 
pathways (Fig. 7) (Bottino et al., 2003). This group of receptors includes 2B4, DNAM-1, 
NKG2D, CD2 and NKp80 (Bryceson et al., 2005; Bryceson & Ljunggren, 2008). 2B4 
receptor is a member of the signaling lymphocyte activation molecule (SLAM) family 
(Claus et al., 2008). It is expressed as monomer and contains, in its cytoplasmic domain, 
four immunoreceptor tyrosine-based switch motifs (ITSMs). 2B4 has divergent functional 
properties, and is involved both in NK cell activation and inhibition. In humans, 2B4 acts 
predominantly as an activating receptor (Lanier, 2005; MacFarlane & Campbell, 2006; 
Lanier, 2008; Watzl & Long, 2010). After receptor crosslinking, the Src-family kinase-
mediated ITSM tyrosine phosphorylation induces the recruitment of small SH2-domain 
containing adaptors, such as the SLAM-associated protein (SAP), which binds to the Src-
family tyrosine kinase Fyn that, in turn, can amplify the signal by further phosphorylating 
2B4 or act on several downstream effectors (Latour et al., 2003; Lanier, 2005; McNerney 
et al., 2005; Tassi et al., 2006; Watzl & Long, 2010). 2B4 stimulation induces 
phosphorylation of LAT, Vav1, PLC-g, c-Cbl, PI3K and Grb2 (Trinchieri, 2003; 
MacFarlane & Campbell, 2006; Tassi et al., 2006; Watzl & Long, 2010). On the other 
hand, 2B4 may also suppress NK cell functions (Sivori et al., 2002; Veillette, 2006; Watzl 
& Long, 2010). The inhibitory signaling is promoted by the high expression levels of 2B4, 
a robust receptor cross-linking and low SAP expression. In this context, phosphorylated 
2B4 recruits inhibitory molecules such as the adaptor molecule EAT2, the phosphatases 
SHP-1, SHP-2 and SHIP as well as the inhibitory kinase Csk (Chen et al., 2004; Eissmann 
et al., 2005; Roncagalli et al., 2005; Watzl & Long, 2010) that compete with SAP for 
receptor binding. DNAM-1 receptor contains, in its cytoplasmatic domain, three tyrosine 
residues that can be phosphorylated by Src-family kinases and associates with leukocyte 
function associated antigen (LFA)-1 integrin (Shibuya et al., 1998; Shibuya et al., 1999; 
Bottino et al., 2003; Bryceson et al., 2005; Bryceson & Ljunggren, 2008; Watzl & Long, 
2010). NKG2D receptor is expressed as a disulfide-bonded homodimer and holds an 
arginine residue in its transmembrane domain which mediates the receptor association 
with the signaling adaptor DAP10 (Watzl & Long, 2010). One homodimer of NKG2D 
associates with two homodimers of DAP10, thus forming a hexameric complex (Garrity 
et al., 2005). DAP10 contains, in its cytoplasmic domain, the unique tyrosine-based motif 
YxxM (TyrXXMeth) that undergoes phosphorylation by Src tyrosine kinases and binds 
either PI3K or the small adaptor molecule Grb2 which is relevant for the recruitment and 
activation of downstream effector molecules such as Vav1, PLC-g2 and SH2 domain-
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containing leukocyte phosphorylation of 76 kDa (SLP-76). NKG2D signaling is 
independent of Syk or ZAP70 kinases and does not require the transmembrane adapters 
LAT and NTAL (Billadeau et al., 2003; Lanier, 2005; Graham et al., 2006; Upshaw et 
al., 2006; Watzl & Long, 2010).   
 
 
 
Fig.7 ITAM-dependent or independent signaling pathways (modified from Watzl & Long, 
Curr Protoc Immunol 2010).  
 
 
1.5 Molecular signals limiting NK cell activation: receptor complex degradation    
The extent and duration of activating signals may be counteracted by several mechanisms 
including the internalization and degradation of engaged receptor complexes and 
associated protein tyrosine kinases. In this regard, ligand-induced ubiquitin modification 
of membrane proteins may promote their internalization and delivery to lysosomes or 
proteasomes for degradation (Molfetta et al., 2014). Ubiquitination is a reversible post-
translational modification in which the small (8-kDa) conserved peptide ubiquitin (Ub) is 
covalently attached to the e-amino group of lysine (K) residues of target proteins 
(Hochstasser, 1996; Weissman, 1997; Ciechanover, 1998; Hershko & Ciechanover, 
1998; Laney & Hochstrasser, 1999; Molfetta et al., 2014). The Ub-conjugating reaction 
is realized by the combined action of an Ub-activating enzime (E1), an Ub-conjugating 
enzime (E2) and an Ub protein ligase (E3) (Molfetta et al., 2014). Protein acting as E3s 
include Cbl, which is the product of the protooncogene c-Cbl and a prominent PTK 
substrate detected in immune receptor-mediated signaling (Joazeiro et al., 1999; Paolini 
et al., 2001). Specifically, ubiquitin modification of target proteins can occur by the 
(CD16, NCRs) 
(NKG2D) (2B4) 
(CD16, NKp30, NKp46)
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addition of a single molecule of Ub to a single (monoubiquitination) or to different 
(multiubiquitination) K residues. These modifications regulate several cellular functions 
including virus budding, nuclear shuttling, transcription and endocytosis (Mukhopadhyay 
& Riezman, 2007; Salmena & Pandolfi, 2007: Molfetta et al., 2014). Moreover, target 
proteins may also be modified by the addition of polyubiquitin chains (Pickart & 
Fushman, 2004; Molfetta et al., 2014) and different topologies of polyUb chains are 
associated with diverse biological functions (Kulathu & Komander, 2012; Molfetta et al., 
2014). Indeed, polyUb chains of at least four Ub molecules linked via K48 direct 
proteosome degradation of the target protein (Thrower et al., 2000; Molfetta et al., 2014) 
whereas K63-linked chains partecipate in several other cellular processes including DNA 
damage repair and endocytosis (Pickart & Fushman, 2004; Woelk et al., 2007; Molfetta 
et al., 2014). In regard to ubiquitination as a modification that generates a signal for 
endocytosis, although monoubiquitination is sufficient for the internalization and 
endosome-to-lysosome trafficking (Shih et al., 2000; Haglund et al., 2003; Molfetta et al., 
2014) multiubiquitination and K63-linked polyubiquitination lead to a higher rate of 
endocytosis/lysosomal transport than monoubiquitination (Barriere et al., 2006; Lauwers 
et al., 2009; Haung et al., 2013; Molfetta et al., 2014). The action of Ub as a signal for 
delivery along the endosomal compartments, including early endosomes, early 
intraluminal vesicles (ILVs) of the multivesicular body (MVB) and lysosomes, involves 
the recognition of ubiquitinated membrane proteins by different endosomal molecular 
adaptors (Hicke & Dunn, 2003; Piper & Lehner PJ, 2011; Molfetta et al., 2014). The best 
characterized Ub-dependent routes are the clathrin-dependent internalization, which 
involves several clathrin-binding adaptors that contain Ub-interacting motif (UIM), and 
the incorporation into ILVs, which fuse with lysosomes, through the action of the 
endosomal sorting complex required for transport (ESCRT) (Barriere et al., 2006; Traub 
& Lukacs GL, 2007; Dikic et al., 2009; Raiborg & Stenmark, 2009; Goh et al., 2010; 
Bertelsen et al., 2011; Henne et al., 2011; Shields & Piper, 2011; Molfetta et al., 2014). 
Among others, Ub act as a sorting signal for several FcRs including the FcgRIIIA/CD16 
receptor (Molfetta et al., 2014). Indeed, it has been reported that, upon receptor 
aggregation, the FcgRIIIA/CD16-associated CD3z subunit undergoes Ub modification 
and lysosomal degradation in a tyrosine phophorylation-dependent manner (Paolini et al., 
1999) and that tyrosine-phophorylated Syk and ZAP-70 kinases may undergo ubiquitin-
dependent degradation (Paolini et al., 2001).  
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1.6 “Adaptive” or “memory” NK cell subpopulation 
Deficiency of the transmembrane adaptor protein FceRIg, which is important for the 
signaling transduction of a number of NK cell activating receptors, is the hallmark of 
the recently described “adaptive” or “memory” NK subset (Table 1). These highly 
differentiated cells are characterized by a long-term persistence (from 4 months to 1 
year) and an enhanced functional responsiveness (Lee et al., 2015; Schlums et al., 
2015; Kovalenko et al., 2017). The presence of high and variable frequencies of 
“memory” NK cells in vivo strikingly correlates with prior exposure to human 
cytomegalovirus (HCMV) (Hwang et al., 2012; Zhang et al., 2013; Lee et al., 2015, 
Schlums et al., 2015; Kovalenko et al., 2017) a common herpesvirus that establishes a 
life-long latent infection in the majority of human population (Dowd et al., 2009). 
Moreover, such NK subset further expands in individuals experiencing HCMV 
reactivation including Hematopoietic Cell Transplant (HCT) recipient patients as well 
as in HCMV-seropositive individuals secondary infected by certain other viruses 
including hantavirus, HIV-1 and EBV (Lee et al., 2015; Kovalenko et al., 2017). It has 
been also described that “memory” NK cells significantly and preferentially expanded 
in vitro upon encounter with HCMV or influenza virus-infected cells only in the 
presence of virus-specific antibodies (Lee et al., 2015; Schlums et al., 2015). The 
adaptive features along with the loss of FceRIg chain of “memory” NK cells are 
acquired and maintained by means of selected stable molecular changes of the 
transcriptional programs (Lee et al., 2015; Schlums et al., 2015; Kovalenko et al., 
2017). Besides FceRIg chain, other B cell- and myeloid-related proteins may be 
silenced (Lee et al., 2015; Schlums et al., 2015; Kovalenko et al., 2017). The lack of 
these molecules, which is variegated and stable over time, correlates with epigenetic 
modifications resulting in DNA hyper-methylation (Lee et al., 2015; Schlums et al., 
2015).  In this regard, it has been described that “memory” NK cells are endowed with 
a specific epigenetic signature and a global DNA methylation pattern which strongly 
diverges from that of “conventional” NK cells being strikingly similar to that of 
cytotoxic effector T cells (Schlums et al., 2015) and which is controlled by 
transcription factors belonging to the BTB-zinc finger (BTB-ZF) family (Mathew et 
al., 2012; Puszyk et al., 2013) such as ZBTB16 (PLZF) that is transcriptionally down-
regulated in “memory” NK cells (Oikawa et al., 2008; Beaulieu et al., 2014; Schlums 
et al., 2015). PLZF binds to the promoter sequences of genes encoding for surface 
receptors and signaling molecules and recruits chromatin-re-modelling co-factors in 
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order to regulate gene expression (Lee & Maeda, 2012; Mathew et al., 2012).  Thus, 
the lack of PLZF results in impaired expression of a group of genes including those 
encoding for FceRIg, Syk and EAT-2 as well as IL-12 (IL12RB2) and IL-18 
(IL18RAP) receptor subunits (Gleimer et al., 2012; Mathew et al., 2012; Schlums et 
al., 2015). Moreover, it has been reported that “memory” NK cells may be deficient 
for the zing finger transcription factor HELIOS as well as for the adaptor molecules 
DAB2 (Lee et al., 2015; Schlums et al., 2015; Kovalenko et al., 2017). On the other 
hand, they express normal levels of the T-box transcription factors T-bet and 
Eomesodermin (EOMES) and of the other Syk family kinase member ZAP-70 as well 
as of the T cell-related signaling molecules CD3z and SAP (Hwang et al., 2012; Zhang 
et al., 2013; Lee et al., 2015; Schlums et al., 2015; Zhou et al., 2015; Kovalenko et al., 
2017). From literature it is well-known that “memory” NK cells significantly differ 
from “conventional” ones for their receptor repertoire and share many phenotypically 
characteristics with terminally differentiated NK cells. In fact, they typically lose the 
expression of NKG2A inhibitory receptor, exhibit increased levels of NKG2C 
activating receptor and express the maturation marker CD57 as well as the inhibitory 
KIR2DL1/2/3 or KIR3DL1 and the activating KIR2DS1/2/4 (Hwang et al., 2012; 
Zhang et al., 2013; Lee et al., 2015; Schlums et al., 2015; Zhou et al., 2015; Kovalenko 
et al., 2017). However, unlike mature NK cells, the “memory” subset may not lose 
CD62L expression, a marker that defines poly-functional and less mature NK cells 
(Zhou et al., 2015). Regarding the receptor repertoire, “memory” NK cells express 
reduced levels of FcgRIIIA/CD16 and reduced amounts of the natural cytotoxicity 
receptors NKp30 and NKp46 (Hwang et al., 2012; Lee et al., 2015; Schlums et al., 
2015; Zhou et al., 2015; Kovalenko et al., 2017) as well as of the lymphocyte 
activation marker CD38 (Zhou et al., 2015) a NADP glycol hydrolase associated with 
FceRIg and CD3z (Mallone et al., 2001; Malavasi et al., 2008). Conversely, they 
exhibit normal levels of the FceRIg-independent activating receptors such as NKG2D, 
2B4, DNAM-1, NTB-A and CRACC and do not express markers that are up-regulated 
on activated NK cells including CD69, CD25 and NKp44 receptors (Hwang et al., 
2012). In addition to the phenotypic characteristics, from literature it is also well-
known that “memory” NK cells significantly differ from “conventional” ones for their 
turnover rates and functional capabilities (Lee et al., 2015; Schlums et al., 2015; 
Kovalenko et al., 2017). In fact, they fail to respond to inflammatory cytokines 
produced by innate immune cells, such as IL-12 and IL-18, show a poorer reactivity 
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toward tumor targets in terms of both IFN-g production and degranulation and may 
lose the ability to recognize and kill activated immune cells (Hwang et al., 2012; 
Schlums et al., 2015). In fact, they display significantly reduced degranulation in 
response to activated T cells (Schlums et al., 2015). However, “memory” NK cells 
may exhibit enhanced functional activity in response to FcγRIIIA/CD16 stimulation 
especially in terms of IFN-g and TNF-a production (Hwang et al., 2012; Zhang et al., 
2013; Lee et al., 2015; Zhou et al., 2015; Kovalenko et al., 2017) due to hypo-
methylation of IFNG and TNF regulatory regions (Schlums et al., 2015).  
 
 
 
Table 1. Features of “adaptive” or “memory” NK cells (modified from Fehniger & 
Cooper, Trends Immunol. 2016) 
 
 
 
 
 
 
 
 
 
 
SURFACE • mature (CD56dim CD57+ NKG2A-)
• NKG2Chigh
• KIRs+
• CD62L+
• ¯ CD16 and NCRs (NKp30 and NKp46)
• normal NKG2D, 2B4, DNAM-1, NTB-A and CRACC
• no CD69, CD25 and NKp44
INTRACELLULAR ADAPTORS • FceRIg-
• ¯ SYK and EAT-2 
• ¯ DAB2 
• ZAP70+
• normal CD3z and SAP 
TRANSCRIPTION FACTORS • PLZF-
• HELIOS-
• normal Tbet and EOMES
DIFFERENTIATION REQUIREMENTS • HCMV-driven, no specific antigen
• CD16 stimulation
• ? inflammatory cytokines
EPIGENETIC CHANGES • FCER1G (FceRIg), SYK, SH2D1B (EAT-2), IL12RB2 and IL18RAP 
• IFNG and TNF
FUNCTION • defective response to inflammatory cytokines (IL-12 and IL-18)
• poor reactivity toward tumor targets 
• reduced responsivity to activated immune cells 
• enhanced functional activity in response to CD16 expecially in terms of IFN-g and TNF-a
production
IN VIVO EXPANSION • HCMV and other viral infections
IN VITRO EXPANSION • HCMV or influenza virus-infected cells plus virus-specific Abs
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2. Anti-CD20 therapeutic monoclonal antibodies  
2.1 Mechanism of action of anti-CD20 mAbs 
Tumor targeting therapeutic anti-CD20 monoclonal antibodies (mAbs) have 
revolutionized the treatment of B cell malignancies and autoimmune diseases (Lim et al., 
2010; Weiner et al., 2010; Maloney, 2012). Anti-CD20-based immunotherapy mediates 
B cell depletion by targeting CD20 molecule which is a B-cell-specific differentiation 
antigen expressed on the surface of human mature B cells and in most B cell-lymphomas, 
but not on early B-cell progenitors or later mature plasma cells (Tedder et al., 1988; Lenz 
& Straudt, 2010; van Meerten & Hagenbeekb, 2010; Maloney, 2012). The CD20 antigen 
is a non-glycosylated protein (Gagez & Cartron, 2014; Goede et al., 2015) with four 
membrane-spanning hydrophobic domains, two extracellular loops bearing the epitopes 
recognized by anti-CD20 mAbs and the amino- and the carboxy-terminal domains located 
within the cytoplasm. Following anti-CD20 mediated aggregation, such cytoplasmatic 
domains undergo phosphorylation and transduce biochemical signals (Gagez & Cartron, 
2014). CD20 antigen is organized into complexes comprising dimers or tetramers (Bubien 
et al., 1993; Gagez & Cartron, 2014) closely associated with other proteins, such as Csk-
binding protein (Cbp), CD40 and MHC class II (Gagez & Cartron, 2014). Anti-CD20 
mAbs mediate B cell depletion through different mechanisms (Fig. 8) including 1. Fc-Fcg 
receptor (FcgR)-based mechanisms represented by ADCC and antibody-dependent 
cellular phagocytosis (ADCP) triggered by FcγRs expressed on monocyte/macrophages, 
neutrophils as well as NK cells (Cartron et al., 2002; Lefebvre et al., 2006; Jaglowski et 
al., 2010; Beers et al., 2010; Lim et al., 2010; Taylor & Lindorfer, 2010; Montalvao et 
al., 2013; Taylor & Lindorfer, 2014) 2. complement-dependent cytotoxicity (CDC) 
involving the activation of the classical cascade via C1q component likely as a result of 
antibody organization into order hexamers, deposition of C3b fragments and generation 
of the membrane attack complex (MAC) (Walport, 2001; Gelderman et al., 2004; Wang 
et al., 2008; Beers et al., 2010; Lim et al., 2010; Taylor & Lindorfer, 2010; Maloney, 
2012; Cook et al., 2016) 3. direct programmed B cell death (PCD) via apoptotic or not 
apoptotic mechanisms (Beers et al., 2010; Lim et al., 2010; Taylor & Lindorfer, 2010;  
van Meerten & Hagenbeek, 2010; Maloney, 2012; Illidge et al., 2014)  
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Notably, the relative contribution of each effector mechanism remains controversial. 
Indeed, while it is widely accepted that Fc-FcgR interactions are critical for their in vivo 
anti-tumor efficacy (Nimmerjahn & Ravetch, 2007; Lim et al., 2010), the role of CDC and 
direct PCD is still disputed (Cragg et al., 2005; Glennie et al., 2007; Lim et al., 2010).  
 
                   
 
Figure 8. Anti-tumor mechanisms of anti-CD20 mAbs. Anti-CD20 mAbs mediate B cell 
depletion through different mechanisms of cellular cytotoxicity. CD20 aggregation induced by 
therapeutic mAbs may induce complement-dependent cytotoxicity (CDC) by the activation of the 
classical complement pathway leading to the generation of the membrane attack complex (MAC) 
that mediates B-cell lysis. Besides CDC anti-CD20 mAbs can recruit FcgR+ immune effector cells 
such as NK cells, monocytes/macrophages and neutrophils to deplete CD20+ target cells through 
antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cell-mediated 
phagocytosis (ADCP). The interaction with NK cells via FcgRIIIA/CD16 stimulates ADCC. The 
recognition of the Fc portion of anti-CD20 mAbs as well as the deposited complement fragments 
by both FcRs and complement receptors on monocytes/macrophages and neutrophils induces both 
ADCC and ADCP. The CD20 crosslinking by anti-CD20 mAbs may have direct anti-proliferative 
effects or may induce direct programmed B cell death (PCD) via apoptotic or not apoptotic 
pathways (modified from Kasi et al., Critical Care  2012).  
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2.2 Type I and II anti-CD20 mAbs 
Anti-CD20 mAbs can be classified as “Type I” and “Type II” on the basis of the antigen-
binding characteristics and the primary mode of action employed (Fig. 9) (Chan et al., 
2003; Cragg et al., 2003; Cragg et al., 2004; Glennie et al., 2007; Beers et al., 2008; 
Niederfellner et al., 2011; Klein et al., 2013). Type I anti-CD20 mAbs bind two CD20 
molecules belonging to different CD20 tetramers (Klein et al., 2013; Gagez & Cartron, 
2014; Illidge et al., 2014; Goede et al., 2015). Such inter-tetrameric binding to CD20 
induces a rapid migration of mAb/CD20 complexes into lipid rafts, which are plasma 
membrane micro domains enriched in cholesterol and sphingolipids and represent a 
platform for signal transduction allowing the co-localization of receptors and signalling 
effector molecules (Cragg et al., 2003; Cragg et al., 2004; Klein et al., 2013; Gagez & 
Cartron, 2014; Illidge et al., 2015). The association between CD20 and lipid rafts is 
dependent on cholesterol and on a short membrane-proximal cytoplasmic domain of 
CD20 molecule (Polyak et al., 1998; Gagez & Cartron, 2014). The translocation of 
mAb/CD20 complexes into lipid rafts leads to strong CDC and PCD because it allows not 
only the clustering of the antibody Fc portions resulting in C1q protein recruitment and 
complement deposition, but also the activation of CD20 calcium channels leading to 
caspase activation and apoptosis (Deans et al., 2002; Cragg et al., 2003; Beers et al., 
2010; van Marteen & Hagenbeek, 2010; Maloney, 2012). Conversely, type II anti-CD20 
mAbs bind two CD20 molecules within the same tetramer (Klein et al., 2013; Gagez & 
Cartron, 2014; Illidge et al., 2014; Goede et al., 2015). Such intra-tetrameric binding to 
CD20 does not localize mAb/CD20 complexes into lipid rafts and induce weak or no 
CDC, but potent PCD because it favours the homotypic B cell adhesion (Chan et al. 2003; 
Cragg et al., 2003; Ivanov et al., 2009; van Meerten & Hagenbeek, 2010; Niederfellner 
et al., 2011; Maloney, 2012; Klein et al., 2013)  that in turn is associated with peripheral 
re-localization of the cellular actin, the polarization of mitochondria toward the cell-to-
cell contact area, the release of lysosomal cathepsin in cytoplasm and in surrounding 
enviroment and the extra-mitochondrial generation of reactive oxigen species via the 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, thus resulting in cell 
death (Ivanov et al., 2009; Alduaij & Illidge, 2011; Alduaij et al., 2011; Dalle et al., 2011; 
Jak et al., 2011; Honeychurch et al., 2012).  
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As a result of the different binding topology, type I and type II anti-CD20 mAbs bind to 
CD20 tetramers in a 2:1 ratio (Klein et al., 2013; Gagez & Cartron, 2014; Illidge et al., 
2014). Furthermore, type I and type II anti-CD20 mAbs share the same ability to induce 
ADCC and ADCP by recruiting FcgR+ effector cells such as monocytes/macrophages, 
neutrophils and NK cells (Cartron et al., 2004; Gagez & Cartron, 2014; Illidge et al., 
2015). Indeed, these properties are related to the Fc portion which does not differ between 
type I and II mAbs (Gagez & Cartron, 2014). Notably, rituximab, ofatumumab, 
ublituximab, veltuzumab, ocrelizumab, ocaratuzumab, PRO131921 belong to the group 
of type I anti-CD20 mAbs (Teeling et al., 2006; Goldenberg et al., 2009; Tobinai et al., 
2011; Wierda et al., 2011; Forero-Torres et al., 2012; Gagez & Cartron, 2014; Le Garff-
Tavernier et al. 2014) while tositumumab and obinutuzumab are type II anti-CD20 mAbs 
(Zelenetz, 2003; Robak, 2009; Mossner et., 2010; Gagez & Cartron, 2014; Goede et al., 
2015; Illidge et al., 2015).    
 
 
 
 
Figure 9. Type I and II anti-CD20 mAbs. Type I mAbs bind two CD20 molecules belonging to 
different tetramers. Their inter-tetrameric binding to CD20 induces rapid traslocation of the 
mAb/CD20 complex into lipid rafts leading to strong CDC but only weak apoptotic PCD. Type II 
mAbs bind two CD20 molecules within the same tetramer. Their intra-tetrameric binding to CD20 
does not localize mAb/CD20 complexes into lipid rafts inducing weak or no CDC but potent non-
apoptotic PCD (modified from Gagez & Cartron, Curr Opin Oncol 2014 and Cragg, Blood 2011).  
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2.3 Rituximab and resistance mechanisms     
The anti-CD20 mAb of 1st generation rituximab (MABTHERA; RITUXAN) was the first 
approved in clinical practice and it has substantially improved the clinical outcomes of 
patients with a broad range of B cell malignancies (Beers et al., 2010; Lim et al., 2010; 
van Meerten & Hagenbeek, 2010; Weiner et al., 2010; Maloney et al., 2012) as well as 
autoimmune disorders (Eisenberg & Albert, 2005; Sabahi & Anolik, 2006; Taylor & 
Lindorfer, 2007). The use of rituximab, as single agent or in combination with standard 
chemotherapy/radiotherapy regimens, represents the standard of care in a variety of B-cell 
malignancies including B cell chronic lymphocytic leukemia (CLL) and non-Hodgkin’s 
lymphomas (NHL), such as diffuse large B cell lymphoma (DLBCL), follicular 
lymphoma (FL) and mantle cell lymphoma (MCL) (Coiffier et al., 2002; Hiddemann et 
al., 2005; Pfreundschuh et al., 2006; Glennie et al., 2007; Schulz et al., 2007; Cheson & 
Leonard, 2008; Marcus et al., 2008; Beers et al., 2010; Gao et al., 2010; Hallek et al., 
2010; Lim et al., 2010; van Meerten & Hagenbeek, 2010; Pfreundschuh et al., 2011; 
Maloney et al., 2012). Rituximab is a chimeric IgG1k mAb with murine light- and heavy-
chain variable and human constant regions (Reff et al., 1994; van Meerten & Hagenbeek, 
2010). The infusion of rituximab, by promoting a rapid opsonization of circulating B cells, 
results in depletion of B cells in peripheral blood, lymph nodes and bone marrow (Reff et 
al., 1994; Kennedy et al., 2003; Uchida et al., 2004; Hamaguchi et al., 2006) and may 
cause immunodeficiency (Maloney, 2012). Infectious complications, such as bacterial, 
viral and fungal infections, are indeed reported in some patients who are treated with 
chemoimmunotherapy (Kimby, 2005, Lau, 2008; Carson et al., 2009). FcgRIIIA/CD16 
receptor plays a relevant role in the anti-tumor activity of rituximab (Cartron et al 2002; 
Montalvao et al., 2013; Gagez & Cartron, 2014; Illidge et al., 2014; Taylor & Lindorfer, 
2014; Illidge et al., 2015). In fact, it has been demonstrated that  rituximab-based therapy 
is ineffective in mice devoid of FcRγ chain (Clynes et al., 1998) and may be affected by 
the FCGR3A-V158F single nucleotide polymorphism (see above). In this regards, it has 
been reported that this polymorphism is clinically relevant for rituximab monotherapy in 
patients with low tumor burden FL. Indeed, the homozygous FcgRIIIA-158V/V patients 
displayed a better clinical response rate than the low-affinity  FcgRIIIA-158F carriers 
(Cartron et al., 2002; Weng & Levy, 2003; Weiner et al., 2010;Persky et al., 2012; Gagez 
& Cartron, 2014; Illidge et al., 2014; Illidge et al., 2015) likely due to an higher affinity 
for rituximab as well as an increased antibody-induced FcgRIIIA-bearing cell activation 
(Dall’Ozzo et al., 2004; Bowles & Weiner, 2005; Hatjiharissi et al., 2007;Veeramani et 
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al., 2011). However, the prognostic significance of the FCGR3A-V158F polymorphism 
is less clear for rituximab given in combination with chemotherapy in NHLs (Kim et al., 
2006; Carlotti et al., 2007; Mitrovic et al., 2007; Zhang et al., 2010; Ahlgrimm et al., 
2011; Fabisiewicz et al., 2011; Prochazka et al., 2011; Ghesquieres et al., 2012; Persky 
et al., 2012; Varoczy et al., 2012; Illidge et al., 2014; Illidge et al., 2015) and has not 
observed in CLL for rituximab monotherapy or immuno-chemotherapy (Farag et al., 
2004; Dornan et al., 2010; Jaglowski et al., 2010; Illidge et al., 2014; Illidge et al., 2015). 
Despite the clinical success of rituximab therapy, after a prologed treatment, a relevant 
fraction of patients develops resistance thus leading to treatment failuire or relapse (Davis 
et al., 2000; Hainsworth et al., 2000; Colombat et al., 2001; Maloney, 2005; Martin et 
al., 2008; Taylor & Lindorfer, 2010; Cartron et al., 2011; Illidge et al., 2014; Goede et 
al., 2015; Illidge et al., 2015). Several and currently poorly understood are the 
mechanisms of resistance to rituximab therapy (Table 2) (Bonavida, 2007; Hiraga et al., 
2009; Taylor & Lindorfer, 2010; Alduaij et al., 2011; Mishima et al., 2011; Beurskens et 
al., 2012; Small et al., 2013; Illidge et al., 2014; Illidge et al., 2015).  
 
 
 
Table 2. Mechanisms of resistance to rituximab therapy (modified from Taylor & Lindorfer, 
Semin Hematol. 2010) 
 
 
 
LOSS	OF	EPITOPE • CD20	gene	mutation
• low membrane	expression of	CD20	
• mAb-mediated CD20	surface down-modulation (e.i
internalization/degradation or	shaving reaction)	
REDUCED	ADCC • saturation/exhaustion of	ADCC
• C3b	deposition on	B	cells		
• polymorphisms in	effector molecules (e.i. FcgR)		
• FcgR surface down-modulation
• FcgRIIIA/CD16-driven	inhibitory signals (i.e.	activation of	
SHP-1	tyrosine phosphatase)
REDUCED	ADCP • saturation/exhaustion of	ADCP
• polymorphisms in	effector molecules (e.i. FcgR)		
• FcgR surface down-modulation
REDUCED	CDC • saturation/exhaustion of	CDC	(i.e.	consumption of	
complement components)
• increased surface expression and	activity of	complement
inhibitory proteins (CRPs)	on	B	cells		
REDUCED	PCD • increased levels of	anti-apoptotic proteins in	B	cells
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Tumor cell resistance to rituximab is multifactorial and may be host- or tumor-related 
(Taylor & Lindorfer, 2010). Host-related mechanisms such as the saturation or exhaustion 
of effector mechanisms responsible for the depletion of anti-CD20-coated targets may 
reduce, expecially in high tumor burden conditions, therapeutic efficacy by impairing 
complement activation, macrophage-mediated phagocytosis and NK-mediated ADCC 
(Kennedy et al., 2004; Glennie et al., 2007; Taylor & Lindorfer, 2008; Taylor & 
Lindorfer, 2010; van Meerten and Hagenbeek, 2010). Defective ADCC may be related to 
down-modulation of FcgRIIIA/CD16 receptor upon recognition of rituximab-opsonized 
targets (Bowles et al., 2006; Taylor & Lindorfer, 2008; Taylor & Lindorfer, 2010; van 
Meerten & Hagenbeekb, 2010; Veeramani et al., 2011; Zent et al., 2014) thus impairing 
the killing of tumor cells until FcgRIIIA/CD16 is re-expressed (Taylor & Lindorfer, 2010). 
Reduced ADCC may be also the conseguence of C3b deposition on opsonized B cells: the 
binding of C3q to an epitope in the Fc portion which is proximal to that recognized by 
FcgRIIIA/CD16 may prevent rituximab-induced receptor aggregation (Wang et al., 2008; 
Wang et al., 2009; van Meerten & Hagenbeekb, 2010). Recently, a different mechanism 
responsible for the exhaustion of NK cytolytic potential has been also described by our 
group. In particular, the sustained stimulation of FcgRIIIA/CD16 by means of rituximab-
coated tumor B cells impairs the cytolytic pontential of NK cells by promoting the long-
lasting recruitment of the tyrosine phosphatase SHP-1 to the aggregated receptor complex. 
Such event leads to the cross-tolerance of several un-releated activating receptors through 
the de-phosphorylation of signaling molecules critically required for the NK-mediated 
cytotoxicity such as SLP-76, PLC-g2 and Vav1 (Capuano et al., 2015). Moreover, clinical 
efficacy of rituximab may be also restricted by the consumption of complement system 
(Kennedy et al., 2004) as well as by polymorphisms in FCGR3A gene encoding for 
FcgRIIIA/CD16 receptor (Vance et al., 1993; de Haas et al., 1996; Koene et al., 1997; 
Wu et al., 1997; Cartron et al., 2002; Hatjiharissi et al., 2007). Tumor-related resistance 
mechanisms comprise CD20 gene mutation, low membrane expression of  CD20 
(Kennedy et al., 2004; Beum et al., 2006; van Meerten et al., 2006; Beum et al., 2008) as 
well as the enhanced surface expression and activity of complement inhibitory proteins 
(CRPs) such as CD55 and CD59 or of anti-apoptotic proteins in circulating malignant B 
cells (Golay et al., 2000; Treon et al., 2001; Kennedy et al., 2003; Czuczman et al., 2008). 
The down-regulation of CD20 surface expression, which differs across different tumors, 
is implicated in imparing the therapeutic efficacy by reducing the antibody half-life and 
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the immune effector cell recruitment and activation (Beers et al., 2010; Lim et al., 2011; 
Gagez & Cartron, 2014; Illidge et al., 2014; Goede et al., 2015; Illidge et al., 2015).  
The removal of rituximab/CD20 complexes from B cells in the “shaving reaction” may 
contribute to the loss of CD20 (Beum et al., 2006; Beum et al., 2008; Taylor & Lindorfer, 
2010). In this antigenic modulation modality Rituximab/CD20 complexes are transferred 
from opsonized B cells to monocytes/macrophages, which express the high affinity FcgRI, 
and internalized (Hudrisier et al., 2007; Beum et al., 2008; Taylor & Lindorfer, 2010; 
Beum et al., 2011). Antigenic modulation may be also due to internalization of mAb-CD20 
complexes by tumor cells (Beers et al., 2010). In order to overcome the resistance 
mechanisms it has been proposed the combination of rituximab with agents potentiating 
the NK cell-mediated ADCC including 1. anti-KIR antagonist mAbs, which block 
inhibitory KIRs (Kohrt et al., 2014) 2. immunoregulatory drugs such as lenalidomide and 
pomalidomide which increase granzyme B and FasL expression (Wu et al., 2008) and 3. 
anti-CD137 agonistic mAbs which up-regulate CD137 surface expression (Kohrt et al., 
2011). At the same time new different anti-CD20 mAbs have been developed (Fig.10) 
(Lim et al., 2010; Taylor & Lindorfer, 2010; van Meerten & Hagenbeek, 2010; Gagez & 
Cartron, 2015; Illidge et al., 2015). Such antibodies are endowed with improved 
properties and enhanced or novel effector mechanisms and are now approching the clinical 
use as potential competitors of rituximab in first-line therapies or for use in rituximab-
refractory diseases (Teeling et al., 2004; Bowles et al., 2006; Lim et al., 2010; Taylor & 
Lindorfer, 2010; van Meerten & Hagenbeek, 2010; Bologna et al., 2011; Klein et al., 
2013; Gagez & Cartron, 2015). 
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Figure 10. Hystory of anti-CD20 mAbs. The time-line summarizes the chronological 
introduction over the last three decades of anti-CD20 mAbs in human trials and the corresponding 
progress in Ab technology from 1st through to 3rd generation reagents: 1st generation mAbs are 
murine or human/mouse chimeric, 2nd generation mAbs are either humanized or fully human and 
3rd generation mAbs have further modifications to the Ab structure e.g. mutation or defucosylation 
of the Fc domain for enhanced FcR binding profiles (modified from Lim et al., Hematologica 
2010). 
 
The development of these next-generation anti-CD20 mAbs, classified as 2nd or 3rd 
generation, has been focused on structural modifications promoting specific cytotoxic 
mechanisms (Illidge et al., 2014). With respect to rituximab, they bind different CD20 
epitopes (Fig. 11) and are more efficient in inducing specific effector functions (Taylor & 
Lindorfer, 2008; van Meerten & Hagenbeekb, 2010).  
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Figure 11. Binding sites of anti-CD20 mAbs. Anti-CD20 mAbs bind to the extracellular domain 
of CD20 molcule. Most of anti-CD20 mAbs, including rituximab and obinutuzumab, bind to the 
larger (large 44-mer) CD20 extracellular loop around the ANP (alanine – N – proline) motif. By 
contrast, ofatumumab recognized an epitope including both the smaller (small 7-mer) CD20 
extracellular loop and the N-terminal region of the larger one (modified from Cragg, Blood 2011). 
 
Anti-CD20 mAbs of 2nd generation include humanized or fully human antibodies (Taylor 
& Lindorfer, 2008; Van Meerten & Hagenbeekb, 2010) such as ofatumumab (ARZERRA) 
which is a IgG1k type I anti-CD20 mAb approved for the treatment of relapsed CLL in 
fludarabine- and alemtuzumab-refractory patients (O’ Brien & Osterborg, 2010). In vitro 
and in vivo studies demonstrated that ofatumumab can be successfully used in rituximab-
resistant tumors as well as in CLL with low membrane expression of CD20 (Teeling et 
al., 2004; Teeling et al., 2006; Coiffier et al., 2008; Hagenbeek et al., 2008; Beers et al., 
2010; Jaglowski et al., 2010; van Meerten & Hagenbeekb, 2010). Unlike rituximab, 
ofatumumab binds, with high affinity, to a CD20 epitope (“small 7-mer loop”) which is 
closer to the plasma membrane, thus showing a greater ability to bind C1q and to induce 
CDC (Teeling et al., 2004; Teeling et al., 2006; Beers et al., 2010; Lim et al., 2010; van 
Meerten & Hagenbeekb, 2010; Wierda et al., 2011; Maloney, 2012).  
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2.4 Third generation of anti-CD20 mAbs: obinutuzumab    
Anti-CD20 mAbs of 3rd generation are humanized mAbs with a modified Fc region 
(Taylor & Lindorfer, 2008; van Meerten & Hagenbeekb, 2010). Fc modification strategies 
include Fc-mutation (Shields et al., 2001; Gagez & Cartron, 2014) and Fc-
glycoengineering (Shields et al., 2002; Jefferis, 2009; Gagez & Cartron, 2014; Illidge et 
al., 2014; Illidge et al., 2015) and lead to the improvement of ADCC and ADCP by 
enhancing the binding affinity between the Fc portion of the therapeutic antibody and the 
FcgRIIIA/B expressed by immune effector cells (Gagez & Cartron, 2014; Goede et al., 
2015; Illidge et al., 2015). Fc-mutation results in the substitution of Fc amino acid residues 
involved in Fc-FcgR interaction while Fc- glycoengineering modifies the composition of 
the two oligosaccharides attached to asparagine (Asn) 297 residues in the CH2 domains 
of Fc portion (Shields et al., 2001; Shields et al., 2002; Jefferis, 2009; Gagez & Cartron, 
2014; Illidge et al., 2014; Illidge et al., 2015). The Fc-modified anti-CD20 mAbs tested 
in clinical trials include the Fc-mutant ocaratuzumab (Forero-Terres et al., 2012; Gagez 
& Cartron, 2014) as well as the Fc-glycoengineered ublituximab (Cazin et al., 2011; 
Gagez & Cartron, 2014) and obinutuzumab (Mossner et al., 2010; Gagez & Cartron, 
2014). Obinutuzumab (GA101; GAZYVA; GAZYVARO) is a humanized Fc-
glycoengineered type II anti-CD20 mAb (IgG1k isotype) of 3rd generation, developed in 
an attempt to enhance both the immune effector cell-mediated and the direct killing of 
cancer cells (Mossner et al., 2010; Gagez & Cartron, 2014; Illidge et al., 2014; Klein et 
al., 2014; Goede et al 2015). Obinutuzumab was derived by humanization of the murine 
B-Ly1 anti-CD20 mAb and was glycoengineered by defucosylation (Mossner et al., 2010; 
Illidge et al., 2014; Klein et al., 2014; Goede et al 2015). Core fucose residues were 
removed from the two oligosaccharides attached to Asn 297 residues in the CH2 domains 
of Fc portion thus resulting in a lower amount of fucose than conventional IgG (Mossner 
et al., 2010; Illidge et al., 2014; Illidge et al., 2015). In particular, the addition of fucose 
to the Fc region carbohydrates was sterically prevented, in the antibody-producing cells, 
by the insertion of extra N-acetylglucosamine (NAG) groups thus enabling the generation 
of an antibody glycovariant lacking fucosylation (Fig. 12) (Mossner et al., 2010; Klein et 
al., 2014; Goede et al 2015).  
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Figure 12. Fc-glycoengineered structure of obinutuzumab. The insertion of extra N-
acetylglucosamine (NAG) groups strerically prevents the addition of fucose to the 
oligosaccharides attached to asparagine (Asn) 297 residues in the CH2 domains of Fc portion 
(modified from Illidge et al., Cancer Treat Rev 2015). 
 
As defucosylated molecule, obinutuzumab exhibits an increased binding affinity for both 
FcγRIIIA, irrespective to the allotype V or F, and FcγRIIIB, thus improving ADCC and 
ADCP mediated by monocytes/macrophages and NK cells through FcγRIIIA as well as 
by neutrophils through FcγRIIIB, which shows high amino acid sequence identity with 
FcγRIIIA in its extra-cellular binding domain (Okazaki et al., 2004; Ferrara et al., 2006; 
Umana et al., 2006; De Romeuf et al., 2008; Jefferis, 2009; Shibata-Koyama et al., 2009; 
Mossner et al., 2010; Ferrara et al., 2011; Mizushima et al., 2011; Golay et al., 2013; 
Gagez & Cartron, 2014; Herter et al., 2014; Illidge et al., 2014; Goede et al., 2015; Illidge 
et al., 2015). In the induction of these Fc-dependent effector mechanisms, obinutuzumab 
overcomes the inhibition mediated by KIRs, by complement or by physiological 
concentrations of competing unspecific endogenous Ig (Mossner et al., 2010; Kern et al., 
2013; Herter et al., 2014; Terszowski et al., 2014; Goede et al., 2015; Illidge et al., 2015). 
With respect to rituximab, obinutuzumab recognizes a different but overlapping epitope 
in the CD20 extracellular domain and binds to the CD20 antigen in an intra-tetrameric 
manner and in a completely different space orientation (Niederfellner et al., 2011; Klein 
et al., 2013; Gagez & Cartron, 2014; Illidge et al., 2014; Illidge et al., 2015). In particular, 
it appears rotated 90° around its middle axis and also tilted 70° towards the carboxyl 
terminus of the CD20 epitope (Goede et al., 2015; Gagez & Cartron, 2014). These binding 
properties of obinutuzumab to CD20 are related to a modified elbow-hinge sequence with 
a valine-for-leucine substitution at Kabat position 11, arising during the process of 
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humanization and resulting in a 30° wider elbow angle (Mossner et al., 2010; 
Niederfellner et al., 2011; Klein et al., 2013; Gagez & Cartron, 2014; Illidge et al., 2014; 
Goede et al., 2015). These special binding characteristics of obinutuzumab prevent its cis 
interaction with the inhibitory FcγRIIB expressed on B cells, thus preventing the rapid 
internalization and degradation of mAb/CD20 complex (Beers et al., 2010; Lim et al., 
2011; Klein et al., 2013; Gagez & Cartron, 2014; Illidge et al., 2014; Goede et al., 2015). 
As a consequence, obinutuzumab does not sequester CD20 molecules within lipid rafts 
and promotes their stable accumulation at sites of homotypic aggregation thus inducing 
minimal CDC but enhanced PCD via a homotypic adhesion-related, caspase-independent, 
lysosome/ROS-mediated mechanism (Mossner et al., 2010; Alduaij et al., 2011; Dalle et 
al., 2011; Jak et al., 2011; Herter et al., 2013; Gagez & Cartron, 2014; Illidge et al., 
2014; Goede et al., 2015; Illidge et al., 2015). Notably, because of the absence of 
characteristic hallmarks of apoptosis, this type of B cell death may overcome apoptosis-
resistance mechanisms, thus leading to the depletion of malignant B cells which are 
refractory to conventional chemotherapy or immune-chemotherapy (Illidge et al., 2014; 
Goede et al., 2015). Furthermore, this effector mechanism is induced independently of the 
Fc-FcγR interactions (Ivanov et al., 2008; Mossner et al., 2010; Alduaij et al., 2011; Dalle 
et al., 2011; Honeychurch et al., 2012; Illidge et al., 2014; Goede et al., 2015; Illidge et 
al., 2015) and potentially remains active in patients with impaired Fc dependent functions 
(Cartron et al., 2002; Glennie et al., 2007; Beurskens et al., 2012; Illidge et al., 2014; 
Goede et al., 2015). Notably, in in vitro and preclinical studies obinutuzumab was shown 
to be superior to rituximab (Gagez & Cartron, 2014; Goede et al., 2015; Illidge et al., 
2015). Obinutuzumab achieved B cell depletion superior to rituximab not only in 
peripheral blood but also in lymphoid tissues including lymph nodes and spleen (Mossner 
et al., 2010; Illidge et al., 2014; Goede et al., 2015; Illidge et al., 2015). In addition, 
obinutuzumab demonstrated a superior anti-tumour activity in lymphoma xenograft 
models, even in rituximab relapsed/refractory tumours (Mossner et al., 2010; Dalle et al., 
2011; Herter et al., 2013; Herting et al., 2014; Illidge et al., 2014; Goede et al., 2015; 
Illidge et al., 2015) as well as an enhanced efficacy in combination with chemotherapies 
such as chlorambucil, fludarabine, bendamustine and cyclophosphamide (Dalle et al., 
2011; Herting et al., 2014; Illidge et al., 2014; Goede et al., 2015). In clinical studies, 
obinutuzumab exhibited promising activity in different CD20 diseases as well as an 
acceptable and manageable safety profile (Gagez & Cartron, 2014; Goede et al., 2015). 
Based on the results of phase III trials, obinutuzumab has been recently approved in 
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combination with chlorambucil for the treatment of patients with previously untreated B-
CLL and co-morbidities, unsuitable for full-dose fludarabine-based therapy (Goede et al., 
2014) as well as in combination with bendamustine for patients with rituximab-
relapsed/refractory indolent B-NHL (Sehn et al., 2016). Further clinical studies are 
planned or ongoing in both untreated and relapsed/refractory patients with B 
lymphoproliferative disorders (Gagez & Cartron, 2014; Goede et al., 2015). 
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Aim 
 
This study is aimed at understanding the cellular and molecular mechanisms underlying 
the modulation of NK cell responsiveness and plasticity induced by therapeutic anti-CD20 
monoclonal antibodies (mAbs) endowed with different binding affinity for the 
FcgRIIIA/CD16 receptor. In this regards, in first we addressed whether the CD16 
aggregation by the chimeric rituximab or the humanized obinutuzumab, in both its Fc-
glycoengineered and non-glycoengineered wild type version, may differently affect the 
receptor dynamics and NK functions. Then we addressed whether the CD16 affinity 
aggregation conditions may impact on the capability of anti-CD20 mAbs to support the 
expansion as well as to affect the phenotypic and functional proprieties of the recently 
identified long-lived and highly functional “memory” NK subset.   
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Materials and Methods  
Antibodies and Reagents  
The following anti-CD20 mAbs were used: the chimeric IgG1k type I rituximab, the 
humanized IgG1k type II obinutuzumab (GA101) and its non-glycoengineered parental 
version (wt-GA101) kindly provided by Roche Glycart (Schlieren, Switzerland); the 
monovalent Fab fragment of obinutuzumab (GA101-Fab) obtained via papain digestion 
by commercial Fab Preparation kit (Thermo Scientific, code 44985), according to 
manufacturer’s instructions. Anti-CD16 (B73.1, provided by Dr. G. Trinchieri National 
Cancer Institute, National Institutes of Health, Frederick, USA), anti-2B4 (C1.7, Beckman 
Coulter), anti-NKp46 (9E2, Biolegend), anti-NKG2D (149810, R&D Systems), anti-
NKp30 (210847, R&D Systems), goat-anti-mouse (GAM) F(ab')2 (Jackson 
Immunoresearch Laboratories). The following fluorochrome-conjugated mAbs for 
NKG2D (149810, R&D Systems), CD107a (H4A3, BD Biosciences), CD16 (Leu11c, BD 
Biosciences; MEM-154, Immunological Sciences; 3G8, BD Biosciences; REA423, 
Miltenyi Biotec), NKp46 (9E2, BD Biosciences; REA808, Miltenyi Biotec), NKp30 (p30-
15, BD Biosciences), CD56 (B159, BD Biosciences; REA196, Miltenyi Biotec), CD3 
(SK7, BD Biosciences; REA613, Miltenyi Biotec), NKG2C (134591, R&D Systems), 
IFN-g (B27, BD Biosciences), FceRIg subunit (Millipore), PLZF (Mags.21F7, 
eBioscience), CD19 (4G7, BD Biosciences) and the goat-anti-human (GAH) k light chain 
(Cappel) Ab were used. For immunoblot analysis were used the following Abs: anti-
phosphotyrosine (4G10, Millipore), anti-FceRIg subunit (Millipore), anti-ZAP-70 (2F3.2, 
Millipore), anti-ubiquitin (FK2, Enzo Life Sciences), anti-CD3z (6B10.2, Santa Cruz 
Biotechnology Inc), anti-Syk (4D10 Santa Cruz Biotechnology Inc.), anti-b-tubulin 
(Tub2.1, Sigma-Aldrich), anti-Cbl-b (Santa Cruz Biotechnology) and anti-c-Cbl (Cell 
Signaling Technology). Monensin, saponin, paraformaldehyde (PFA), poli-L-lysine, 
brefeldin A (BFA), ammonium chloride (NH4Cl), protease and phosphatase inhibitors 
were from Sigma-Aldrich. Nonionic detergent Triton X-100 and glycin were from Biorad. 
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Cell systems  
Peripheral blood mononuclear cells and primary cultured human NK cells  
Peripheral blood mononuclear cells (PBMCs) were freshly isolated from whole blood 
samples of healthy donors of Blood Transfusion Center of Sapienza University of Rome 
over a Ficoll-Hypaque gradient. The study was conducted according to protocols approved 
by our local institutional review board and in accordance with Declaration of Helsinky. 
Primary cultured human NK cells were obtained from 10-day co-cultures of PBMCs with 
irradiated Epstein-Barr virus positive (EBV+) RPMI 8866 lymphoblastoid cell line 
(Galandrini et al., 1999). On day 8 to 10, cell population was assayed by cytofluorimetric 
analysis for CD56, CD16, CD3 expression and the experiments were performed on NK 
cell populations (CD3-CD56+) that were more than 80% pure. Primary cultures were 
maintained in RPMI 1640 medium supplemented with 1% L-glutamine and 10% Fetal 
Calf Serum (FCS).  
 
Cell lines  
The following cell lines were used as targets: the human CD20+ lymphoblastoid Raji 
provided by Dr. F.D. Batista (Cancer Research UK, London), the murine FcR+ 
mastocytoma P815 and the human erytroleukemia K562, all kept in culture for less than 
two consecutive months in RPMI 1640 medium supplemented with 10% FCS and 1% L-
glutamine and regularly checked for mycoplasma negativity.  
 
Anti-CD20-mediated CD16 aggregation  
CD20+ Raji cells were opsonized by incubating with saturating dose of rituximab (1 
µg/106), obinutuzumab (GA101) (0.1 µg/106), or when indicated, wt-GA101 (0.1 µg/106) 
or GA101-Fab (1 µg/106) for 20 minutes at room temperature. Not opsonized Raji, used 
as control, and anti-CD20-opsonized targets were washed and allowed to interact with NK 
cells at effector (E): target (T) ratio 2:1 for the indicates times. To obtain “anti-CD20 
experienced NK cells”, Raji cells were biotinylated by loading with 10 µg/ml of EZ-Link 
Sulfo-NHS-SS-Biotin (Thermo Fisher Scientific) for 30 minutes at room temperature, 
washed twice with Phosphate-Buffered Saline (PBS) supplemented with 1% FCS and then 
opsonized with rituximab or obinutuzumab as above described. Primary cultured NK cells 
were mixed (2:1) with biotinylated anti-CD20 opsonized or not opsonized targets and co-
cultured for the indicated times.  
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At the end of stimulation cellular conjugates were mechanically disrupted by washing 
twice with 5mM ethylenediaminetetraacetic acid (EDTA) containing PBS. In order to 
immunomagnetically isolate NK populations, conjugates were incubated for 30 minutes 
at 4 °C with streptavidin-coated magnetic beads (Dynabeads Biotin Binder, Invitrogen, 
Life Technologies) at beads: cells ratio 4:1. NK populations were recovered by negative 
selection and then assayed for phenotypic, functional and biochemical analysis using as 
control population NK cells derived from the co-culture with not opsonized target cells 
(Fig. 13).  For experiments requiring lysosomal inhibitor, 20mM NH4Cl was added during 
co-culture. Where indicated, immunomagnetically isolated NK populations were re-plated 
in culture medium for up to 48 hours. 
 
	
 
Figure 13. Experimental model to obtain anti-CD20-experienced NK cells.  
 
Anti-CD20-induced in vitro expansion of “memory” NK subset   
Freshly isolated PBMCs from healthy donors were seeded (50.000 cells/well) in round-
bottom 96-well plates and cultured for 10 days in RPMI 1640 supplemented with 10% 
FCS, 1% L-glutamine, 1% Penicillin/Streptomycin plus 100 U/ml of human recombinant 
IL-2 (R&D system). Two days after cell plating, irradiated Raji cells were added (2:1) in 
the absence or presence of rituximab or obinutuzumab (10 µg/ml). Half of culture media 
was removed and replenished with media containing IL-2 every 2-3 days. At the end of 
the co-culture, cells were harvested from each culture condition and used for phenotypic 
and functional analysis. For functional assays, 10 ng/ml of IL-15 (Peprotech) were added 
during the last three days of co-culture (Fig. 14).  
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interaction
CD16
internalization
functional assays
biochemical analysis
phenotipic analysis
	 43	
 
 
 
 
 
Figure 14. Experimental setting for anti-CD20-induced in vitro expansion of “memory” NK 
cells.  
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Cytofluorimetric analysis 
Titration of anti-CD20 antibodies   
To determine the minimum saturating doses of anti-CD20 mAbs, Raji cells (1x106) were 
incubated with increasing amounts (0.05 µg, 0.1 µg, 1 µg, 10 µg, 100 µg) of rituximab, 
obinutuzumab (GA101), wt-GA101 or GA101-Fab for 20 minutes at 4°C, washed and 
then stained with FITC-conjugated GAH k light chain Ab, that specifically recognizes the 
k light chain of immunoglobulins.   
 
Determination of FcgRIIIA-158V/F allotype  
To determine FcgRIIIA-158V/F allotype, freshly isolated PBMCs were stained with APC-
conjugated anti-CD56 and the following anti-CD16 mAbs: FITC-conjugated 3G8, that 
binds to a not polymorphic epitope of CD16, or FITC-conjugated MEM-154, whose 
binding to CD16 is dependent on the presence of valine (Bottcher et al.,2005). The ratio 
between the mean fluorescence intensity (MFI) of MEM-154 and 3G8 allows to classify 
three different phenotypes: F/F (ratio <0.04), V/V (ratio >0.62), and V/F (ratio between 
0.15 and 0.48).  
 
Analysis of activating receptor expression levels  
To evaluate CD16 modulation, primary cultured NK cells were mixed (2:1) with anti-
CD20 opsonized or not opsonized Raji targets, briefly pelleted for 2 minutes at 600 rpm 
to allow conjugate formation and incubated for different lengths of time at 37°C. To block 
the stimulation, samples were treated with 0.1% NaN3 in cold PBS for 5 minutes on ice 
and then washed with 5mM EDTA containing PBS to obtain conjugate disruption. After 
washing, samples were stained with PE-conjugated anti-CD16 (B73.1) and APC- 
conjugated anti-CD56 mAbs and then fixed for 20 minutes at room temperature with 1% 
PFA. For each time point, normalized MFI was calculated as follows: (MFI of the 
stimulated sample/MFI of Ctrl sample) x 100, assuming as 100% the MFI value of NK 
cells stimulated with not opsonized targets for each time of stimulation. To examine 
activating receptor expression levels, control and anti-CD20-experienced NK populations 
were stained with PE-conjugated anti-CD16, anti-NKp46, anti-NKp30 or anti-NKG2D 
mAbs and then fixed with 1% PFA as above described.  
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Characterization of “memory” NK cell subset 
To identify “memory” NK cells, freshly isolated or cultured PBMCs were stained with 
APC-Vio770-conjugated anti-CD56, PE-Vio 770-conjugated anti-CD16 and PerCP-
Vio700-conjugated anti-CD3 mAbs and then fixed for 20 minutes at room temperature 
with 2% PFA. For the analysis of cell surface markers, samples were stained with APC-
conjugated anti-NKp46 and PE-conjugated anti-NKG2C mAbs before fixing. For 
intracellular FceRIg detection, samples were permeabilized by incubating for 30 minutes 
at room temperature with 0.05% Triton-X in 2mM EDTA and 2% FCS containing PBS, 
washed and then stained with FITC-conjugated anti-FceRIg mAb. The absolute 
number/106 of NK cells was calculated as follows: (percentage of NK cells) x 106/100.  
The absolute number/106 of “conventional” or “memory” NK subset was calculated 
according to the formula: (percentage of “conventional” or “memory” NK cells) x 
(absolute number/106 of NK cells)/100.  
 
Functional flow cytometry assays  
To determine CD16-mediated CD107a (LAMP-1) surface mobilization and intracellular 
IFN-g production, freshly isolated PBMCs or, when specified, primary cultured NK cells 
were combined (2:1) with not opsonized or anti-CD20-opsonized Raji targets for 6 hours 
at 37°C in the presence of PE-conjugated anti-CD107a mAb and 50 µM Monensin (Golgi-
stop). After the first hour, 10 µg/ml BFA was added. At the end of stimulation, cells were 
washed with PBS supplemented with 5mM EDTA to promote conjugate disruption and, 
before fixing for 20 minutes at room temperature with 2% PFA, cells were stained with 
FITC-conjugated anti-CD56 and PerCP-conjugated anti-CD3 mAbs. For intracellular 
IFN-g detection, samples were then permeabilized by incubating for 30 minutes at room 
temperature with 0.5% saponin in PBS supplemented with 1% FCS, washed and stained 
with APC-conjugated anti-IFN-g mAb.   
To determine CD107a surface expression in response to CD16 and other NK activating 
receptors, control and anti-CD20-experienced NK populations were stimulated with 
1µg/well plastic-immobilized anti-CD16 (B73.1), anti-NKG2D, anti-NKp46 and anti-2B4 
mAbs, alone or in combination and treated as above described.  
To assess the functional responses of the “memory” NK cell subset, freshly isolated or 
cultured PBMCs were allowed to interact (2:1) with not opsonized or anti-CD20-
opsonized Raji as well as with K562 targets for 6 hours at 37°C as above described.  
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At the end of stimulation, cells were washed with PBS supplemented with 2% FCS and 
2mM EDTA to promote conjugate disruption and, before fixing for 20 minutes at room 
temperature with 2% PFA, samples were stained with APC-Vio770-conjugated anti-
CD56 and PerCP-Vio700-conjugated anti-CD3 mAbs. For intracellular FceRIg and IFN-
g detection, samples were then permeabilized by incubating for 30 minutes at room 
temperature with 0.05% Triton-X in 2% FCS and 2mM EDTA containing PBS, washed 
and stained with FITC-conjugated anti-FceRIg and APC-conjugated anti-IFN-g mAbs.   
All results were analysed using FlowJo version 9.3.2 software (Tree Star, Ashland, OR). 
 
Confocal microscopy   
To evaluate the co-localization of CD16 with the lysosomal compartment, primary 
cultured NK cells were pre-treated for 30 minutes at 37°C with 10 µM LysoTracker Red 
DND-99 (Life Technologies) and then allowed to interact (2:1) with not opsonized or anti-
CD20-opsonized Raji cells previously labeled for 30 minutes at 37°C with 0.5 µM 7-
amino-4-cholromethylcoumarin (CMAC) (Life Technologies). Conjugates were gently 
re-suspended, spun onto multichamber poly-L-lysine-coated glass slides, incubated for 15 
minutes at 37°C followed by incubation at 4°C for 10 minutes to block the stimulation 
and promote spontaneous adhesion to the slide. Cells were fixed for 20 minutes at room 
temperature with 3.7% PFA, permeabilised for 5 minutes with 0.5% saponin, incubated 
for 15 minutes with 0.1 M glycin followed by Blocking Buffer (1%FCS, 0.05% saponin) 
for 10 minutes and stained with anti-CD16 (B73.1) (1 µg/1x106) followed by Alexa Fluor 
488-conjugated GAM (Invitrogen) Abs. After washing, slides were mounted with 
SlowFade Gold reagent (Life Technologies). High-resolution images (800 × 800 pixel, 8 
µs/pixel) were acquired, on randomly acquired fields, with a IX83 FV1200 laser-scanning 
confocal microscope (Olympus) with a 60×/1.35 NA UPlanSAPO oil immersion 
objective. Sequential acquisition was used to avoid crosstalk between different 
fluorophores. Fluorescence and DIC (Differential Interference Contrast) images were 
acquired with zoom3. Co-localization was assessed in NK/Raji conjugates (n=50) 
showing an extensive membrane contact between effector and target cells and expressed 
as percentage of conjugates containing co-localized CD16 and lysosomes with respect to 
total conjugates, considering co-localization indexes (Pearson’s correlation coefficient 
>0.2) obtained by FluoView 4.2 software, between two channels on single cells (ROI) 
after background correction. Images were processed with ImageJ1.41o software.  
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CD16 polymorphism analysis  
Genomic DNA was extracted from PBMCs by commercial Isolate II Genomic DNA kit 
(Bioline) in a cohort of 125 healthy donors according to manufacturer’s instructions. 
Briefly, samples (up to 107 cells) were re-suspended in Lysis Buffer GL (200 µl/sample), 
incubated at 70°C for 15 minutes with Proteinase K (25 µl/sample) in Lysis Buffer G3 
(200 µl/sample) and briefly vortexed. 96-100% ethanol (210 µl/sample) was added to the 
samples which in turn were vigorously vortexed. Samples were loaded to silica 
membrane-containing ISOLATE II Genomic DNA spin columns, placed in 2 ml 
Collection Tubes, and centrifuged 1 minute at 11.000 x g. Wash Buffer GW1 (500 
µl/sample) followed by Wash Buffer GW2 (600 µl/sample) were added to the samples 
which in turn were centrifuged 1 minute at 11.000 x g. Another centrifugation was 
performed in oder to dry silica membrane. For DNA elution, 70°C-prewarmed Elution 
Buffer G (100 µl/sample) was added to the samples loaded in ISOLATE II Genomic DNA 
spin columns placed in 1.5 ml Collection Tubes. Samples were incubated at room 
temperature for 1 minute and centrifuged 1 minute at 11.000 x g collecting flow-through. 
The concentration and the quality of the extracted DNA were determined by using 
NanoDrop 2000 (Thermo Scientific). The genomic region containing the polymorphic 
c.559 site was amplified by two distinct PCR assays, as described (Leppers-van de Straat 
et al., 2000; Quartuccio et al., 2014). Specifically, for PCR assay 1, PCR primers: 
forward1 5’-CCCTTCACAAAGCTCTGCACT-3’; reverse1 5-
ATTCTGGAGGCTGGTGCTACA-3’; sequencing primer: 5-
CCCCAAAAGAATGGACTGAA-3’: for PCR assay 2, PCR primers: forward2 5’ 
TGTAAAACGACGGCCAGTTCATCATAATTCTGACCTCT-3’, reverse2 5-
CAGGAAACAGCTATGACCCTTGAGTGATGGTGATGTTCA-3’; sequencing 
primers: 21M13 or M13. PCR products were sequenced using the BigDye Terminator 
v3.1 Cycle Sequencing Kit and a 3130xl Genetic Analyzer (Thermo Fisher Scientific) and 
analysed by the Sequencing Software Analysis 6 (Applied Biosystems).  
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Biochemical analysis  
Analysis of cellular levels of CD16-coupled signaling elements  
Control and anti-CD20 experienced NK cells were lysed 20 minutes at 4°C in 1% Triton-
X 100 lysis buffer (50 mM Tris pH7.5, 150 mM NaCl, 1 mM ethylene glycol tetraacetic 
acid (EGTA) pH8, 1 mM MgCl2 and 50 mM NaF) supplemented with 1mM each of 
phenylmethanesulfonylfluoride (PMSF) and Na3VO4 as well as with 1 µg/ml each of 
aprotinin and leupeptin. Cell lysates were centrifuged for 20 minutes at 13000 x g at 4°C, 
supernatants were collected and protein concentration was evaluated by Bradford 
colorimetric assay (Bio-Rad Laboratories). The absorbance was measured at 620 and 690 
nm by using a known concentration curve of bovine serum albumin (BSA) as standard. 
Equal protein amounts from each sample were diluted in Laemmli Sample Buffer (0.3 M 
Tris HCl, 10% SDS, 20% glycerol and 2% b-mercaptoethanol) and boiled at 95 °C. 
 
Immunoprecipitation studies  
To explore Syk ubiquitination or c-Cbl and Cbl-b tyrosine phosphorylation, CD16 
stimulation was obtained by mixing primary cultured NK cells with not opsonized or anti-
CD20-opsonized Raji cells for the indicated times at 37°C. Before mixing, targets cells 
were fixed (0.5% PFA) for 5 minutes at room temperature, washed three times with 
complete medium, incubated at 37°C for 1 hour and washed once more. At the end of 
stimulation, samples were lysed in 1% Triton-X 100 lysis buffer (see above) supplemented 
with 1 mM each of PMSF and Na3VO4 as well as with 1 µg/ml each of aprotinin and 
leupeptin as above described. Samples were pre-cleared and immunoprecipitated with 
anti-Syk or anti-Cbl-b pre-loaded protein G Sepharose beads (Sigma-Aldrich) or with 
anti-c-Cbl pre-loaded protein A Sepharose beads (GE Healthcare Life Science) for 2 hours 
at 4°C. Immunoprecipites were washed five times with lysis buffer supplemented as above 
described. Proteins were eluted using 50 µl/sample of Laemmli Sample Buffer and boiled 
at 95 °C. 
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SDS-polyacrylamide gel electrophoresis (PAGE) and Western Blotting  
Depending on the experiment, whole lysates or immunoprecipitated samples were 
separated by SDS-PAGE. SDS-PAGE maintains polypeptides in a denatured state once 
they have been treated with strong reducing agents to remove secondary and tertiary 
structure (disulfide bonds and sulfhydryl groups) thus allowing separation of proteins by 
their molecular weight. Sample proteins become covered in the negatively charged SDS 
and move to the positively charged electrode through the acrylamide mesh of the gel and 
transferred to a nitrocellulose membrane. Blocking of non-specific binding was achieved 
by 5% Bovine Serum Albumin (BSA) in TBS-T (20 mM Tris-HCl pH 7.8, 150 mM NaCl, 
0.05% Tween-20). Membranes were incubated with the proper primary antibodies, 
followed by a secondary peroxidase-linked antibody. Enhanced chemiluminescence 
(ECL) (Amersham Pharmacia Biotech) was used to detect the signal.  
 
Cytotoxicity assay  
To analyse the cytotoxic response primary cultured or control and anti-CD20 experienced 
NK populations were assessed in standard 51Cr-release assays. Briefly, target cells were 
labeled with 51Cr (Amersham) (100 µCi/1x106 cells) for 1 hour at 37°C and then washed 
twice. In ADCC assays, rituximab- or obinutuzumab-opsonized or not opsonized 51Cr-
labeled Raji cells were used as targets. In redirected killing assays 51Cr-labeled FcR+ P815 
cells were used as targets in the presence of anti-CD16, anti-NKp46, anti- NKp30 or anti-
NKG2D mAbs. Serial dilutions of effector cells and 5000/well 51Cr-labelled target cells 
were plated in round-bottom 96-well plates in a final volume of 200 µl RPMI 
supplemented with 10% FCS, 1% L-glutamine and 1% Hepes at effector:target (E:T) 
ratios ranging from 50:1 to 0.04:1. After 4 hours at 37°C, 30 µl of supernatants were 
collected from each well and counted by a b-counter instrument (TopCount, PerkinElmer 
Life and Analytical Sciences). Maximal and spontaneous releases were obtained by 
incubating 51Cr-labeled individual targets, used for each stimulation condition, with SDS 
10% or medium alone, respectively. The percentage of specific lysis was calculated 
according to the formula: (experimental release-spontaneous release) / (maximal release-
spontaneous release) x 100. Where indicated, results were reported also as lytic units that 
have been defined as the number of effector cells required to mediate 10% specific lysis 
of target cells. Lytic units for 1×106 effector cells were calculated as follows: 1×106 / (n. 
of target cells × X), where X is the E:T ratio resulting in 10% specific lysis.  
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Enzyme-linked immunosorbent assays (ELISA)  
IFN-γ release 
Control and anti-CD20-experienced NK cells were mixed (2:1) with the indicated targets 
in the presence or absence of recombinant human IL-12 (10 ng/ml) (Peprotech) or IL-2 
(100 U/ml) (R&D Systems) for 18 hours at 37°C. Supernatants were then collected and 
analysed by a commercial ELISA kit (Thermo Scientific) according to the manufacturer’s 
instructions. Briefly, 50 µl of supernatants were incubated for 2 hours with a biotinylated 
antibody (Biotinylated Antibody Reagent) in anti-human IFN-γ pre-coated 96-well Stripe 
Plate. After 3 washes, 100 µl/well of Streptavidin-HRP Solution were added and the plate 
was incubated for 30 minutes at room temperature. Concentrated chromogen substrate 
Tetramethylbenzidine (TMB) (100 µl/well) was added to allow color reaction. The 
reaction was stopped by adding 100 µl/well of Stop Solution and the absorbance was 
measured on an ELISA plate reader at 450 nm and normalized by using the standard curve 
of recombinant human IFN-γ.  
 
Serological status for human Cytomegalovirus (HCMV)  
The anti-HCMV IgG titre was determined, in donor plasma samples, by using Human 
Anti-Cytomegalovirus (CMV) IgG ELISA Kit (Abcam) according to the manufacturer’s 
instructions. Briefly, 100 µl/well of controls (IgG Positive, IgG Negative and IgG Cut-
off) or test samples, diluted 1: 100 with IgG Sample Diluent, were added to a 96-well 
Stripe Plate pre-coated with HCMV antigens and incubated at 37°C for 1 hour. After three 
washes, 100 µl/well of horseradish peroxidase (HRP) labelled anti-Human IgG Conjugate, 
which binds to the immobilized HCMV-specific antibodies, were added to the wells and 
the plate was incubated for 30 minutes at room temperature. After three washes, 100 
µl/well of chromogen substrate Tetramethylbenzidine (TMB) were added to each well and 
the plate was incubated for 15 minutes at room temperature in the dark to allow color 
reaction. The reaction was stopped by adding 100 µl/well of Stop Solution and the 
absorbance was measured on an ELISA plate reader at 450 nm. Samples with an 
absorbance value greater than 10% over the cut-off control value are considered positive. 
By contrast, if the absorbance value is lower than 10% below the cut-off control value, 
samples are considered negative. Finally, samples with an absorbance value of less than 
10% above or below the cut-off control value should be considered as inconclusive (grey 
zone) i.e. neither positive or negative. Results were reported in Standard Units according 
to the formula: sample absorbance value x 10 / cut-off control value.  
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Statistical and densitometric analysis 
Differences among multiple groups were compared by one-way ANOVA with Tukey 
post-test correction, by Friedman with Dunn’s post-test correction, or by two-way 
ANOVA with Bonferroni post-test correction, as appropriated. Differences between two 
groups were determined by performing Wilcoxon matched pairs test or Mann Whitney 
test. Differences were considered to be statistically significant when p value was less than 
0.05. Analyses were performed using Prism 5 software (GraphPad). Quantification of 
specific bands was performed with ImageJ1.41o software (National Institutes of Health, 
Bethesda, MD). 
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DATA ANALYSIS
Results in Standard Units
Patient (mean) absorbance value x 10   =   Standard Units 
         Cut-off
Example:   1.786 x 10    =   47  Standard Units
                             0.38
Cut-off: 10 Standard Units
Grey zone: 9-11 Standard Units
Negative: <9 Standard Units
Positive: >11 Standard Units
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Results 
1. CD16 engagement by obinutuzumab-opsonized targets results in 
enhanced cytotoxicity and IFN-g production 
 
It is well-known that obinutuzumab was glyco-engineered by de-fucosylation of its Fc 
portion and that this modification substantially enhances the antibody binding affinity for 
CD16 receptor consequently improving the killing of mAb-opsonized targets via both 
ADCC and ADCP (Mossner et al., 2010; Bologna et al., 2011; Golay et al., 2013; Herter 
et al., 2014). While the increased ability of obinutuzumab to induce NK cell-mediated 
ADCC has been widely proven (Bologna et al., 2011; Gagez & Cartron, 2014; Terszowski 
et al., 2014), no studies addressed its ability to induce cytokine production by NK cells. 
In order to investigate the impact of CD16 affinity ligation conditions on the full NK 
functional program, we compared the ability of rituximab or obinutuzumab, in the 
defucosylated (GA101) or wild type (wt-GA101) version, to stimulate NK cell 
degranulation and/or cytokine production. To this end, in peripheral blood NK cells 
interacting with anti-CD20 opsonized targets we investigated, by multicolor flow 
cytometry both the intracellular production of IFN-g and the surface expression of 
CD107a, which is a useful tool to evaluate lytic granule release since it becomes detectable 
at plasma membrane upon lytic granule exocytosis (Alter et al., 2004). Hereafter, we 
stimulated CD16 by combining NK cells with CD20+ B cell lymphoma Raji cell line 
opsonized with anti-CD20 mAbs used at saturating concentrations as illustrated in            
Fig. 15. 
 
 
Figure 15. Determination of minimum saturating doses of anti-CD20 monoclonal antibodies 
on Raji cell line. The CD20+ human lymphoblastoid Raji cells were incubated with the indicated 
doses of rituximab (RTX), obinutuzumab (GA101) or wt-GA101 followed by PE-conjugated 
GAH Ab or with the indicated doses of obinutuzumab Fab fragment (GA101-Fab) followed by 
FITC-conjugated GAH k light chain Ab for FACS analysis. The overlays of histograms from one 
representative experiment are shown. Gray histogram represents GAH Ab.  
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As reported in Fig. 16A and B, while the NK cell interaction with not opsonized targets, 
that we kept as control population, did not result in significant CD107a surface expression 
and IFN-g production, the interaction with rituximab-opsonized Raji promoted both 
degranulation and IFN-g production with a higher portion of degranulating than of IFN-g 
producing cells, thus confirming the hierarchy existing in NK cell functions (Fauriat et 
al., 2010). Moreover, under such CD16 aggregation conditions only few NK cells 
acquired the ability to both degranulate and produce IFN-g. On the other hand, NK cell 
stimulation with obinutuzumab-opsonised Raji resulted not only in an increased 
degranulation, as described in literature, but also in an enhanced IFN-g production with 
respect to rituximab. Notably, the portion of NK cells that performed both degranulation 
and IFN-g production appeared almost twice in response to obinutuzumab- than to 
rituximab-opsonized targets. It was evident that this increased ability of obinutuzumab to 
activate NK cells was due to its defucosylated status. In fact, wt-GA101 was less efficient 
and superimposable to rituximab in stimulating NK responses. Moreover, as shown by the 
median fluorescence intensity values reported in Fig. 16C, also the IFN-g amount on a per 
cell basis appeared enhanced in response to obinutuzumab-opsonized Raji cells.   
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Figure 16. CD16 engagement by obinutuzumab-opsonized targets enhances both CD107a 
mobilization and IFN-g production in freshly isolated NK cells. PBMCs were left alone 
(baseline) or combined (2:1) with rituximab (Raji-RTX)-, obinutuzumab (Raji-GA101)-, wt-
GA101 (Raji-wt-GA101)-opsonized or not opsonized Raji (Raji-Ctrl) for 6 hours. The percentages 
of IFN-g+ and CD107a+ cells among NK cells (CD3-CD56+) were analysed by flow cytometry. 
(A) Plots from one representative donor are shown. (B) Data (mean ± SEM) from 9 donors are 
presented as median with the interquartile range. *p < 0.05, **p < 0.01, ***p < 0.0001. Compared 
to baseline or Raji-Ctrl samples, all the differences were statistically significant (p < 0.0001). (C) 
The median fluorescence intensity (FI) values of IFN-g+ NK cells from 9 individuals are reported 
in the graph. Each line represents a single donor. **p < 0.01, ***p < 0.0001.  
 
In line with data obtained in peripheral blood NK cells, we observed that in response to 
obinutuzumab also primary cultured NK cells exhibited an increased killing ability, 
evaluated by a standard chromium-release based ADCC assay (Fig. 17A), as well as an 
enhanced IFN-g producing potential, evaluated by flow cytometry (Fig. 17B).  
 
 
Figure 17. Obinutuzumab-mediated CD16 aggregation induces an enhanced ADCC and 
IFN-g production in primary cultured NK cells. (A) Primary cultured NK cells were assessed 
in a standard 51Cr-release ADCC assay against rituximab (Raji-RTX)-, obinutuzumab (Raji-
GA101)-opsonized or not opsonized (Raji-Ctrl) targets. Specific lysis from 4 independent 
experiments is shown (mean ± SD). (B) Primary cultured NK cells were left alone (baseline) or 
allowed to interact (2:1) with rituximab (Raji-RTX)-, obinutuzumab (Raji-GA101)-opsonized or 
not opsonized (Raji-Ctrl) targets for 6 hours. The percentage of IFN-g+ cells was analysed by flow 
cytometry gating on CD56+ population. Data from 4 independent experiments (mean ± SEM) are 
shown. *p < 0.05, **p < 0.001, ***p < 0.0001.  
 
 
Overall our results show that, due to its defucosylation, obinutuzumab improves NK cell 
functions also inducing multiple effector responses in individual NK cells.  
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2. CD16 engagement by obinutuzumab-opsonized targets promotes an 
enhanced receptor down-modulation and lysosomal targeting 
 
Several groups, including ours, demonstrated that upon interaction with anti-CD20 coated 
targets CD16 receptor undergoes a marked surface down-modulation (Bowles & Weiner, 
2005; Bowles et al., 2006; Veeramani et al., 2011; Zent et al., 2014; Capuano et al 2015). 
In order to investigate the impact of CD16 affinity ligation conditions on receptor 
dynamics, we compared the ability of rituximab or obinutuzumab, in the defucosylated 
(GA101) or wild type (wt-GA101) version, to induce CD16 surface down-modulation. To 
this end, by flow cytometry we monitored the CD16 expression levels in primary cultured 
NK cells interacting, for different lengths of time, with anti-CD20-opsonized Raji cells by 
using B73.1 mAb, whose binding to CD16 is not affected by Fc masking (Grier et al., 
2012). As reported in Fig. 18, we observed that, NK cell stimulation with anti-CD20-
opsonized targets resulted in a progressive and marked CD16 surface down-modulation 
with maximal levels between 2 and 18 hours of interaction. However, in response to 
obinutuzumab-opsonized targets, the down-modulation of CD16 was faster and deeper, 
leaving almost a 20% of residual receptor surface levels. It was evident that this increased 
ability of obinutuzumab to induce CD16 surface down-modulation was due to its 
enhanced CD16 binding affinity obtained by defucosylation. In fact, wt-GA101 was 
overall less efficient and superimposable to rituximab in inducing receptor down-
modulation.  
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Figure 18. CD16 engagement by anti-CD20-opsonized targets induces receptor down-
modulation. Primary cultured NK cells were combined (2:1) for the indicated times with 
rituximab (Raji-RTX)-, obinutuzumab (Raji-GA101)-, wt-GA101 (Raji-wt-GA101)-opsonized or 
not opsonized Raji (Raji-Ctrl). CD16 surface expression was evaluated by FACS analysis by anti-
CD16 (Leu11c) mAb gating on CD56+ population. (Upper panels) The overlays of histograms 
from one representative experiment are shown. (Lower panel) Normalized CD16 MFI was 
calculated as follows: (MFI of the stimulated sample/MFI of Ctrl sample) x 100, assuming as 
100% the MFI value of NK cells co-cultured with not opsonized (Raji-Ctrl) targets for each time 
of stimulation. Data (mean ± SEM) from 6 independent experiments are shown. *p < 0.05. 
 
Based on these data, we then investigated the persistency of the CD16 surface down-
modulated status. To this end, by flow cytometry we assessed the CD16 expression levels 
in primary cultured NK cells immuno-magnetically derived from 18 hour co-cultures with 
biotinylated anti-CD20-opsonized or not opsonized Raji cells (hereafter defined 
“experienced” NK cells) and cultured for different lengths of time after target detachment. 
As shown in Fig. 19, we observed a progressive and almost complete recovery of CD16 
expression levels within 48 hours.  
 
 
Figure 19. Surface CD16 levels undergo progressive recovery in anti-CD20-experienced NK 
cells. Primary cultured NK cells were isolated upon 18 hours co-culture (2:1) with biotinylated 
rituximab (RTX-exp)-, obinutuzumab (GA101-exp)-opsonized or not opsonized Raji (Ctrl-exp), 
re-plated for the indicated times and analysed for CD16 surface expression by FACS analysis. Bar 
graph depicts the normalized CD16 MFI calculated for each time point as follows: (MFI of the 
stimulated sample/MFI of Ctrl sample) x 100, assuming as 100% the MFI value of NK cells 
isolated from co-culture with not opsonized (Ctrl-exp) targets. Data (mean ± SEM) from 8 
independent experiments are reported in bar graph. *p < 0.05. 
 
It has been reported that both internalization (Capuano et al., 2015) and receptor shedding 
mediated by metalloproteases such as ADAM-17 (Romee et al., 2013) may contribute to 
anti-CD20 induced CD16 surface down-modulation. By confocal fluorescence 
microscopy we evaluated the fate of the down-regulated CD16 receptor. With the aim to 
address CD16 lysosomal targeting we used the lysosome marker Lysotracker. 
Lysotracker-labeled primary cultured NK cells were stimulated with anti-CD20-
opsonized Raji cells for 15 minutes. To discriminate target cells in cellular conjugates, we 
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took advantage of cell tracker CMAC. As shown in Fig. 20A, with respect to the ring 
pattern of CD16 receptor observed in unconjugated NK cells, in anti-CD20-stimulated 
NK cells, CD16 distributed in intracellular dots thus confirming the occurrence of an 
internalization process, as already demonstrated for other immune-receptors (Quatrini et 
al., 2015). By evaluating E/T conjugates in randomly acquired fields, we observed that a 
substantial portion of internalized CD16 receptor co-localized with lysosomes (Fig. 20A) 
and that the percentage of conjugated NK cells with CD16/lysosome co-localization was 
significantly higher in response to obinutuzumab- than to rituximab- or wt-GA101-
opsonized Raji cells (Fig. 20B).  
 
 
Figure 20. CD16 engagement by anti-CD20-opsonized targets induces receptor lysosomal 
targeting. (A) LysoTracker-labeled NK cells (red) were combined (2:1) for 15 minutes with 
CMAC-labeled rituximab (NK/Raji-RTX)-, obinutuzumab (NK/Raji-GA101)- or wt-GA101 
(NK/Raji-wt-GA101)-opsonized targets (blue). Cell conjugates were fixed, permeabilized and 
stained with anti-CD16 (B73.1) followed by Alexa Fluor 488-GAM (green) Abs. A representative 
image of NK/target conjugate and isolated NK cell are shown. The overlay of the three-color 
merged image and the differential interference contrast (DIC) is shown. Scale bar, 5µm. (B) The 
percentage of conjugates containing CD16/lysosome co-localization (Pearson’s correlation 
coefficient > 0.2) was analysed on randomly acquired fields of 3 independent experiments (mean 
± SEM; n=50 conjugates). *p < 0.05, **p < 0.01. 
 
 
Overall our data indicate that obinutuzumab induces a more rapid and profound CD16 
surface down-modulation as well as an enhanced co-localization of the internalized 
receptor with lysosomes.  
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3. Preferential FceRIg degradation induced by obinutuzumab: impact of 
FCGR3A-V158F polymorphism  
 
Several studies demonstrated that polymorphisms exist in the gene FCGR3A encoding for 
CD16 receptor and that the single nucleotide polymorphism (FCGR3A c.559G > T) 
resulting in valine (V) or phenylalanine (F) expression at aminoacid position 158 
(FCGR3A-V158F) influences CD16 binding affinity for the Fc portion of IgG by 
generating a lower (FcgRIIIA-158F) or higher (FcgRIIIA-158V) affinity receptor variants. 
In particular, it is known that the clinical response rate to rituximab therapy may be 
affected by the different CD16 allotypes. In fact, it has been observed that individuals 
homozygous for phenylalanine (F/F) showed a worse response rate to rituximab therapy 
due to a reduced CD16 binding affinity for the antibody Fc portion (Rascu et al., 1997; 
Cartron et al., 2002; Persky et al., 2012). In this regards, we investigated the impact of 
FCGR3A-V158F polimorphism on CD16 aggregation and dependent functions induced 
by anti-CD20 mAbs. To this end, we typed healthy donors by cytofluorimetric analysis 
(Bottcher et al., 2005) by staining donor-derived PBMCs with two different anti-CD16 
mAbs: 3G8 and MEM-154, that specifically recognizes residues of valine at CD16 
aminoacid position 158. Based on the MEM/3G8 MFI ratio, we classified the donors in 
low (F/F)-, intermediate (V/F)- or high (V/V)-affinity (Fig. 21A lower panels) and data 
obtained were compared and confirmed by sequencing approaches (Fig. 21A upper 
panels) as described in literature (Leppers-van de Straat et al., 2000; Quartuccio et al., 
2014). Among our cohort of 125 donors, 21 and 34 were V/V and F/F homozygous 
respectively while 70 were V/F heterozygous thus confirming a higher frequency of the 
intermediate (V/F) or high (V/V) affinity individuals (Fig. 21B). As shown in Fig. 21C, 
when we compared the ability of rituximab and obinutuzumab to induce CD107a surface 
mobilization on peripheral blood NK cells among different CD16 genotypes, we noted 
that, in low (F/F) affinity donors, NK cells degranulated better in response to 
obinutuzumab than to rituximab. This was in line with the widely described ability of 
obinutuzumab to promote an increased ADCC regardeless of the CD16 genotype, thus 
overcoming the individual heterogeneity in therapy response (Terszowski et al., 2014; 
Herter et al., 2013). 
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Figure 21. CD16 engagement by obinituzumab-opsonized targets results in enhanced 
degranulation irrespective of FCGR3A-V158F polymorphism. (A) The low (F/F)-, 
intermediate (V/F)- and high (V/V)-affinity variants of FcgRIIIA/CD16 were assessed by 
sequencing and cytofluorimetric approaches. (Upper panels) Genomic DNA from PBMCs was 
amplified by PCR and sequenced. (Lower panels) PBMCs were evaluated by flow cytometry upon 
staining with the FITC-conjugated anti-CD16 antibody 3G8 or MEM-154 and donors were typed 
on the basis of the MEM/3G8 MFI ratio. (B) The distribution of the CD16 polymorphic variants 
observed in a cohort of 125 donors is reported in the pie chart. (C) PBMCs were left alone 
(baseline) or allowed to interact (2:1) with rituximab (Raji-RTX)-, obinutuzumab (Raji-GA101)-
opsonized or not opsonized (Raji-Ctrl) Raji cells for 6 hours. The percentage of CD107a+ cells 
was evaluated by FACS analysis gating on NK population (CD3-CD56+) in individuals grouped 
by FCGR3A genotype (high-affinity V, low-affinity F; V/V, n=6; V/F, n=6; F/F, n=6). Data are 
presented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001. For each group, compared to 
baseline or Raji-Ctrl samples, all the differences were statistically significant (p < 0.001).  
 
Furthermore, we also investigated the impact of FCGR3A-V158F polymorphism on 
CD16 dynamics induced by anti-CD20 mAbs. To this purpose, we compared the ability 
of rituximab and obinutuzumab to induce CD16 surface down-modulation among 
different CD16 genotypes evaluating by flow cytometry the receptor expression levels in 
experienced NK cells. As shown in Fig. 22A, we found that, in low (F/F) affinity donors, 
only obinutuzumab induced a significant CD16 surface down-modulation. Indeed, while 
rituximab-induced CD16 down-modulation was less marked in F/F donors than in V/F or 
V/V donors, in response to obinutuzumab receptor down-modulation was enhanced and 
not substantially affected by the CD16 genotype.  
It is well-established that, in NK cells, CD16 receptor is associated with homo or 
heterodimers of CD3z and/or FceRIg signaling chains (Letourneur et al., 1991).  
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In experienced NK cells, we evaluated by biochemical approaches the cellular levels of 
both CD3z and FceRIg chains among different CD16 genotypes. Data obtained 
highlighted that in low (F/F) affinity donors only obinutuzumab induced a selective and 
marked decrease of FceRIg chain, being CD3z chain only marginally affected (Fig. 22B 
and C). Conversely, as reported in Fig. 22D and 22E, we noted that both rituximab-and 
obinutuzumab-mediated CD16 aggregation promoted FceRIg and, to a lesser extent, 
CD3z chain down-modulation in intermediate (V/F) and high (V/V) affinity donors. 
Moreover, as shown in Fig. 22B to E, we also found that the down-regulation of FceRIg 
and CD3z chains was in part due to lysosomal degradation since it was partially, but 
significantly, reverted in the presence of the lysosome inhibitor ammonium chloride 
(NH4Cl).   
 
Figure 22. CD16 engagement by obinituzumab-opsonized targets results in enhanced FceRIg 
lysosomal degradation irrespective of FCGR3A-V158F polymorphism. Primary cultured NK 
cells (n=5/genotype) were isolated upon 18 hours co-culture (2:1) with biotinylated rituximab 
(RTX-exp)-, obinutuzumab (GA101-exp)-opsonized or not opsonized Raji (Ctrl-exp) in the 
presence of medium alone (medium) or, when indicated, with 20mM NH4Cl. (A) CD16 surface 
expression was evaluated by FACS analysis by anti-CD16 (Leu11c) mAb in individuals grouped 
by FCGR3A genotype. (Upper panels) Histogram overlay of one representative donor/genotype 
is shown and (lower panel) normalized CD16 MFI values calculated as described in Fig. 2A are 
depicted in bar graph (mean ± SEM). *p < 0.05. (B,D) An equal amount of proteins from whole 
cell lysates was immunoblotted as indicated. The same membrane was immunoblotted with anti-
FceRIg and, after stripping, with anti-CD3z Abs followed by anti-b-tubulin for sample 
normalization. Membranes containing untreated- (medium) or NH4Cl-treated samples were 
developed in the same film. The black vertical lines indicate that intervening lanes were sliced 
out. The numbers represent the relative protein amount of the indicated proteins obtained by 
normalizing to the level of b-tubulin and expressed as fold change respect to Ctrl-exp samples 
(arbitrarily set to 1). One representative experiment is shown. (C,E) The relative values (mean ± 
SEM) of CD3z or FceRIg chains from 5 independent experiments are depicted in bar graphs. *p 
< 0.05, **p < 0.01. 
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Then we focused our analysis on intermediate (V/F) and high (V/V) affinity donors in 
which both rituximab and obinutuzumab were able to induce lysosomal degradation of 
FceRIg and, to a lesser extent, of CD3z chains. As shown in Fig. 23A, we analysed the 
cellular levels of CD16-dependent tyrosine kinases. Data obtained by biochemical 
approaches showed that the cellular levels of Syk, but not of ZAP-70, kinase were 
markedly down-regulated in anti-CD20-experienced NK cells. It has been reported a key 
role of ubiquitin modification in Syk degradation in response to CD16 stimulation (Paolini 
et al., 2001). With the aim to investigate whether the anti-CD20-mediated receptor 
aggregation could promote Syk ubiquinitination, primary cultured NK cells were allowed 
to interact with fixed anti-CD20 opsonized or not opsonized Raji cells. In Syk 
immunoprecipitated samples, we evaluated the levels of tyrosine phosphorylation and 
ubiquitination, using as negative control the obinutuzumab monovalent Fab fragment 
which does not bind to CD16. As illustrated in Fig. 23B, the immunoblot analysis of Syk 
immunoprecipitates revealed that CD16 stimulation by anti-CD20 mAbs induced a rapid 
tyrosine phosphorylation of Syk with a pattern consisting of multiple molecular species 
with a regular increase of the molecular weight, thus suggesting that ubiquitination 
process has occured. Indeed, the immunoblotting with anti-ubiquitin Ab visualized 
multiple bands in the region of phosphorylated Syk. Interestingly, Syk ubiquitin 
modification resulted more persistent and stronger in NK cells interacting with 
obinutuzumab- than with rituximab-opsonized targets.                               
Cbl proteins are known to act, upon tyrosin phosphorylation, as ubiquitin ligases driving 
the ubiquitination of several molecules and their sorting to lysosomes for degradation 
(Molfetta et al., 2014). Based on these evidences, we focused our interest on Cbl ligases. 
The analysis of c-Cbl and Cbl-b tyrosine phosphorylation levels did not reveal major 
differences in rituximab- and obinutuzumab-stimulated NK cells (Fig.23C).  
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Figure 23. CD16 engagement by anti-CD20-opsonized targets promotes Syk kinase 
ubiquitination and the tyrosine phosphorylation of c-Cbl and Cbl-b ligases. (A) Primary 
cultured NK cells from V/F and V/V individuals were isolated upon 18 hours co-culture (2:1) with 
biotinylated rituximab (RTX-exp)-, obinutuzumab (GA101-exp)-opsonized or not opsonized Raji 
(Ctrl-exp). (Left panel) An equal amount of proteins from whole cell lysates was immunoblotted 
with anti-Syk or anti-ZAP-70 followed by anti-b-tubulin mAbs as indicated. One representative 
experiment is shown. (Right panel) Syk protein amounts were calculated by normalizing to the 
levels of b-tubulin. Data (mean ± SEM) from 5 independent experiments are depicted in bar graph. 
**p < 0.005, ***p < 0.0005.  (B,C) Primary cultured NK cells from V/F individuals were allowed 
to interact (2:1) with rituximab (Raji-RTX)-, obinutuzumab (Raji-GA101)-, obinutuzumab Fab 
fragment (Raji-GA101-Fab)-opsonized or not opsonized (Raji-Ctrl) fixed Raji for the indicated 
times. (B) Syk immunoprecipitates were run on the 8% SDS-PAGE and sequentially 
immunoblotted with anti-Syk followed by anti-ubiquitin, and, after stripping, with anti-
phosphotyrosine (pY) mAbs, as indicated. The position of molecular weight markers is reported. 
For ubiquitin analysis, different times of exposure of the same membrane are shown. One 
representative of 3 independent experiments is shown. (C) Cell lysates were splitted and 
immunoprecipitated with anti-c-Cbl or anti-Cbl-b Abs. Immunoprecipitates were run on 8% SDS-
PAGE and immunoblotted with the indicated Abs. One representative of 3 independent 
experiments is shown. 
 
Overall our results demonstrate that the affinity ligation conditions dictate the ability of 
anti-CD20 mAbs to induce CD16 internalization and lysosomal degradation of receptor-
associated signaling molecules with FceRIg chain and Syk kinase being more susceptible 
to degradative event. Further, while in intermediate/high affinity donors both rituximab 
and obinutuzumab behave similarly in inducing the degradation of FceRIg and, at lower 
degree, of CD3z chain and Syk kinase, in low affinity donors only obinutuzumab activates 
a degradative pathway selectively involving FceRIg chain. 
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4. NK cell interaction with anti-CD20-opsonized targets results in the 
impairment of NKp46 and NKp30-dependent cytotoxic response  
 
Several evidences demonstrated that the exhaustion of the NK cell cytolytic potential may 
contribute to the resistance to anti-CD20 mAb-based immunotherapy, thus limiting the 
clinical efficacy in patients with hematological malignancies (Berdeja et al., 2007; 
Hatjiharissi et al., 2007; Taylor & Lindorfer, 2010; Veeramani et al., 2011; Capuano et 
al., 2015). In this regards, we assessed whether the anti-CD20-induced CD16 receptor 
complex internalization and degradation, leading to reduced cellular levels of FceRIg, 
CD3z chains and Syk kinase, could impact on NK cytolytic potential. Besides ADCC, NK 
cells also mediate the spontaneous/natural cytotoxicity which is regulated by a balance of 
signals derived from the aggregation of multiple inhibitory and activating receptors and 
which requires the simultaneous engagement of different activating receptors by the 
ligands expressed by target cells (Lanier, 2008; Long et al., 2013). With the aim to explore 
the ability of ITAM-dependent or -independent activating receptors to induce cytotoxicity, 
experienced NK cells, derived from intermediate (V/F) or high (V/V) affinity donors, were 
tested in a standard chromium-release based redirected killing assay in the presence of 
anti-CD16, anti-NKp46, anti-NKp30 or anti-NKG2D mAbs. As control population we 
used NK cells isolated from not opsonized targets. As expected, on the basis of the reduced 
expression levels of CD16, we observed that in anti-CD20 experienced NK cells CD16-
dependent killing (reverse ADCC) was strongly compromised (Fig. 24A).  Moreover, we 
also noted that both rituximab- and obinutuzumab-experienced NK cells exhibited a 
significant impairment of the killing activity induced by NKp46 and NKp30 (Fig. 24A), 
which share with CD16 the CD3z and FceRIg chains (Kruse et al., 2014). Conversely, the 
statistical analysis of lytic units (LU) reported in Fig. 24A showed that in anti-CD20 
experienced NK cells the killing activity induced by NKG2D, which signals through 
DAP10 molecular adaptor (Long et al., 2013), was not affected. Finally, data obtained by 
cytofluorimetric analysis highlighted a partial decrease of NKp46 surface levels in anti-
CD20 experienced NK cells (Fig. 24A), thus confirming a non-redundant role for CD3z 
and FceRIg chains as molecular chaperones for the surface expression of this receptor.  
 
 
 
 
	 64	
To confirm these functional data, we explored the ability of experienced NK cells to 
secrete lytic granules in response to activating receptor stimulation. To this end, we 
evaluated, by flow cytometry, the CD107a surface expression levels in experienced NK 
cells stimulated for 4 hours with plastic-immobilized mAbs specific for different 
activating receptors, alone or in combination. As shown in Fig. 24B, we found that the 
degranulation induced by CD16 or NKp46 is also strongly compromised in anti-CD20 
experienced NK cells. No differences with respect to the control population were observed 
following stimulation of NKG2D and 2B4, all CD3z- and FceRIg-independent activating 
receptors, which are able to induce degranulation only when engaged in paired 
combinations (Bryceson et al., 2006).  
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Figure 24. CD16 engagement by anti-CD20-opsonized targets results in the impairment of 
FceRIg- and CD3z-dependent NKp46- and NKp30-mediated killing. (A) Primary cultured NK 
cells from V/F and V/V individuals (n=5) were isolated upon 18 hours co-culture (2:1) with 
biotinylated rituximab (RTX-exp)-, obinutuzumab (GA101-exp)-opsonized or not opsonized Raji 
(Ctrl-exp). Cells were stained as indicated for FACS analysis and tested in 51Cr-release redirected 
killing assays toward P815 FcR+ cells in presence of Abs for the indicated receptors. Histogram 
overlays and the specific lysis from one representative experiment of 5 performed are shown. Grey 
histogram represents isotype control Ab. Lytic units (LU) from 5 independent experiments are 
shown. Bar graphs depict mean ± SEM. *p < 0.05, **p < 0.005, ***p < 0.0005. (B) NK cells as 
in A were stimulated for 4 hours with the indicated plastic-immobilized mAbs. The percentage of 
CD107a+ cells was evaluated by FACS analysis gating on CD56+ cells.  Data (mean ± SEM) from 
3 independent experiments are shown. **p < 0.01, ***p < 0.001.  
 
We also assessed the cytotoxic activity of experienced NK cells derived from low (FF) 
affinity donors. In line with the lack of CD16 adaptor degradation in response to rituximab 
reported in Fig. 8B and C, we observed that the killing activity induced by NKp46 (Fig. 
25A) and NKp30 (Fig. 25B) was less compromised in rituximab- than in obinutuzumuab-
experienced NK cells.  
 
 
 
Figure 25. NKp46- and NKp30-mediated killing in anti-CD20 experienced cells from F/F 
individuals. Primary cultured NK cells from F/F individuals were isolated upon 18 hours co-
culture (2:1) with biotinylated rituximab (RTX-exp)-, obinutuzumab (GA101-exp)-opsonized or 
not opsonized Raji (Ctrl-exp). Cells were tested in 51Cr-release redirected killing assays toward 
P815 FcR+ cells in presence of anti-NKp46 (A) or anti-NKp30 (B) mAbs. (Left panels) The 
percentage of specific lysis from one representative experiment of 3 performed is shown. (Right 
panels) Lytic units (LU) from 3 independent experiments are shown. Bar graphs depict mean ± 
SEM. *p < 0.05, **p < 0.005.  
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Taken together these data provide evidences that anti-CD20-induced CD16 receptor 
complex internalization and degradation promotes a hyporesponsive status of NK cells by 
inducing cross-tolerance of the CD3z- and FceRIg-dependent, but not independent, 
activating receptors.   
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5. Obinutuzumab-experienced NK cells are primed for IFN-g production 
 
Several studies demonstrated that cytotoxic activity and cytokine production can be 
uncoupled in NK cells (Rajasekaran et al., 2013). In this regards, we explored whether 
anti-CD20-induced internalization and degradation of CD16 receptor complex could 
impact on IFN-g producing potential. To this end, we evaluated the ability of experienced 
NK cells, from intermediate (VF) or high (VV) affinity donors, to secrete IFN-g in 
response to different stimuli. Experienced NK cells, which were maintained in culture for 
12 hours upon target detachment to allow a partial CD16 re-expression, were stimulated 
for 18 hours. As control population we used NK cells isolated from not opsonized targets. 
In spite of the lower CD16 expression levels observed in obinutuzumab-experienced NK 
cells (Fig. 26A, yellow highlight) we found that they efficiently released IFN-g in response 
to obinutuzumab re-stimulation (Fig. 26B, blue highlight) behaving similarly to control 
and rituximab-experienced NK cells. On the opposite CD16 re-stimulation by rituximab 
was ineffective in inducing IFN-g release in anti-CD20 experienced NK cells (Fig. 26B). 
Importantly, when we evaluated the ability of experienced NK cells to repond to cytokine 
stimulation, we observed that IFN-g production induced by IL-12 or IL-2 treatment was 
substantially higher in obinutuzumab- with respect to control or rituximab-experienced 
NK cells (Fig. 26C, red highlight). Further, when we evaluated the ability of experienced 
NK cells to respond to target cells, we found that IFN-g production induced by Raji cells 
was increased in obinutuzumab- but not in rituximab-experienced NK cells, with respect 
to the control population (Fig. 26B, green highlight), thus indicating that obinutuzumab-
experienced NK cells were more prone to respond to the activating receptors engaged by 
target-expressed ligands (Joyce et al., 2011).  
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Figure 26. Obinutuzumab-experienced NK cells exhibit an enhanced IFN-g production in 
response to cytokines, targets or obinutuzumab re-stimulation. Primary cultured NK cells 
were isolated upon 90 minute co-culture (2:1) with biotinylated rituximab (RTX-exp)-, 
obinutuzumab (GA101-exp)-opsonized or not opsonized Raji (Ctrl-exp) and re-plated for 12 
hours. (A) NK cells were stained with anti-CD16 (Leu11c) mAb for FACS analysis. Graph depicts 
CD16 MFI and data are presented as median with the interquartile range. **p < 0.01, ***p < 
0.0005. NK cells were (B) re-stimulated (2:1) with not opsonized targets (Raji), rituximab-
opsonized (Raji-RTX) or obinutuzumab-opsonized (Raji-GA101) target cells in the presence of 
IL-12 as well as (C) were left alone (baseline) or treated with IL-2 (100 U/ml) or IL-12 (10 ng/ml). 
After 18 hours, supernatants were collected and assessed for IFN-g levels. Data are presented as 
mean ± SEM of 7 independent experiments. *p < 0.05, **p < 0.01, ***p < 0.0001. Compared to 
baseline or Raji-Ctrl samples, all the differences were statistically significant (p < 0.001). 
 
 
Overall these results highlight that obinutuzumab-experienced NK cells exhibit an 
enhanced IFN-g production in response to cytokines or Raji target cells as well as in 
response to obinutuzumab-mediated CD16 re-stimulation. 
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6. Identification of “memory” NK cells in individuals grouped by HCMV 
serological status 
 
Data reported here have shown that the sustained interaction of NK cells with anti-CD20 
opsonized targets leads to the down-regulation of FceRIg chain and Syk kinase that may 
be associated with an enhanced ability to produce IFN-g in response to CD16 re-
stimulation. Relaying on the observation that such molecular and functional 
characteristics resemble the distinctive features of the recently identified long-lived and 
highly functional “memory” NK cells (Zhang et al., 2013; Lee et al., 2015; Schlums et al., 
2015; Cerwenka & Lanier, 2016) we assessed the capability of tumor targeting anti-CD20 
mAbs to drive the expansion and to affect the phenotypic and functional properties of this 
specific NK subset. We firstly evaluated the frequency (%) of “memory” NK cells in a 
cohort of 218 healthy donors. As illustrated in Fig. 27A, “memory” NK cells were 
identified by multicolour flow cytometry as CD3-CD56+FceRIg-CD16+ lymphocytes. As 
reported in Fig. 27B, we observed that 112 out of 218 analysed donors exhibited a 
detectable population of “memory” NK cells accounting for 3 to 50% of peripheral blood 
NK cells.  
 
 
Fig. 27. Identification of “memory” NK cells in the peripheral blood of healthy donors. The 
frequency (%) of FceRIg-  CD16+ NK cells was evaluated by multicolour flow cytometry gating 
on CD3-CD56+ population in freshly isolated PBMCs from 218 healthy donors. (A) Plots from 
one representative donor and the gating strategy used for determining the proportion of “memory” 
(CD3-CD56+FceRIg-CD16+) NK cells are shown. (B)  The distribution of the individuals with a 
detectable “memory” NK population accounting for more than 3% of peripheral blood NK cells is 
depicted in the pie chart. 
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Several studies demonstrated a strong correlation between “memory” NK cells and prior 
exposure to human cytomegalovirus (HCMV) (Hwang et al., 2012; Zhang et al., 2013; 
Lee et al., 2015, Schlums et al., 2015; Zhou et al., 2015; Kovalenko et al., 2017). By 
evaluating the HCMV seropositivity within a cohort of healthy donors, we observed that 
87 out of 118 analysed donors were seropositive for IgG anti-HCMV (Fig. 28A) and that 
63.5% of HCMV seropositive individuals exhibited a detectable “memory” NK population 
while almost none (0.06%) of seronegative donors showed such population (Fig. 28B). 
By contrast, the HCMV serological status did not affect the frequency (%) of NK cells, 
identified as CD3-CD56+ lymphocytes (Fig. 28B). 
 
 
Fig. 28. Only HCMV seropositive individuals exhibit ex vivo a “memory” NK cell population. 
A cohort of 118 healthy donors was screened for the serological status for HCMV. (A) The 
distribution of the HCMV seropositive or seronegative individuals, observed in our cohort, is 
depicted in the pie chart. (B) The frequency (%) of CD3-CD56+ (NK) and CD3-CD56+FceRIg-
CD16+ (memory) cells was evaluated by multicolour flow cytometry in freshly isolated PBMCs. 
Data are presented as median with interquartile range. Each point represents a single donor. The 
dashed line indicates the arbitrary cut-off value of 3%. ***p < 0.0001.  
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7. Anti-CD20-dependent in vitro expansion of “memory” NK cells  
It has been reported that “memory” NK cells may be expanded in vitro in an antibody-
dependent manner in response to HCMV or influenza virus-infected cells (Lee et al., 
2015; Schlums et al., 2015). Based on such evidences, we addressed whether the 
stimulation of NK cells by means of rituximab- or obinutuzumab-coated tumor B cells 
may support the in vitro expansion of “memory” (CD3-CD56+FceRIg-CD16+) or 
“conventional” (CD3-CD56+FceRIg+CD16+) NK subsets. To this end, we set up the 
experimental system illustrated in Fig. 29, that we used for all the experiments described 
below. Freshly isolated PBMCs from HCMV+ donors were screened, by multicolour flow 
cytometry, to select individuals with a detectable and well-defined FceRIg- CD16+ 
population among CD3- CD56+ lymphocytes. PBMCs were cultured for 10 days in the 
presence of IL-2. At day 3, irradiated Raji cells were added (2:1) in the absence or 
presence of rituximab or obinutuzumab. At the end of the co-cultures (day 10), cells were 
analysed by multicolour flow cytometry.  
 
 
Fig. 29. Experimental setting for anti-CD20-induced in vitro expansion of “memory” NK 
subset.  
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As reported in Fig. 30, we observed that the frequency (%) and the absolute number of 
NK (CD3-CD56+) cells increased at the end of 10-day co-cultures, thus indicating that our 
experimental conditions were efficient in driving the selective expansion of NK cells. In 
particular, NK cells significantly and comparably expanded in response to not opsonized 
or anti-CD20 opsonized targets, thus demonstrating that it was largely independent from 
anti-CD20-mediated CD16 stimulation.  
 
 
Fig. 30. 10 day PBMC co-colture with Raji cells promotes NK cell expansion in an antibody-
independent manner. Freshly isolated PBMCs were seeded in 96-well plates, in the presence of 
100 U/ml IL-2, and co-cultured for 10 days with irradiated rituximab- (Raji-RTX), obinutuzumab 
(Raji-GA101)-opsonized or not opsonized (Raji) target cells (E:T ratio 2:1). The frequency (%) of 
NK cells (CD3-CD56+) was assessed by multicolour flow cytometry before (day 0) and at the end 
(day 10) of co-coltures. For each time point, the absolute number/106 of NK cells was calculated 
as follows: (percentage of NK cells) x 106/100.  Data from 30 different donors are shown. Each 
line represents a single donor. **p < 0.005, ***p < 0.001. 
 
 
When we analysed “memory” vs “conventional” NK cells, we observed that “memory” 
NK cells underwent a significant expansion only in response to anti-CD20-mediated 
CD16 aggregation (Fig. 31C). In fact, only in the presence of anti-CD20 mAbs we 
observed a marked increase of their absolute number. We also noted that rituximab was 
more efficient in driving “memory” NK expansion than obinutuzumab (Fig. 31C).  
By contrast, the expansion of “conventional” NK cells was largely independent from anti-
CD20-mediated CD16 aggregation (Fig. 31B).  
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Fig. 31. “Memory” but not “conventional” NK cells undergo in vitro expansion in an anti-
CD20-dependent manner. Freshly isolated PBMCs were seeded in 96-well plates, in the 
presence of 100 U/ml IL-2, and co-cultured for 10 days with irradiated rituximab- (Raji-RTX), 
obinutuzumab (Raji-GA101)-opsonized or not opsonized (Raji) target cells (E:T ratio 2:1). Cells 
were assessed by multicolour flow cytometry before (day 0) and at the end (day 10) of co-coltures. 
(A) Plots from one representative donor are shown. (B-C) Graphs depict the absolute number/106 
of (B) “conventional” (CD3-CD56+FceRIg+CD16+) and (C) “memory” (CD3-CD56+FceRIg-
CD16+) NK subsets calculated as follows: (percentage of “conventional” or “memory” NK cells) 
x (absolute number/106 of NK cells)/100. Data from 30 different donors are shown. Each line 
represents a single donor. **p < 0.005, ***p < 0.0005.  
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Based on these results, we investigated whether anti-CD20-dependent expansion of 
“memory” NK cells may also occur in HCMV seronegative donors. To this end, PBMCs 
derived from HCMV- individuals, in which as shown in Fig. 28 the frequency (%) of 
“memory” NK cells was lower than 3%, were co-cultured as above described and analysed 
by multicolour flow cytometry upon 10 days. At the end of co-culture, no expansion of 
“memory” NK cells was detected (Fig. 32B), in front of a marked proliferation of 
“conventional” NK cells (Fig. 32A), thus suggesting that only HCMV in vivo primed 
“memory” NK cells may undergo anti-CD20-dependent in vitro expansion.  
 
 
 
Fig. 32. Anti-CD20-driven in vitro expansion of “memory” NK cells may require the in vivo 
priming induced by HCMV infection. PBMC suspensions, freshly isolated from HCMV 
seronegative donors, were seeded in 96-well plates, in the presence of 100 U/ml IL-2, and co-
cultured for 10 days with irradiated rituximab- (Raji-RTX), obinutuzumab (Raji-GA101)-
opsonized or not opsonized (Raji) target cells (E:T ratio 2:1). Cells were assessed by multicolour 
flow cytometry before (day 0) and at the end (day 10) of co-cultures. Graphs depict the absolute 
number/106 of (A) “conventional” (CD3-CD56+FceRIg+CD16+) and (B) “memory” (CD3-
CD56+FceRIg-CD16+) NK subsets calculated as follows: (percentage of “conventional” or 
“memory” NK cells) x (absolute number/106 of NK cells) /100. Data from different donors are 
shown. Each line represents a single donor.  
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8. In vitro expanded “memory” NK cells maintain the phenotypic profile 
of their freshly isolated counterpart  
 
It has been reported that “memory” NK cells display a unique receptor repertoire (Hwang 
et al., 2012; Zhang et al., 2013; Lee et al., 2015; Schlums et al., 2015; Zhou et al., 2015; 
Kovalenko et al., 2017). Herein, we analysed by multicolour flow cytometry the 
phenotypic profile of “conventional” and “memory” NK cells in both ex vivo (Fig.33A) 
and in vitro expanded (Fig.33B) settings. In line with literature, we observed that freshly 
isolated “memory” NK cells exhibited a higher frequency of NKG2C receptor along with 
reduced levels of CD16 and lower frequency of NKp46 receptor, with respect to 
“conventional” ones. Of note, such phenotypical features were maintained in in vitro 
expanded populations.  
 
 
 
Fig. 33. Phenotypic profile of freshly isolated and in vitro expanded “conventional” and 
“memory” NK cells. Freshly isolated PBMCs were seeded in 96-well plates, in the presence of 
100 U/ml IL-2, and co-cultured for 10 days with irradiated rituximab-opsonized (Raji-RTX) target 
cells (E:T ratio 2:1). The surface levels of CD16, NKG2A or NKp46 were assessed by multicolour 
flow cytometry on “conventional” (CD3-CD56+FceRIg+CD16+) and “memory” (CD3-
CD56+FceRIg-CD16+) NK cell subsets (A) before and (B) at the end of co-coltures. Data from 
different donors are shown. Each line represents a single donor. **p < 0.01, ***p < 0.0005.  
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9. In vitro expanded “memory” NK cells exhibit enhanced functional 
responses to CD16 re-stimulation  
 
It has been reported that “memory” NK cells significantly differ from “conventional” ones 
for their functional capabilities (Lee et al., 2015; Schlums et al., 2015; Kovalenko et al., 
2017). In fact, recent reports demonstrated that, despite a poor responsivity toward tumor 
targets, “memory” NK cells exhibit an enhanced functional activity in response to CD16 
stimulation, particularly in terms of IFN-g and TNF-a production (Hwang et al., 2012; 
Zhang et al., 2013; Lee et al., 2015; Zhou et al., 2015; Kovalenko et al., 2017). Herein, 
we characterized the functional profile of in vitro expanded “memory” NK cells with 
respect to “conventional” ones as well as to their freshly isolated counterpart. To this end, 
freshly isolated (Fig. 34A-B) or 10-day co-cultured (Fig. 34C-D) NK cells were stimulated 
with anti-CD20 opsonized or not opsonized Raji as well as with K562 targets and assessed 
by multicolour flow cytometry for IFN-g production or degranulation.  
By evaluating the CD16 responsiveness, we observed that “memory” NK cells exhibited 
an enhanced IFN-g production, with respect to “conventional” ones, in response to both 
rituximab- and obinutuzumab-opsonized targets in freshly isolated (Fig. 34A-B) as well 
as in vitro expanded (Fig. 34C-D) settings. On the other hand, regarding degranulation, 
while freshly isolated “memory” NK cells showed an increased functional activity in 
response to both rituximab- and obinutuzumab-coated targets (Fig. 34A-B) in vitro 
expanded “memory” NK cells respond better to obinutuzumab (Fig. 34C-D).  
By evaluating the direct responsiveness to MHC-I positive Raji tumor target, which is 
almost resistant to the direct NK lysis, we observed that freshly isolated “memory” NK 
cells exhibited an enhanced ability to degranulate, but not to produce IFN-g, with respect 
to “conventional” ones (FIG. 34A-B). On the other hand, we noted that in vitro expanded 
“conventional” and “memory” NK subsets comparably respond to Raji cells (Fig. 34C-D).  
Our data also revealed a reduced ability of both freshly isolated (Fig. 34A-B) and in vitro 
expanded (Fig. 34C-D) “memory” NK cells to respond to K562 tumor target which, being 
MHC-I negative, efficiently activates functional responses in “conventional” NK cells.  
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Fig. 34. In vitro expanded “memory” NK cells exhibit an enhanced functional activity in 
response to CD16 re-stimulation. PBMC suspensions (A-B) freshly isolated or (C-D) recovered 
from 10-day co-coltures with irradiated rituximab-opsonized (Raji-RTX) target cells (E:T ratio 
2:1) in presence of 100 U/ml IL-2 and 10 ng/ml IL-15 were combined (2:1) with not opsonized or 
anti-CD20-opsonized Raji cells as well as K562 targets. The percentage (%) of IFN-g+ or CD107a+ 
cells were analysed by multicolour flow cytometry among “conventional” (CD3-CD56+FceRIg+) 
and “memory” (CD3-CD56+FceRIg-) NK subsets. (A, C) Plots from representative donors are 
shown. (B, D) Graphs depict data from independent experiments. Each line represents a single 
donor. *p< 0.05, **p< 0.01, ***p< 0.001.   
 
 
Looking at the differences between the two anti-CD20 mAbs, we noted that obinutuzumab 
is more active than rituximab in enhancing IFN-g production, degranulation as well as 
multifunctional responses from both “conventional” and “memory” NK cells in freshly 
isolated (Fig. 35A) and in vitro expanded (Fig. 35B) cellular subsets.  
 
 
Fig. 35. “Memory” NK cells exhibit enhanced functional responses to obinutuzumab with 
respect to rituximab stimulation. PBMC suspensions (A) freshly isolated or (B) recovered from 
10-day co-coltures with irradiated rituximab-opsonized (Raji-RTX) target cells (E:T ratio 2:1) in 
presence of 100 U/ml IL-2 and 10 ng/ml IL-15 were combined (2:1) with anti-CD20-opsonized 
Raji cells. The percentage (%) of IFN-g+ and/or CD107a+ cells were analysed by multicolour flow 
cytometry among “conventional” (CD3-CD56+FceRIg+) and “memory” (CD3-CD56+FceRIg-) NK 
subsets. Graphs depict data from independent experiments. Each line represents a single donor. 
*p< 0.05, ***p< 0.001.   
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Taken together these data demonstrate that “memory” NK subset may selectively expand 
in vitro in response to anti-CD20-opsonized tumor B cells and that such in vitro expanded 
population shows the phenotypic and functional hallmarks of their freshly isolated 
counterpart.  
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Discussion 
Anti-CD20 mAbs are widely used in the treatment of B-cell malignancies and 
autoimmune disorders. Despite anti-CD20-based therapy has substantially changed the 
natural history of B-cell malignancies a relevant fraction of patients still relapses and 
becomes resistant to the therapy. For this reason, different strategies, including Fc-
mutation or Fc-glycoengeneering, have been designed to enhance the clinical efficacy of 
anti-CD20 mAbs. Such Fc optimised mAbs include obinutuzumab which is, in fact, the 
first glycongineered anti-CD20 mAb approved for clinical use (Klein et al., 2013; Goede 
et al., 2014). The defucosylated Fc domain of this mAb substantially increases the affinity 
for FcgRIIIA/CD16 receptor, thus improving the capability to stimulate NK cells. Of note, 
although some studies demonstrated that obinutuzumab is more efficient in stimulating 
NK cell-mediated tumor target cell killing with respect to the reference mAb rituximab 
(Mossner et al., 2010; Bologna et al., 2011; Pincetic et al., 2014), the impact of mAb 
defucosylation on the ability to induce cytokine production in NK cells remained 
unexplored. Herein, by comparing the ability of rituximab and obinutuzumab to induce 
the activation of NK cells, we demonstrated that obinutuzumab, used at ten times lower 
concentration than rituximab, stimulates NK cell-mediated IFN-g production more 
efficiently than rituximab by enhancing both the portion of IFN-g producing cells and the 
amount of IFN-g on a per cell basis. On the other hand, in line with literature, 
obinutuzumab is more potent than rituximab in stimulating NK 
degranulation/cytotoxicity. Such increased efficacy of obinutuzumab is attributable to 
glycoengineering since the non-defucosylated wild type (wt) mAb is less efficient in 
inducing NK functions. The observation that the wt version has enhanced activity with 
respect to rituximab indicates that the superiority of obinutuzumab is not exclusively due 
to differences in the Fc domain, but also to other features that may impact on CD16 
stimulation such as the missed ability to induce CD20 surface down-modulation (Herter 
et al., 2013; Klein et al., 2013). It is well-known that the interaction of NK cells with 
opsonized targets results in both cytotoxicity and cytokine production with a higher 
activation threshold required for cytokine secretion (Fauriat et al., 2010; Long et al., 
2013). In line with this notion, we observed that in response to rituximab or obinutuzumab 
the portion of NK cells that degranulate is higher than the portion of NK cells that produce 
IFN-g. Notably, we found that the fraction of NK cells performing both effector functions 
is higher following obinutuzumab than rituximab stimulation, thus suggesting that the 
increased binding affinity of obinutuzumab for CD16 allows more cells to reach the 
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signaling threshold required for cytokine production. Such enhanced IFN-g production in 
response to obinutuzumab may explain the cytokine release syndrome observed in treated 
patients, characterized by high levels of circulating IFN-g (Freeman et al., 2015). Several 
studies, including ours, reported that CD16 undergoes surface down-modulation in 
response to anti-CD20-opsonized targets (Veeramani et al., 2011; Capuano et al., 2015; 
Cox et al., 2015) which may result from either receptor shedding (Romee et al., 2013) or 
internalization (Capuano et al., 2015). When we compared the ability of rituximab and 
obinutuzumab to induce CD16 surface down-modulation, we noted that in response to 
obinutuzumab CD16 undergoes a more rapid, marked and progressive surface down-
modulation reaching, upon 18 hours of stimulation, almost 17% of initial levels (vs 40 % 
in rituximab-stimulated cells). It has been reported that obinutuzumab is endowed with a 
higher affinity for CD16 regardless from receptor allotype (Mossner et al., 2010; Herter 
et al., 2013). In line with this notion, we found that the interaction with obinutuzumab-
opsonized targets leads to a stronger CD16 down-modulation accross all allotypes, 
whereas rituximab induces only a marginal receptor down-modulation in donors bearing 
the low affinity CD16 allotype. In low affinity (F/F) donors, obinutuzumab is able to 
induce a robust degranulation, thus confirming the correlation existing between affinity 
aggregation conditions, receptor down-modulation and functional responses. The stronger 
CD16 surface down-modulation observed in obinutuzumab stimulated cells is not in 
conflict with the enhanced functional responses. To this purpose, it has been recently 
reported that internalized activating receptors in NK cells can still transduce signals from 
intracellular compartments before their lysosomal targeting (Quatrini et al., 2015). In this 
regard, we noted that upon interaction with anti-CD20-opsonized targets a fraction of 
CD16 receptor internalizes and co-localizes with lysosomes. Moreover, we observed that 
the stimulation of NK cells with anti-CD20-opsonized targets leads to the lysosomal 
degradation of CD16-coupled signaling molecules with affinity aggregation conditions 
affecting the strength and the quality of the response. In particular, we found that the 
cellular levels of CD16-associated FceRIg chain are significantly reduced in response to 
obinutuzumab in all CD16 allotypes, whereas rituximab-mediated stimulation induces 
FceRIg  degradation only in intermediate/high affinity donors. On the other hand, CD3z 
chain is more marginally affected by degradation. Such different behaviour between 
CD16-associated chains may be due to the greater amount of g/g homodimers than g/z 
heterodimers or z/z homodimers coupled to CD16 receptor in human NK cells 
(Letourneur et al., 1991). Since it is well-known that upon receptor engagement the ITAM 
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sequences of FceRIg and CD3z chains undergo tyrosine phosphorylation followed by the 
recruitment and activation of Syk and ZAP-70 tyrosine kinases, we investigated whether 
anti-CD20-activated degradative pathway could involve other CD16-coupled signaling 
molecules. We observed that in intermediate/high affinity donors the stimulation of NK 
cells with anti-CD20-opsonized targets leads to the selective degradation of Syk kinase, 
likely by an ubiquitin-dependent pathway. The reduced cellular levels of FceRIg  and 
CD3z chains as well as of Syk kinase, heavily impact on NK functions. Indeed, we found 
a significant impairment of NK cell ability to kill targets via CD16 as well as NKp46 and 
NKp30 activating receptors, which share FceRIg and CD3z chains with CD16 (Kruse et 
al., 2014). The impaired cytotoxic activity of both rituximab- and obinutuzumab-
experienced NK cells shows that the residual levels of CD3z chain are not sufficient to 
allow the optimal signals required for degranulation. Indeed, the defective cytotoxicity 
observed in F/F donors, where obinutuzumab selectively induces the degradation of 
FceRIg, indicates a non-redundant role for such molecule in ITAM receptor-dependent 
killing which may be explained by a different coupling of CD3z and FceRIg chains to 
downstream signaling elements (Galandrini et al., 1997). The observation that in F/F 
donors rituximab-experienced NK cells exhibit a significant defect of NKp46- and 
NKp30-mediated cytotoxicity despite the lack of CD16 adaptor degradation is not very 
surprising; in fact, in such low affinity aggregation conditions receptor-driven inhibitory 
signals may occur. In this regard, we have recently demonstrated that aggregation of CD16 
in low affinity conditions, obtained by rituximab, results in NK cell hyporesponsiveness 
due to the activation of Shp-1 tyrosine phosphatase (Capuano et al., 2015). Such 
observation is in line with the emerging paradigm considering that the targeting of some 
classically activating ITAM-bearing FcRs with low affinity ligands parodoxically trasmits 
inhibitory signals through the recruitment of Shp-1 leading to the inhibition of a number 
of innate immune responses (Aloulou et al., 2012). On the other hand, the down-regulation 
of CD16-coupled signaling elements in obinutuzumab-experienced NK cells is associated 
with an enhanced ability to produce IFN-g thus indicating that the aggregation of CD16 
in high affinity conditions may prime NK cells to a reduced signaling threshold leading to 
enhanced effector functions. Moreover, we observed that, while anti-CD20-experienced 
NK cells appears desensitized to a subsequent rituximab-mediated CD16 re-stimulation, 
they efficiently respond to obinutuzumab re-stimulation. Such response is also observed 
in obinutuzumab-experienced NK cells despite the lower residual CD16 surface 
expression. Such enhanced response, independent from CD16 levels, may be likely due 
	 83	
to the favoured coupling of CD16 receptor to CD3z chain that leads to more robust and 
efficient biochemical signals given the quantitative differences in ITAM motifs (3 ITAM 
in CD3z vs 1 ITAM in FceRIg). Moreover, the residual CD3z levels observed in anti-
CD20 experienced NK cells may also preserve the co-stimulatory activity of CD2/CD58 
interaction during target cell contact (Grier et al., 2012). Indeed, obinutuzumab-
experienced NK cells exhibit an enhanced IFN-g production in response to Raji cell 
stimulation. The identification of the molecular mechanisms underlying the enhanced 
IFN-g production observed in obinutuzumab-experienced NK cells requires further 
investigation. In particular, we are currently evaluating whether post-trascriptional as well 
as epigenetic or signaling modifications may account for the primed status of NK cells 
dictated by the high affinity CD16 ligation conditions. Overall, our data demonstrate that 
CD16 ligation in optimised affinity aggregation conditions, by means of the Fc-
glycoengineered anti-CD20 mAb obinutuzumab, may shift NK functional program 
toward cytokine production, thus potentially affecting the clinical response and immuno-
competence of anti-CD20 treated patients. Interestingly, it has been recently described the 
capability of mAb-based therapy to favour a long-lasting protective anti-tumor response 
through the generation of effector/memory T lymphocytes, the so-called “vaccinal effect” 
(Abès et al., 2010; DiLillo & Ravetech, 2015). In this scenario, the role of NK-derived 
IFN-g in promoting DC maturation/antigen-presentation functions and the development 
of adaptive responses has been demonstrated (Martin-Fontecha et al., 2004; Walzer et al., 
2005; Crouse et al., 2015) thus indicating that, besides short-term cytotoxic properties, 
NK cells may be relevant actors in promoting a long-term anti-tumor protective immunity 
in response to mAb-based therapeutic strategies. Our data also highlight that 
obinutuzumab-experienced NK cells are reminescent, under molecular and functional 
profile, of the recently identified long-lived and highly fuctional NK population called 
“memory” NK cells, which is in fact defined by the lack of expression of FceRIg  chain 
and the ability to produce high amounts of IFN-g (Zhang et al., 2013; Lee et al., 2015; 
Schlums et al., 2015; Cerwenka & Lanier, 2016). It is known that the presence of 
“memory” NK cells in the peripheral blood of healthy donors is associated with a prior 
exposure to human cytomegalovirus (HCMV) (Hwang et al., 2012; Zhang et al., 2013; 
Lee et al., 2015; Schlums et al., 2015; Kovalenko et al., 2017) a herpesvirus that 
establishes a life-long latent infection in the majority of the human population (Dowd et 
al., 2009). In line with this notion, by evaluating the presence of the “memory” (CD3-
CD56+FceRIg-CD16+) NK subset in a cohort of healthy individuals, we observed that the 
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vast majority of HCMV seropositive individuals exhibits a detectable population of 
“memory” NK cells accounting for 3 to 50% of peripheral blood NK cells. Several recent 
studies demonstrated that the CD16 receptor may play a key role in driving the in vitro 
expansion of the “memory” NK subset. Indeed, it has been reported that “memory” NK 
cells may be expanded in vitro upon encounter with HCMV or influenza virus-infected 
cells only in the presence of virus-specific antibodies (Lee et al., 2015; Schlums et al., 
2015). Based on such evidences, we assessed the capability of tumor targeting anti-CD20 
mAbs to affect the expansion as well as the phenotypic and functional properties of 
“memory” NK subset. Herein, we observed that “memory” NK cells udergo a significant 
expansion only in response to anti-CD20-mediated CD16 aggregation. On the opposite 
the expansion of “conventional” (CD3-CD56+FceRIg+CD16+) NK cells is not affected by 
CD16 stimulation since they comparably proliferate in response to anti-CD20 opsonized 
or not opsonized targets in the presence of IL-2. Looking at the differences between the 
two anti-CD20 mAbs, we also noted that rituximab is more efficient in driving “memory” 
NK cell expansion with respect to obinutuzumab. It remains to establish whether such 
different efficiency may be due to the CD16 affinity aggregation conditions and/or to the 
different CD20 epitope bound on tumor cells. Furthermore, the observation that the in 
vitro culture with anti-CD20-coated targets fails to induce the expansion of the “memory” 
NK subset in HCMV seronegative donors confirms that mAb-dependent in vitro 
expansion of “memory” NK cells may require an in vivo priming likely mediated by 
HCMV. Because of a specific epigenetic signature, “memory” NK cells significantly 
differ from “conventional” ones for their receptor repertoire. Indeed, they express 
increased levels of the activating receptor NKG2C as well as lower amounts of CD16 and 
of the natural cytotoxicity receptors NKp30 and NKp46  (Hwang et al., 2012; Zhang et 
al., 2013; Lee et al., 2015; Schlums et al., 2015; Zhou et al., 2015; Kovalenko et al., 2017). 
We reported here that the phenotypic profile of in vitro expanded “memory” NK cells 
recapitulates their freshly isolated counterpart. In addition, “memory” NK cells 
significantly differ from “conventional” ones for their functional capabilities (Lee et al., 
2015; Schlums et al., 2015; Kovalenko et al., 2017). In fact, despite a poor reactivity 
toward tumor targets, “memory” NK cells exhibit an enhanced CD16 responsiveness 
particularly in terms of IFN-g and TNF-a production (Hwang et al., 2012; Zhang et al., 
2013; Lee et al., 2015; Zhou et al., 2015; Kovalenko et al., 2017). On this purpose, in line 
with literature we found a superior capacity of freshly isolated “memory” NK cells to 
produce IFN-g and to degranulate with respect to “conventional” NK cells. The 
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observation that such enhancement is less evident in anti-CD20-expandent “memory” NK 
cells, especially in terms of degranulation, may be explained by the increased 
responsiveness of “conventional” NK cells induced by IL-2 plus IL-15 exposure. Further, 
both freshly isolated and cultured “memory” NK cells exhibit a reduced functional activity 
in response to K562 stimulation. These data are consistent with the prominent role of 
NKp46 receptor in K562 NK-mediated recognition (Sivori et al., 1999; Hwang et al., 
2012). Obinutuzumab exhibits an enhanced ability to activate both “conventional” and 
“memory” NK cells by increasing IFN-g production and/or degranulation in freshly 
isolated as well as in in vitro expanded cellular subsets. Such enhanced functional 
activation, which is in contrast to what we have observed for the cellular expansion, led 
us to hypothesize that the molecular signals governing proliferation vs functional 
activation downstream CD16 may be uncoupled. With the aim to improve the clinical 
response rate to mAb-based therapy scientific interest is now focused in exploring the 
possibility to arm the host immune system in order to mediate a long-lasting effect.  In 
this context, it is tempting to speculate that, due to their long persistance and peculiar 
functional capabilities (i.e. enhanced ability to kill and expecially to produce IFN-g in 
response to CD16 stimulation), anti-CD20-expanded memory NK cells may be highly 
relevant for the promotion and maintenance of a long-term protection in treated patients 
thus ultimately reducing the relapsing rate after treatment. Indeed, given the well-
recognized role of IFN- g in the shaping of adaptive immunity by modulating the 
responses of both dendritic and T cells, it is tempting to speculate that anti-CD20-
expanded memory NK cells may represent a potentially very actrative tool to be exploited 
for the potentiation of the “vaccinal effect” in patients after anti-CD20-based therapy. In 
this regard, our next goal will be to explore the impact of anti-CD20-based therapeutic 
regimens on in vivo dynamics and anti-tumor relevance of “memory” NK cells in the 
mAb-induced “vaccinal effect”.	 
In conclusion, our data highlight a new aspect of the interplay between anti-CD20 
therapeutic mAbs and NK cell functions and plasticity and provide advancements in the 
knowledge of NK cell anti-tumor functions. Our data may also offer potential tools for the 
clinical exploitation of NK effector functions in the context of novel therapy protocols 
aimed at optimizing the efficacy of therapeutic mAbs.   
 
  
	 86	
References  
Abès R, Gélizé E, Fridman WH, Teillaud JL. Long-lasting antitumor protection by anti-
CD20 antibody through cellular immune response. Blood. 2010;116(6):926-34.  
 
Ahlgrimm M, Pfreundschuh M, Kreuz M, Regitz E, Preuss KD, Bittenbring J. The impact 
of Fc-γ receptor polymorphisms in elderly patients with diffuse large B-cell 
lymphoma treated with CHOP with or without rituximab. Blood. 2011;118(17):4657-
62.  
 
Alduaij W, Illidge TM. The future of anti-CD20 monoclonal antibodies: are we making 
progress? Blood. 2011;117(11):2993-3001.  
 
Alduaij W, Ivanov A, Honeychurch J, Cheadle EJ, Potluri S, Lim SH, Shimada K, Chan 
CH, Tutt A, Beers SA, Glennie MJ, Cragg MS, Illidge TM. Novel type II anti-CD20 
monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, 
lysosome-mediated cell death in B-cell malignancies. Blood. 2011;117(17):4519-29.  
 
Aloulou M, Ben Mkaddem S, Biarnes-Pelicot M, Boussetta T, Souchet H, Rossato E, 
Benhamou M, Crestani B, Zhu Z, Blank U, Launay P, Monteiro RC. IgG1 and IVIg 
induce inhibitory ITAM signaling through FcγRIII controlling inflammatory 
responses. Blood. 2012;119(13):3084-3096.  
 
Alter G, Malenfant JM, Altfeld M. CD107a as a functional marker for the identification 
of natural killer cell activity. J Immunol Methods. 2004; 294(1-2):15-22. 
 
Arnon TI, Lev M, Katz G, Chernobrov Y, Porgador A, Mandelboim O.	Recognition of 
viral hemagglutinins by NKp44 but not by NKp30.	Eur J Immunol. 2001;31(9):2680-9. 
 
Arnon TI, Achdout H, Lieberman N, Gazit R, Gonen-Gross T, Katz G, Bar-Ilan 
A, Bloushtain N, Lev M, Joseph A, Kedar E, Porgador A, Mandelboim O. The 
mechanisms controlling the recognition of tumor-and virus-infected cells by NKp46. 
Blood 2004; 103(2):664-72. 
 
Azzoni L, Kamoun M, Salcedo TW, Kanakaraj P, Perussia B.	Stimulation of Fc gamma 
RIIIA results in phospholipase C-gamma 1 tyrosine phosphorylation and p56lck 
activation.	J Exp Med. 1992;176(6):1745-50. 
 
Barriere H, Nemes C, Lechardeur D, Khan-Mohammad M, Fruh K, Lukacs GL. Molecular 
basis of oligoubiquitin-dependent internalization of membrane proteins in 
Mammalian cells. Traffic. 2006; 7(3):282-97. 
 
Beaulieu AM, Zawislak CL, Nakayama T, Sun JC. The transcription factor Zbtb32 
controls the proliferative burst of virus-specific natural killer cells responding to 
infection. Nat Immunol. 2014;15(6):546-53.  
	 87	
Beers SA, Chan CH, James S, French RR, Attfield KE, Brennan CM, Ahuja A, Shlomchik 
MJ, Cragg MS, Glennie MJ. Type II (tosimumab) anti-CD20 monoclonal antibody out 
performs type I (rituximab-like) reagents in B-cell depletion regardless of 
complement activation. Blood 2008;112(10):4170-7. 
 
Beers SA, Chan CH, French RR, Cragg MS, Glennie MJ. CD20 as a target for 
therapeutic type I and II monoclonal antibodies. Semin Hematol 2010;47(2):107-114.  
 
Beers SA, French RR, Chan HT, Lim SH, Jarrett TC, Vidal RM, Wijayaweera SS, Dixon 
SV, Kim H, Cox KL, Kerr JP, Johnston DA, Johnson PW, Verbeek JS, Glennie MJ, Cragg 
MS. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications 
for antibody selection. Blood 2010; 115(25):5191-201.  
 
Berdeja JG, Hess A, Lucas DM, O'Donnell P, Ambinder RF, Diehl LF, Carter-Brookins 
D, Newton S, Flinn IW. Systemic interleukin-2 and adoptive transfer of lymphokine-
activated killer cells improves antibody-dependent cellular cytotoxicity in patients 
with relapsed B-cell lymphoma treated with rituximab. Clin Cancer 
Res 2007;13(8):2392-9. 
 
Bertelsen V, Sak MM, Breen K, Rodland MS, Johannessen LE, Traub LM, Stang E, 
Madshus IH 2011. A chimeric pre-ubiquitinated EGF receptor is constitutively 
endocytosed in a clathrin-dependent, but kinase-independent manner. Traffic 12: 
507–520 
 
Beum PV, Kennedy AD, Williams ME, Lindorfer MA, Taylor RP. The shaving reaction: 
rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic 
lymphocytic leukemia cells by THP-1 monocytes. J Immunol 2006; 176(4):2600-9. 
 
Beum PV, Lindorfer MA, Taylor RP. Within peripheral blood mononuclear cells, 
antibody-dependent cellular cytotoxicity of rituximab-opsonized Daudi cells is 
promoted by NK cells and inhibited by monocytes due to shaving. J Immunol  2008; 
181(4):2916-24. 
 
Beum PV, Peek EM, Lindorfer MA, Beurskens FJ, Engelberts PJ, Parren PW, van de 
Winkel JG, Taylor RP. Loss of CD20 and bound CD20 antibody from opsonized B cells 
occurs more rapidly because of trogocytosis mediated by Fc receptor-expressing 
effector cells than direct internalization by the B cells. J Immunol 2011; 187(6):3438-
47.  
 
Beurskens FJ, Lindorfer MA, Farooqui M, Beum PV, Engelberts P, Mackus WJ, Parren 
PW, Wiestner A, Taylor RP. Exhaustion of cytotoxic effector systems may limit 
monoclonal antibody-based immunotherapy in cancer patients. J Immunol. 
2012;188(7):3532-41.  
 
	 88	
Bezombes C, Grazide S, Garret C, Fabre C, Quillet-Mary A, Müller S, Jaffrézou JP, 
Laurent G. Rituximab antiproliferative effect in B-lymphoma cells is associated with 
acid-sphingomyelinase activation in raft microdomains. Blood. 2004;104(4):1166-73. 
 
Bhat R, Watzl C. Serial killing of tumor cells by human natural killer cells-
enhancement by therapeutic antibodies. PLoS ONE  2007; 2(3):e326. 
Billadeau DD, Upshaw JL, Schoon RA, Dick CJ, Leibson PJ. NKG2D-DAP10 triggers 
human NK cell-mediated killing via a Syk-independentregulatory pathway. Nat 
Immunol. 2003;4(6):509-10. 
	
Bologna L, Gotti E, Manganini M, Rambaldi A, Intermesoli T, Introna M, Golay J. 
Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody 
GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with 
rituximab and alemtuzumab. J immunol 2011; 186(6):3762-9.  
 
Bonavida B. Rituximab-induced inhibition of antiapoptotic cell survival pathways: 
implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic 
and novel therapeutic interventions. Oncogene. 2007;26(25):3629-36. 
 
Bossi G, Griffiths GM: CTL secretory lysosomes: biogenesis and secretion of a harmful 
organelle. Semin Immunol 2005; 17:87-94. 
 
Böttcher S, Ritgen M, Brüggemann M, Raff T, Lüschen S, Humpe A, Kneba M, Pott C. 
Flow cytometric assay for determination of FcgammaRIIIA-158 V/F polymorphism. 
J Immunol Methods.2005;306(1-2):128-136.   
 
Bottino C, Castriconi R, Pende D, Rivera P, Nanni M, Carnemolla B, Cantoni C, Grassi 
J, Marcenaro S, Reymond N, Vitale M, Moretta L, Lopez M, Moretta A. Identification of 
PVR (CD155) and nectin-2 (CD112) as cell surface ligands for the human DNAM-1 
(CD226) activating molecule. J Exp Med 2003; 198: 557-67. 
 
Bottino C, Moretta L, Pende D, Vitale M, Moretta A. Learning how to discriminate 
between friends and enemies, a lesson from Natural Killer cells. Mol Immunol 2004; 
41:569–575. 
 
Bowles JA, Wang SY, Link BK, Allan B, Beuerlein G, Campbell MA, Marquis D, Ondek 
B, Wooldridge JE, Smith BJ, Breitmeyer JB, Weiner GJ. Anti-CD20 monoclonal 
antibody with enhanced affinity for CD16 activates NK cells at lower concentrations 
and more effectively than rituximab. Blood 2006; 108(8):2648-54.  
 
Brandt CS, Baratin M, Yi EC, Kennedy J, Gao Z, Fox B, Haldeman B, Ostrander CD, 
Kaifu T, Chabannon C, Moretta A, West R, Xu W, Vivier E, Levin SD. The B7 family 
member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor 
NKp30 in humans. J Exp Med 2009; 206(7): 1495-503. 
 
	 89	
Brumbaugh KM, Binstadt BA, Leibson PJ. Signal transduction during NK cell 
activation: balancing opposing forces. Curr Top Microbiol Immunol 1998; 230:103-122. 
 
Bryceson YT, March ME, Barber DF, Ljunggren HG, Long EO: Cytolytic granule 
polarization and degranulation controlled by different receptors in resting NK cells. 
J Exp Med 2005; 202: 1001-1012. 
 
Bryceson YT, March ME, Ljunggren HG, Long EO: Activation, coactivation, and 
costimulation of resting human natural killer cells. Immunol Rev 2006; 214:73-91. 
 
Bryceson YT, March ME, Ljunggren HG, Long EO. Synergy among receptors on resting 
NK cells for activation of natural cytotoxicity and cytokine secretion. Blood 2006, 
107:159-166. 
 
Bryceson YT, Ljunggren HG. Tumor cell recognition by the NK activating receptor 
NKG2D. Eur J Immunol 2008, 38:2927-2968. 
 
Bryceson YT, Long EO. Line of attack: NK cell specificity and integration of signals. 
Curr Opin Immunol 2008, 20:344-352. 
 
Bryceson YT, Ljunggren HG, Long EO. Minimal requirement for induction of natural 
cytotoxicity and intersection of activation signals by inhibitory receptors. Blood 2009, 
114:2657-2666. 
 
Bryceson YT, Chiang SC, Darmanin S, Fauriat C, Schlums H, Theorell J, Wood SM. 
Molecular mechanisms of natural killer cell activation. J Innate Immun 2011;3(3):216-
26.  
 
Bubien JK, Zhou LJ, Bell PD, Frizzell RA, Tedder TF. Transfection of the CD20 cell 
surface molecule into ectopic cell types generates a Ca2+ conductance found 
constitutively in B lymphocytes. J Cell Biol. 1993 Jun;121(5):1121-1132. 
 
Caligiuri M. Human natural killer cells. Blood 2008; 112:461–9. 
 
Capuano C, Romanelli M, Pighi C, Cimino G, Rago A, Molfetta R, Paolini R, Santoni A, 
Galandrini R. Anti-CD20 Therapy Acts via FcγRIIIA to Diminish Responsiveness of 
Human Natural Killer Cells. Cancer Res. 2015;75(19):4097-4108.  
 
Carlotti E, Palumbo GA, Oldani E, Tibullo D, Salmoiraghi S, Rossi A, Golay J, Pulsoni A, 
Foà R, Rambaldi A. FcgammaRIIIA and FcgammaRIIA polymorphisms do not 
predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with 
sequential CHOP and rituximab. Haematologica. 2007;92(8):1127-30. 
 
Carrega P, Ferlazzo G. Natural killer cell distribution and trafficking in human tissues. 
Front Immunol 2012;3:347.  
	 90	
Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, Laubach J, 
Bawn SD, Gordon LI, Winter JN, Furman RR, Vose JM, Zelenetz AD, Mamtani R, Raisch 
DW, Dorshimer GW, Rosen ST, Muro K, Gottardi-Littell NR, Talley RL, Sartor O, Green 
D, Major EO, Bennett CL. Progressive multifocal leukoencephalopathy after rituximab 
therapy in HIVnegative patients: a report of 57 cases from the Research on Adverse 
Drug Events and Reports project. Blood 2009; 113: 4834-40. 
 
Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H. 
Therapeutic activity of humanized anti-CD20 monoclonal antibody and 
polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002; 99(3):754-758. 
 
Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to 
improve rituximab efficacy. Blood. 2004;104(9):2635-42.  
 
Cartron G, Trappe RU, Solal-Céligny P, Hallek M. Interindividual variability of 
response to rituximab: from biological origins to individualized therapies. Clin Cancer 
Res. 2011;17(1):19-30.   
 
Cazin B, Leprêtre S, Coiffier B, Aurran T, Cartron G, Feugier P, Brehar O, Sadoun A, 
Segaud F, Ribrag V. Multicentre Phase I Study with an 8-Dose Regimen of Single 
Agent Anti-CD20 Monoclonal Antibody LFB-R603 in Patients with Relapsed 
Chronic Lymphocytic Leukemia (CLL). Blood.2011; 118:2862; 
 
Cerboni C, Ardolino M, Santoni A, Zingoni A. Detuning CD8+ T lymphocytes by down-
regulation of the activating receptor NKG2D: role of NKG2D ligands released by 
activated T cells. Blood 2009; 113(13):2955-64. 
 
Cerwenka A, Lanier LL. Natural killer cells, viruses and cancer. Nat Rev Immunol 2001; 
1:41-49. 
 
Cerwenka A, Lanier LL. Natural killer cell memory in infection, inflammation and 
cancer. Nat Rev Immunol. 2016;16(2):112-123.  
 
Chan HT, Hughes D, French RR, Tutt AL, Walshe CA, Teeling JL, Glennie MJ, Cragg 
MS. CD20-induced lymphoma cell death is independent of both caspases and its 
redistribution into triton X-100 insoluble membrane rafts. Cancer 
Res 2003;63(17):5480-9. 
 
Chen R, Relouzat F, Roncagalli R, Aoukaty A, Tan R, Latour S, Veillette A. Molecular 
dissection of 2B4 signaling: implications for signal transduction by SLAM-related 
receptors. Mol Cell Biol 2004; 24(12):5144-56. 
 
Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin's 
lymphoma. N Engl J Med. 2008;359(6):613-626.   
 
	 91	
Chinen H, Matsuoka K, Sato T, Kamada N, Okamoto S, Hisamatsu T, Kobayashi T, 
Hasegawa H, Sugita A, Kinjo F, Fujita J, Hibi T. Lamina propria c-kit+ immune 
precursors reside in human adult intestine and differentiate into natural killer cells. 
Gastroenterology 2007; 133(2):559-73. 
 
Ciechanover A.	The ubiquitin-proteasome pathway: on protein death and cell life. 
EMBO J. 1998;17(24):7151-60. 
 
Clark R, Griffiths GM: Lytic granules, secretory lysosomes and disease. Curr Opin 
Immunol 2003;15:516-521. 
 
Claus M, Meinke S, Bhat R, Watzl C. Regulation of NK cell activity by 2B4, NTB-A 
and CRACC. Front Biosci. 2008; 13:956–965.  
 
Clynes R, Takechi Y, Moroi Y, Houghton A, Ravetch JV. Fc receptors are required in 
passive and active immunity to melanoma. Proc Natl Acad Sci U S A 1998; 95 (2):652-
6. 
 
Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den 
Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C. CHOP chemotherapy 
plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-
cell lymphoma. N Engl J Med. 2002;346(4):235-42. 
 
Coiffier B, Lepretre S, Pedersen LM, Gadeberg O, Fredriksen H, van Oers MH, 
Wooldridge J, Kloczko J, Holowiecki J, Hellmann A, Walewski J, Flensburg M, Petersen 
J, Robak T. Safety and efficacy of Ofatumumab, a fully human monoclonal anti- CD20 
antibody, in patients with relapsed or refractory B-cell chronic lymphocytic 
leukemia: a phase 1–2 study. Blood 2008 111:1094–100. 
 
Colombat P, Salles G, Brousse N, Eftekhari P, Soubeyran P, Delwail V, Deconinck 
E, Haïoun C, Foussard C, Sebban C, Stamatoullas A, Milpied N, Boué F,Taillan 
B, Lederlin P, Najman A, Thièblemont C, Montestruc F, Mathieu-Bouè A, Benzohra A, 
Solal-Cèligny P. Rituximab (anti-CD20 monoclonal antibody) as single first-line 
therapy for patients with follicular lymphoma with a low tumor burden: clinical and 
molecular evaluation. Blood 2001;97(1):101-6. 
 
Colucci F, Caligiuri MA, Di Santo JP: What does it take to make a natural killer? Nat 
Rev Immunol 2003;3:413-425. 
 
Cook EM, Lindorfer MA, van der Horst H, Oostindie S, Beurskens FJ, Schuurman J, Zent 
CS, Burack R, Parren PW, Taylor RP. Antibodies That Efficiently Form Hexamers 
upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under 
Complement-Limiting Conditions. J Immunol. 2016;197(5):1762-75.  
 
 
	 92	
Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell 
subsets. Trends Immunol 2001; 22:633–40. 
 
Cooper MA, Fehninger TA, Turner SC, Chen KS, Ghaderi BA, Ghayur T, Carson WE, 
Caligiuri MA. Human natural killer cells: a unique innate immunoregulatory role for 
the CD56 (bright) subset. Blood 2001; 97:3146-51. 
 
Cox MC, Battella S, La Scaleia R, Pelliccia S, Di Napoli A, Porzia A, Cecere F, Alma E, 
Zingoni A, Mainiero F, et al. Tumor-associated and immunochemotherapy-dependent 
long-term alterations of the peripheral blood NK cell compartment in DLBCL 
patients. Oncoimmunology. 2015;4(3):e990773.   
 
Cragg MS, Morgan SM, Chan HT, Morgan BP, Filatov AV, Johnson PW, French RR, 
Glennie MJ. Complement-mediated lysis by anti-CD20 mAb correlates with 
segregation into lipid rafts. Blood. 2003;101(3):1045-52. 
 
Cragg MS, Glennie MJ. Antibody specificity controls in vivo effector mechanisms of 
anti-CD20 reagents. Blood 2004; 103:2738-43 
 
Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and its potential 
as a target for mAb therapy. Curr Dir Autoimmun. 2005; 8:140–174. 
 
Cragg MS.	CD20 antibodies: doing the time warp.	Blood. 2011;118(2):219-20.  
 
Crouse J, Xu HC, Lang PA, Oxenius A. NK cells regulating T cell responses: 
mechanisms and outcome. Trends Immunol. 2015;36(1):49-58.  
	
Czuczman MS, Olejniczak S, Gowda A, Kotowski A, Binder A, Kaur H, Knight 
J, Starostik P, Deans J, Hernandez-Ilizaliturri FJ. 
Acquirement of rituximab resistance in lymphoma cell lines is associated with 
both global CD20 gene and protein down-regulation regulated at 
the pretranscriptional and posttranscriptional levels. Clin Cancer 
Res 2008;14(5):1561-70.  
 
Dall'Ozzo S, Tartas S, Paintaud G, Cartron G, Colombat P, Bardos P, Watier H, Thibault 
G. Rituximab-dependent cytotoxicity by natural killer cells: influence of 
FCGR3A polymorphism on the concentration-effect relationship. Cancer Res 2004; 
64(13):4664-9. 
 
Dalle S, Reslan L, Besseyre de Horts T, Herveau S, Herting F, Plesa A, Friess T, Umana 
P, Klein C, Dumontet C. Preclinical studies on the mechanism of action and the anti-
lymphoma activity of the novel anti-CD20 antibody GA101. Mol Cancer Ther. 
2011;10(1):178-85.  
 
	 93	
Davis DM. Assembly of the immunological synapse for T cells and NK cells. Trends 
Immunol 2002, 23(7):356-63  
 
Davis TA, Grillo-López AJ, White CA, McLaughlin P, Czuczman MS, Link BK, Maloney 
DG, Weaver RL, Rosenberg J, Levy R. Rituximab anti-CD20 monoclonal antibody 
therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin 
Oncol 2000;18(17):3135-43. 
 
de Haas M, Koene HR, Kleijer M, de Vries E, Simsek S, van Tol MJ, Roos D, von dem 
Borne AE. Fc receptor type IIIA polymorphism influences the binding of human IgG 
by NK cell FcRIIIA. J Immunol 1996; 156:2948-2955. 
 
De Maria A, Bozzano F, Cantoni C, Moretta L. Revisiting human natural killer cell 
subset function revealed cytolytic CD56 dim CD16+ NK cells as rapid producers of 
abundant IFN-gamma on activation. Proc Natl Acad Sci U S A 2011; 108:728-32. 
 
de Romeuf C, Dutertre CA, Le Garff-Tavernier M, Fournier N, Gaucher C, Glacet A, 
Jorieux S, Bihoreau N, Behrens CK, Béliard R, Vieillard V, Cazin B, Bourel D, Prost JF, 
Teillaud JL, Merle-Béral H. Chronic lymphocytic leukaemia cells are efficiently killed 
by an anti-CD20 monoclonal antibody selected for improved engagement of 
FcgammaRIIIA/CD16. Br J Haematol. 2008;140(6):635-43.  
 
Deans JP, Li H, Polyak MJ. CD20-mediated apoptosis: signalling through lipid rafts. 
Immunology. 2002;107(2):176-182. 
 
Di Santo JP. Functionally distinct NK-cell subsets: developmental origins and 
biological implications. Eur J Immunol 2008, 38(11):2948-51  
 
Dikic I, Wakatsuki S, Walters KJ. Ubiquitin-bindingdomains–from structures to 
functions. Nat Rev Mol Cell Biol. 2009; 10:659–71. 
 
DiLillo DJ, Ravetch JV. Differential Fc-Receptor Engagement Drives an Anti-tumor 
Vaccinal Effect. Cell. 2015;161(5):1035-1045.   
 
Dornan D, Spleiss O, Yeh RF, Duchateau-Nguyen G, Dufour A, Zhi J, Robak T, Moiseev 
SI, Dmoszynska A, Solal-Celigny P, Warzocha K, Loscertales J, Catalano J, Afanasiev 
BV, Larratt L, Rossiev VA, Bence-Bruckler I, Geisler CH, Montillo M, Wenger MK, 
Weisser M. Effect of FCGR2A and FCGR3A variants on CLL outcome. Blood. 
2010;116(20):4212-22.  
 
Dowd JB, Aiello AE, Alley DE. Socioeconomic disparities in the seroprevalence of 
cytomegalovirus infection in the US population: NHANES III. Epidemiol Infect. 
2009;137(1):58-65.  
 
	 94	
Eisenberg R, Albert D. B-cell targeted therapies in rheumatoid arthritis and systemic 
lupus erythematosus. Nat Clin Pract Rheumatol 2005; 2:1–8. 
 
Eissmann P, Beauchamp L, Wooters J, Tilton JC, Long EO, Watzl C. Molecular basis for 
positive and negative signaling by the natural killer cell receptor 2B4 (CD244). Blood. 
2005; 105:4722–4729. 
 
Ernst LK, Metes D, Herberman RB, Morel PA.	 Allelic polymorphisms in the 
FcgammaRIIC gene can influence its function on normal human natural killer cells.	
J Mol Med (Berl). 2002;80(4):248-57.  
 
Fabisiewicz A, Paszkiewicz-Kozik E, Osowiecki M, Walewski J, Siedlecki JA. FcγRIIA 
and FcγRIIIA polymorphisms do not influence survival and response to rituximab, 
cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy 
in patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2011;52(8):1604-6.  
 
Farag SS, Flinn IW, Modali R, Lehman TA, Young D, Byrd JC. Fc gamma RIIIa and Fc 
gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic 
lymphocytic leukemia. Blood 2004; 103 (4):1472-4. 
 
Fauriat C, Long EO, Ljunggren HG, Bryceson YT. Regulation of human NK-cell 
cytokine and chemokine production by target cell recognition. Blood 2010; 115: 2167-
76. 
 
Fehniger TA, Cooper MA. Harnessing NK Cell Memory for Cancer Immunotherapy. 
Trends Immunol. 2016;37(12):877-888.  
 
Ferlazzo G, Thomas D, Lin SL, Goodman K, Morandi B, Muller WA, Moretta A, Münz 
C. The abundant NK cells in human secondary lymphoid tissues require activation to 
express killer cell Ig-like receptors and become cytolytic. J Immunol 2004;172(3):1455-
62. 
 
Ferrara C, Stuart F, Sondermann P, Brünker P, Umaña P. The carbohydrate at 
FcgammaRIIIa Asn-162. An element required for high affinity binding to non-
fucosylated IgG glycoforms. J Biol Chem. 2006;281(8):5032-6. 
 
Ferrara C, Grau S, Jäger C, Sondermann P, Brünker P, Waldhauer I, Hennig M, Ruf A, 
Rufer AC, Stihle M, Umaña P, Benz J. Unique carbohydrate-carbohydrate interactions 
are required for high affinity binding between FcgammaRIII and antibodies lacking 
core fucose. Proc Natl Acad Sci U S A. 2011;108(31):12669-74.   
 
Filipe-Santos O, Bustamante J, Chapgier A, Vogt G, de Beaucoudrey L, Feinberg 
J, Jouanguy E, Boisson-Dupuis S, Fieschi C, Picard C, Casanova JL. Inborn errors of IL-
12/23 and IFN-gamma-mediated immunity: molecular, cellular, and clinical features. 
Semin Immunol 2006; 18:347-361. 
	 95	
Flodström-Tullberg M, Bryceson YT, Shi FD, Höglund P, Ljunggren HG. Natural killer 
cells in human autoimmunity. Curr Opin Immunol 2009; 21(6):634-40.  
 
Forero-Torres A, de Vos S, Pohlman BL, Pashkevich M, Cronier DM, Dang NH, Carpenter 
SP, Allan BW, Nelson JG, Slapak CA, Smith MR, Link BK, Wooldridge JE, Ganjoo KN. 
Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized 
monoclonal anti-CD20 antibody, in FcγRIIIa-genotyped patients with previously 
treated follicular lymphoma. Clin Cancer Res. 2012;18(5):1395-403.   
 
Freeman CL, Morschhauser F, Sehn L, Dixon M, Houghton R, Lamy T, Fingerle-Rowson 
G, Wassner-Fritsch E, Gribben JG, Hallek M, et al. Cytokine release in patients with 
CLL treated with obinutuzumab and possible relationship with infusion-related 
reactions. Blood. 2015;126(24):2646-2649. 
 
Freud AG, Becknell B, Roychowdhury S, Mao HC, Ferketich AK, Nuovo GJ, Hughes TL, 
Marburger TB, Sung J, Baiocchi RA, Guimond M, Caligiuri MA. A human CD34(+) 
subset resides in lymph nodes and differentiates into CD56bright natural killer cells. 
Immunity 2005; 22(3):295-304. 
 
Froelich CJ, Orth K, Turbov J, Seth P, Gottlieb R, Babior B, Shah GM, Bleackley RC, 
Dixit VM, Hanna W. New paradigm for lymphocyte granule-mediated cytotoxicity. 
Target cells bind and internalize granzyme B, but an endosomolytic agent is necessary 
for cytosolic delivery and subsequent apoptosis. J Biol Chem 1996; 271(46):29073-9. 
 
Gagez AL, Cartron G. Obinutuzumab: a new class of anti-CD20 monoclonal antibody. 
Curr Opin Oncol. 2014 Sep;26(5):484-91.   
 
Gagez AL1, Cartron G. New anti-CD20 monoclonal antibodies: which is the best? Leuk 
Lymphoma. 2015;56(1):1-2.   
 
Galandrini R, Palmieri G, Paolini R, Piccoli M, Frati L, Santoni A. Selective binding of 
shc-SH2 domain to tyrosine-phosphorylated zeta but not gamma-chain upon CD16 
ligation on human NK cells. J Immunol. 1997;159(8):3767-3773.  
 
Galandrini R, Palmieri G, Piccoli M, Frati L, Santoni A: Role for the Rac1 exchange 
factor Vav in the signaling pathways leading to NK cell cytotoxicity. J Immunol 
1999;162:3148-3152. 
 
Galandrini R, Capuano C, Santoni A.	Activation of Lymphocyte Cytolytic Machinery: 
Where are We? Front Immunol. 2013;4:390. 
 
Gao G, Liang X, Jiang J, Zhou X, Huang R, Chu Z, Zhan Q. A systematic review and 
meta-analysis of immunochemotherapy with rituximab for B-cell non-Hodgkin's 
lymphoma. Acta Oncol. 2010;49(1):3-12.   
	 96	
Garrity D, Call ME, Feng J, Wucherpfennig KW. The activating NKG2D receptor 
assembles in the membrane with two signaling dimers into a hexameric structure. 
Proc Natl Acad Sci U S A. 2005; 102:7641–7646.  
 
Gasser S, Raulet D. The DNA damage response, immunity and cancer. Semin Cancer 
Biol 2006; 16:344-7. 
 
Geldermann KA, Tomlinson S, Ross GD, Gorter A. Complement function in mAb-
mediated cancer immunotherapy. Trends Immunol 2004; 25:158-164. 
 
Ghesquières H, Cartron G, Seymour JF, Delfau-Larue MH, Offner F, Soubeyran P, Perrot 
A, Brice P, Bouabdallah R, Sonet A, Dupuis J, Casasnovas O, Catalano JV, Delmer A, 
Jardin F, Verney A, Dartigues P, Salles G. Clinical outcome of patients with follicular 
lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by 
FCGR3A and FCGR2A polymorphisms. Blood. 2012;120(13):2650-7. 
 
Gillis C, Gouel-Chéron A, Jönsson F, Bruhns P.	 Contribution of Human FcγRs to 
Disease with Evidence from Human Polymorphisms and Transgenic Animal Studies.	
Front Immunol. 2014;5:254.  
 
Gleimer M, von Boehmer H, Kreslavsky T. PLZF Controls the Expression of a Limited 
Number of Genes Essential for NKT Cell Function. Front Immunol. 2012;3:374.  
 
Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti-CD20 
monoclonal antibodies. Mol Immunol 2007; 44: 3823-37. 
 
Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, Chagorova T, de la 
Serna J, Dilhuydy MS, Illmer T, Opat S, Owen CJ, Samoylova O, Kreuzer KA, 
Stilgenbauer S, Döhner H, Langerak AW, Ritgen M, Kneba M, Asikanius E, Humphrey 
K, Wenger M, Hallek M. Obinutuzumab plus chlorambucil in patients with CLL and 
coexisting conditions. N Engl J Med. 2014;370(12):1101-10.   
 
Goede V, Klein C, Stilgenbauer S. Obinutuzumab (GA101) for the treatment of chronic 
lymphocytic leukemia and other B-cell non-hodgkin's lymphomas: a glycoengineered 
type II CD20 antibody. Oncol Res Treat. 2015;38(4):185-192.   
 
Goh LK, Huang F, Kim W, Gygi S, Sorkin A. Multiple mechanisms collectively regulate 
clathrin-mediated endocytosis of the epidermal growth factor receptor. J Cell Biol. 
2010; 189:871–83. 
 
Golay J, Zaffaroni L, Vaccari T, Lazari M, Borleri G, Bernasconi S, Tedesco F, Rambaldi 
A, IntronaM. Biologic response of B lymphoma cells to anti-CD20 monoclonal 
antibody rituximab in vitro: CD55 and CD59 regulate complement mediated cell 
lysis. Blood 2000; 95:3900–3908. 
 
	 97	
Golay J, Da Roit F, Bologna L, Ferrara C, Leusen JH, Rambaldi A, Klein C, Introna M. 
Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates 
phagocytosis through CD16B more efficiently than rituximab. Blood. 
2013;122(20):3482-91.  
 
Goldenberg DM, Rossi EA, Stein R, Cardillo TM, Czuczman MS, Hernandez-Ilizaliturri 
FJ, Hansen HJ, Chang CH. Properties and structure-function relationships of 
veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody. Blood. 
2009;113(5):1062-70.   
 
Graham DB, Cella M, Giurisato E, Fujikawa K, Miletic AV, Kloeppel T, Brim K, Takai 
T, Shaw AS, Colonna M, Swat W. Vav1 controls DAP10-mediated natural cytotoxicity 
by regulating actin and microtubule dynamics. J Immunol 2006; 177:2349-2355. 
 
Grier JT, Forbes LR, Monaco-Shawver L, Oshinsky J, Atkinson TP, Moody C, Pandey R, 
Campbell KS, Orange JS. Human immunodeficiency-causing mutation 
defines CD16 in spontaneous NK cell cytotoxicity. J Clin Invest 2012;122(10):3769-80.  
 
Griffiths GM, Tsun A, Stincombe JC: The immunological synapse: a focal point for 
endocytosis and exocytosis. J Cell Biol 2010; 189: 399-406. 
 
Hagenbeek A, Gadeberg O, Johnson P, Pedersen LM, Walewski J, Hellmann A, Link BK, 
Robak T, Wojtukiewicz M, Pfreundschuh M, Kneba M, Engert A, Sonneveld P, Flensburg 
M, Petersen J, Losic N, Radford J. First clinical use of ofatumumab, a novel fully human 
anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: 
results of a phase 1/2 trial. Blood 2008; 111:5486–95. 
 
Haglund K, Sigismund S, Polo S, Szymkiewicz I, Di Fiore PP, Dikic I. Multiple 
monoubiquitination of RTKs is sufficient for their endocytosis and degradation. Nat 
Cell Biol. 2003;5(5):461-6. 
 
Hainsworth JD, Burris HA 3rd, Morrissey LH, Litchy S, Scullin DC Jr, Bearden JD 
3rd, Richards P, Greco FA. Rituximab monoclonal antibody as initial systemic therapy 
for patients with low-grade non-Hodgkin lymphoma. Blood 2000;95(10):3052-6. 
 
Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, 
Hopfinger G, Hess G, von Grünhagen U, Bergmann M, Catalano J, Zinzani PL, Caligaris-
Cappio F, Seymour JF, Berrebi A, Jäger U, Cazin B, Trneny M, Westermann A, Wendtner 
CM, Eichhorst BF, Staib P, Bühler A, Winkler D, Zenz T, Böttcher S, Ritgen M, Mendila 
M, Kneba M, Döhner H, Stilgenbauer S; International Group of Investigators.; German 
Chronic Lymphocytic Leukaemia Study Group. Addition of rituximab to fludarabine 
and cyclophosphamide in patients with chronic lymphocytic leukaemia: a 
randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164-74.   
 
	 98	
Hamaguchi Y, Xiu Y, Komura K, Nimmerjahn F, Tedder TF. Antibody isotype-specific 
engagement of Fcγ receptors regulates B lymphocyte depletion during CD20 
immunotherapy. J Exp Med 2006; 203:743–753. 
	
Hatjiharissi E, Xu L, Santos DD, Hunter ZR, Ciccarelli BT, Verselis S, Modica M, Cao 
Y, Manning RJ, Leleu X, Dimmock EA, Kortsaris A, Mitsiades C, Anderson KC, Fox 
EA, Treon SP. Increased natural killer cell expression of CD16, augmented binding 
and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-
158 V/V and V/F polymorphism. Blood 2007;110(7):2561-4.  
 
Henne WM, Buchkovich NJ, Emr SD. The ESCRT pathway. Dev Cell. 2011; 21:77–91. 
 
Herberman RB, Nunn ME, Lavrin DH.	 Natural cytotoxic reactivity of mouse 
lymphoid cells against syngeneic acid allogeneic tumors. I. Distribution of reactivity 
and specificity.	Int J Cancer. 1975;16(2):216-29. 
 
Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem. 1998; 68:425–
479. 
 
Herter S, Herting F, Mundigl O, Waldhauer I, Weinzierl T, Fauti T, Muth G, Ziegler-
Landesberger D, Van Puijenbroek E, Lang S, Duong MN, Reslan L, Gerdes CA, Friess T, 
Baer U, Burtscher H, Weidner M, Dumontet C, Umana P, Niederfellner G, Bacac M, Klein 
C. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared 
with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Ther. 
2013;12(10):2031-42.  
 
Herter S, Birk MC, Klein C, Gerdes C, Umana P, Bacac M. Glycoengineering of 
therapeutic antibodies enhances monocyte/macrophage-mediated phagocytosis and 
cytotoxicity. J Immunol. 2014;192(5):2252-60.   
 
Herting F, Friess T, Bader S, Muth G, Hölzlwimmer G, Rieder N, Umana P, Klein C. 
Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody 
obinutuzumab (GA101) in combination with chemotherapy in xenograft models of 
human lymphoma. Leuk Lymphoma. 2014;55(9):2151-5160.   
 
Hibbs M, Tolvanen M, Carpen O. Membrane proximal Ig-like domain of Fc gamma 
RIIIA (CD16) contains residues critical for ligand binding. J Immunol 1994; 152(9): 
4466-4474. 
 
Hicke L & Dunn R. Regulation of membrane protein transport by ubiquitin and 
ubiquitin-binding proteins. Annu Rev Cell Dev Biol. 2003; 19:141–72. 
 
 
 
	 99	
Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, Reiser M, 
Metzner B, Harder H, Hegewisch-Becker S, Fischer T, Kropff M, Reis HE, Freund M, 
Wörmann B, Fuchs R, Planker M, Schimke J, Eimermacher H, Trümper L, Aldaoud A, 
Parwaresch R, Unterhalt M. Frontline therapy with rituximab added to the 
combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) 
significantly improves the outcome for patients with advanced-stage follicular 
lymphoma compared with therapy with CHOP alone: results of a prospective 
randomized study of the German Low-Grade Lymphoma Study Group. Blood. 
2005;106(12):3725-32. 
 
Hiraga J, Tomita A, Sugimoto T, Shimada K, Ito M, Nakamura S, Kiyoi H, Kinoshita T, 
Naoe T. Down-regulation of CD20 expression in B-cell lymphoma cells after treatment 
with rituximab-containing combination chemotherapies: its prevalence and clinical 
significance. Blood. 2009;113(20):4885-93.   
 
Hochstasser M. Ubiquitin-dependent protein degradation. Annu Rev Genet. 1996; 
4:405–439.  
 
Honeychurch J, Alduaij W, Azizyan M, Cheadle EJ, Pelicano H, Ivanov A, Huang P, Cragg 
MS, Illidge TM. Antibody-induced nonapoptotic cell death in human lymphoma and 
leukemia cells is mediated through a novel reactive oxygen species-dependent 
pathway. Blood. 2012;119(15):3523-33.  
 
Huang F, Zeng X, Kim W, Balasubramani M, Fortian A, Gygi SP, Yates NA, Sorkin A. 
Lysine 63-linked polyubiquitination is required for EGF receptor degradation. Proc 
Natl Acad Sci U S A. 2013;110(39):15722-7.  
 
Hudrisier D, Aucher A, Puaux AL, Bordier C, Joly E. Capture of target cell membrane 
components via trogocytosis is triggered by a selected set of surface molecole on T or 
B. J Immunol 2007; 178:3637-47. 
 
Hulett MD, Hogarth PM.	Molecular basis of Fc receptor function.	Adv Immunol. 1994;	
57:1-127.  
 
Hwang I, Zhang T, Scott JM, Kim AR, Lee T, Kakarla T, Kim A, Sunwoo JB, Kim S. 
Identification of human NK cells that are deficient for signaling adaptor FcRγ and 
specialized for antibody-dependent immune functions. Int Immunol. 2012;24(12):793-
802.  
 
Illidge T, Cheadle EJ, Donaghy C, Honeychurch J. Update on obinutuzumab in the 
treatment of B-cell malignancies. Expert Opin Biol Ther. 2014;14(10):1507-1517.  
 
Illidge T, Klein C, Sehn LH, Davies A, Salles G, Cartron G. Obinutuzumab in 
hematologic malignancies: lessons learned to date. Cancer Treat Rev. 2015;41(9):784-
92.  
	 100	
Ivanov A, Beers SA, Walshe CA, Honeychurch J, Alduaij W, Cox KL, Potter KN, Murray 
S, Chan CH, Klymenko T, Erenpreisa J, Glennie MJ, Illidge TM, Cragg MS. Monoclonal 
antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by 
lysosome-mediated cell death in human lymphoma and leukemia cells. J Clin Invest. 
2009;119(8):2143-59.   
 
Jaglowski SM, Alinari L, Lapalombella R, Muthusamy N, Byrd JC. The clinical 
application of monoclonal antibodies in chronic lymphocytic leukemia. Blood 2010; 
116(19):3705-14. 
 
Jak M, van Bochove GG, Reits EA, Kallemeijn WW, Tromp JM, Umana P, Klein C, van 
Lier RA, van Oers MH, Eldering E. CD40 stimulation sensitizes CLL cells to lysosomal 
cell death induction by type II anti-CD20 mAb GA101. Blood. 2011;118(19):5178-88.  
 
Jarahian M, Fiedler M, Cohnen A, Djandji D, Hämmerling GJ, Gati C, Cerwenka A, Turner 
PC, Moyer RW, Watzl C, Hengel H, Momburg F. Modulation of NKp30- and NKp46-
mediated natural killer cell responses by poxviral hemagglutinin. PLoS 
Pathog 2011;7(8):e1002195. 
 
Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat 
Rev Drug Discov. 2009;8(3):226-34.  
 
Jiang K, Zhong B, Gilvary DL, Corliss BC, Hong-Geller E, Wei S, Djeu JY. Pivotal role 
of phosphoinositide-3 kinase in regulation of cytotoxicity in natural killer cells. Nat 
Immunol 2000; 1(5):419-25 
 
Jiang K, Zhong B, Gilvary DL, Corliss BC, Vivier E, Hong-Geller E, Wei S, Djeu JY: Syk 
regulation of phosphoinositide 3-kinase-dependent NK cell function. J Immunol. 2002; 
168:3155-3164. 
 
Joazeiro CA, Wing SS, Huang H, Leverson JD, Hunter T, Liu YC.	The tyrosine kinase 
negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase.	
Science. 1999; 286(5438):309-12. 
 
Joyce MG, Tran P, Zhuravleva MA, Jaw J, Colonna M, Sun PD. Crystal structure of 
human natural cytotoxicity receptor NKp30 and identification of its ligand binding 
site. Proc Natl Acad Sci U S A. 2011;108(15):6223-8.   
 
Karre K. NK cells, MHC class I molecules and the missing self. Scand J Immunol 2002, 
55:221-228. 
 
Kasi PM, Tawbi HA, Oddis CV, Kulkarni HS.	Clinical review: Serious adverse events 
associated with the use of rituximab - a critical care perspective.	 Crit 
Care. 2012;16(4):231.  
	 101	
Kennedy AD, Solga MD, Schuman TA, Chi AW, Lindorfer MA, Sutherland WM, Foley 
PL, TaylorRP. An anti-C3b(i) mAb enhances complement activation, C3b(i) 
deposition, and killing of CD20+ cells by Rituximab. Blood 2003; 101:1071–1079. 
 
Kennedy AD, Beum PV, Solga MD, Di Lillo DJ, Lindorfer MA, Hess CE, Densmore 
JJ, Williams ME, Taylor RP. Rituximab infusion promotes rapid complement depletion 
and acute CD20 loss in chronic lymphocytic leukemia. J Immunol 2004;172(5): 3280-
8. 
 
Kern DJ, James BR, Blackwell S, Gassner C, Klein C, Weiner GJ. GA101 induces NK-
cell activation and antibody-dependent cellular cytotoxicity more effectively than 
rituximab when complement is present. Leuk Lymphoma. 2013;54(11):2500-5.  
 
Kiessling R, Klein E, Wigzell H.	 "Natural" killer cells in the mouse. I. 
Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and 
distribution according to genotype.	Eur J Immunol. 1975;5(2):112-7. 
	
Kim DH, Jung HD, Kim JG, Lee JJ, Yang DH, Park YH, Do YR, Shin HJ, Kim MK, Hyun 
MS, Sohn SK. FCGR3A gene polymorphisms may correlate with response to frontline 
R-CHOP therapy for diffuse large B-cell lymphoma. Blood. 2006 Oct 15;108(8):2720-
5.  
 
Kim HS, Das A, Gross CC, Bryceson YT, Long EO. Synergistic signals for natural 
cytotoxicity are required to overcome inhibition by c-Cbl ubiquitin ligase. Immunity 
2010; 32(2):175-86. 
 
Kim HS, Long EO. Complementary phosphorylation sites in the adaptor protein SLP-
76 promote synergistic activation of natural killer cells. Sci Signal 2012; 5(232):ra49.  
 
Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005; 
31:456-73. 
 
Klein C, Lammens A, Schäfer W, Georges G, Schwaiger M, Mössner E, Hopfner KP, 
Umaña P, Niederfellner G. Epitope interactions of monoclonal antibodies targeting 
CD20 and their relationship to functional properties. MAbs. 2013;5(1):22-33.   
 
Klein C, Bacac M, Umana P, Wenger M. Obinutuzumab (GAZYVA®), a novel 
glycoengineered type II CD20 antibody for the treatment of chronic lymphocytic 
leuke- mia and non-Hodgkin’s lymphoma; in Dübel S, Reichert JM (eds): Handbook 
of Therapeutic Antibodies. Wein- heim, Wiley-VCH Verlag GmbH & Co. KGaA, 2014.  
 
Koene HR, Kleijer M, Algra J, Roos D, von dem Borne AE, de Haas M. Fc gammaRIIIa- 
158V/F polymorphism influences the binding of IgG by natural killer cell Fc 
gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood 1997; 
90(3):1109-1114. 
	 102	
Kohrt HE, Houot R, Goldstein MJ, Weiskopf K, Alizadeh AA, Brody J, Müller 
A, Pachynski R, Czerwinski D, Coutre S, Chao MP, Chen L, Tedder TF, Levy R. 
CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. 
Blood 2011;117(8):2423-32.  
 
Kohrt HE, Thielens A, Marabelle A, Sagiv-Barfi I, Sola C, Chanuc F, Fuseri N, Bonnafous 
C, Czerwinski D, Rajapaksa A, Waller E, Ugolini S, Vivier E, Romagné F, Levy R, Bléry 
M, André P. Anti-KIR antibody enhancement of anti-lymphoma activity of natural 
killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood 
2014;123(5):678-86.  
 
Korbel DS, Norman PJ, Newman KC, Horowitz A, Gendzekhadze K, Parham P, Riley EM. 
Killer Ig-like receptor (KIR) genotype predicts the capacity of human KI 
ppositive CD56dim NK cells to respond to pathogen-associated signals. J 
Immunol 2009. 15;182(10):6426-34.  
 
Kovalenko, E.I., Streltsova, M.A., Kanevskiy, L.M., Erokhina, S.A., Telford, W.G. 
Identification of human memory-like NK cells. Curr. Protoc. Cytom. 2017; 79:9.50.1-
9.50.11. 
 
Kruse PH, Matta J, Ugolini S, Vivier E. Natural cytotoxicity receptors and their ligands. 
Immunol Cell Biol. 2014;92(3):221-229.   
 
Krzewski K, Chen X, Orange JS, Strominger JL: Formation of a WIP-, WASp-, actin-, 
and myosin IIA-containing multiprotein complex in activated NK cells and its 
alteration by KIR inhibitory signaling. J Cell Biol 2006;173:121-132. 
 
Krzewski K, Chen X, Strominger JL: WIP is essential for lytic granule polarization and 
NK cell cytotoxicity. Proc Natl Acad Sci U S A 2008;105:2568-2573. 
 
Krzewski K, Strominger JL. The killer’s kiss: the many functions of NK cell 
immunological synapses. Curr Opin Cell Biol 2008, 20(5):597-605.  
 
Kulathu Y, Komander D. Atypical ubiquitylation - the unexplored world of 
polyubiquitin beyond Lys48 and Lys63 linkages. Nat Rev Mol Cell 
Biol. 2012;13(8):508-23.  
 
Langlet C, Bernard AM, Drevot P, He HT: Membrane rafts and signaling by the 
multichain immune recognition receptors. Curr Opin Immunol 2000;12:250-255. 
 
Laney JD & Hochstrasser M. Substrate targeting in the ubiquitin system. Cell. 1999; 
97:427–30. 
 
	 103	
Lanier LL, Yu G, Phillips JH. Analysis of Fc gamma RIII (CD16) membrane expression 
and association with CD3 zeta and Fc epsilon RI-gamma by site-directed mutation. J 
Immunol 1991; 146(5):1571–1576. 
 
Lanier  LL. Natural killer cell receptor signaling. Curr Opin Immunol 2003; 15(3):308-
14. 
 
Lanier LL. NKG2D. J Biol Regul Homeost Agents. 2003;17(4):338-40.  
 
Lanier LL. NK cell recognition. Annu Rev Immunol. 2005; 23:225-74. 
 
Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nat Rev 
Immunol 2008; 9(5):495-502. 
 
Latour S, Roncagalli R, Chen R, Bakinowski M, Shi X, Schwartzberg PL, Davidson 
D, Veillette A. Binding of SAP SH2 domain to Fyn SH3 domain reveals a novel 
mechanisms of receptor signaling in immune regulation. Nat Cell Biol 2003. 5:149-54. 
 
Lau GK. Hepatitis B reactivation after chemotherapy: two decades of clinical 
research. Hepatol Int 2008; 2:152-62. 
 
Lauwers E, Jacob C, André B. K63-linked ubiquitin chains as a specific signal for 
protein sorting into the multivesicular body pathway. J Cell Biol. 2009;185(3):493-
502. 
 
Le Garff-Tavernier M, Herbi L, de Romeuf C, Nguyen-Khac F, Davi F, Grelier A, 
Boudjoghra M, Maloum K, Choquet S, Urbain R, Vieillard V, Merle-Béral H. Antibody-
dependent cellular cytotoxicity of the optimized anti-CD20 monoclonal antibody 
ublituximab on chronic lymphocytic leukemia cells with the 17p deletion. Leukemia. 
2014;28(1):230-3.  
 
Lee J, Zhang T, Hwang I, Kim A, Nitschke L, Kim M, Scott JM, Kamimura Y, Lanier LL, 
Kim S. Epigenetic modification and antibody-dependent expansion of memory-like 
NK cells in human cytomegalovirus-infected individuals. Immunity. 2015;42(3):431-
442.  
 
Lee SU, Maeda T. POK/ZBTB proteins: an emerging family of proteins that regulate 
lymphoid development and function. Immunol Rev. 2012;247(1):107-19.  
 
Lefebvre M-L, Krause SW, Salcedo M, Nardin A. Ex vivo-activated human 
macrophages kill chronic lymphocytic leukemia cells in the presence of Rituximab: 
mechanism of antibody-dependent cellular cytotoxicity and impact of human serum. 
J Immunother 2006; 29:388–397. 
 
	 104	
Leibson PJ: Signal transduction during natural killer cell activation: inside the mind 
of a killer. Immunity 1997; 6:655-661. 
 
Lenz G, Staudt LM. Aggressive lymphomas. N Engl J Med 2010; 362:1417-29. 
 
Leppers-van de Straat FG, van der Pol WL, Jansen MD, Sugita N, Yoshie H, Kobayashi 
T, van de Winkel JG. A novel PCR-based method for direct Fc gamma receptor IIIa 
(CD16) allotyping. J Immunol Methods. 2000;242(1-2):127-132.   
 
Letourneur O, Kennedy IC, Brini AT, Ortaldo JR, O'Shea JJ, Kinet JP. Characterization 
of the family of dimers associated with Fc receptors (Fc epsilon RI and Fc gamma 
RIII).  J Immunol. 1991;147(8):2652-6.  
 
Lettau M., Schmidt H., Kabelitz D., Janssen O. Secretory lysosomes and their cargo in 
T and NK cells. Immunol letters 2007; 108:10-19. 
 
Lieberman J: The ABCS of granule-mediated cytotoxicity: new weapons in the arsenal. 
Nat Rev Immunol 2003; 3:361-370. 
 
Lim SH, Beers SA, French RR, Johnson PW, Glennie MJ, Cragg MS. Anti-CD20 
monoclonal antibodies: historical and future perspectives. Haematologica 2010; 
95(1):135-143. 
 
Lim SH, Vaughan AT, Ashton-Key M, Williams EL, Dixon SV, Chan HT, Beers SA, 
French RR, Cox KL, Davies AJ, Potter KN, Mockridge CI, Oscier DG, Johnson PW, Cragg 
MS, Glennie MJ. Fc gamma receptor IIb on target B cells promotes rituximab 
internalization and reduces clinical efficacy. Blood. 2011;118(9):2530-40.   
 
Liu J. Control of protein synthesis and mRNA degradation by microRNAs. Curr Opin 
Cell Biol. 2008;20(2):214-21.  
 
Lodoen MB, Lanier LL. Natural killer cells as an initial defense against 
pathogens. Curr Opin Immunol 2006; 18(4):391-398. 
 
Long EO, Rajagopalan S. Stress signals activate natural killer cells. J Exp Med 2002; 
196:1399-1402. 
 
Long EO, Kim HS, Liu D, Peterson ME, Rajagopalan S. Controlling natural killer cell 
responses: integration of signals for activation and inhibition. Annu Rev Immunol 2013; 
31: 227-58. 
 
Lou Z, Billadeau DD, Savoy DN, Schoon RA, Leibson PJ. A role for a Rho/ROCK/LIM-
kinase pathway in the regulation of cytotoxic lymphocytes. J Immunol 2001; 167:5749-
5757. 
 
	 105	
Lowin B., Peitsch MC, Tschopp J.. Perforin and Granzymes: crucial effector molecules 
in cytolitic T lymphocyte and Natural Killer cell-mediated cytotoxicity. CTMI 1995; 
198:1-22. 
 
MacFarlane AW, Campbell KS: Signal transduction in natural killer cells. Curr Top 
Microbiol Immunol 2006; 298:23-57. 
 
Maher SG, Romero-Weaver AL, Scarzello AJ, Gamero AM. Interferon: cellular 
executioner or white knight? Curr Med Chem 2007; 14:1279-1289. 
 
Malavasi F, Deaglio S, Funaro A, Ferrero E, Horenstein AL, Ortolan E, Vaisitti T, Aydin 
S. Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology 
and pathology. Physiol Rev. 2008;88(3):841-86.  
 
Mallone R, Funaro A, Zubiaur M, Baj G, Ausiello CM, Tacchetti C, Sancho J, Grossi C, 
Malavasi F. Signaling through CD38 induces NK cell activation. Int Immunol. 
2001;13(4):397-409. 
 
Maloney DG. Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies 
and vaccines. J Clin Oncol. 2005;23(26):6421-8. 
 
Maloney DG. Anti-CD20 Antibody Therapy for B-Cell Lymphomas. N Engl J Med 
2012; 366:2008-16. 
 
Mandelboim O, Lieberman N, Lev M, Paul L, Arnon TI, Bushkin Y, Davis DM, 
Strominger JL, Yewdell JW, Porgador A. Recognition of haemagglutinins on virus-
infected cells by NKp46 activates lysis by human NK cells. Nature 2001; 
409(6823):1055-60. 
 
Marcus R, Imrie K, Solal-Celigny P, Catalano JV, Dmoszynska A, Raposo JC, Offner FC, 
Gomez-Codina J, Belch A, Cunningham D, Wassner-Fritsch E, Stein G. Phase III study 
of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in 
patients with previously untreated advanced follicular lymphoma. J Clin Oncol. 2008 
Oct 1;26(28):4579-86.  
 
Martín A, Conde E, Arnan M, Canales MA, Deben G, Sancho JM, Andreu R, Salar 
A, García-Sanchez P, Vázquez L, Nistal S, Requena MJ, Donato EM,González JA, León 
A, Ruiz C, Grande C, González-Barca E, Caballero MD; Grupo Español de 
Linfomas/Trasplante Autólogo de Médula Osea (GEL/TAMO Cooperative Group). R-
ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-
cell lymphoma: the influence of prior exposure to rituximab on outcome. A 
GEL/TAMO study. Haematologica  2008; 93(12):1829-36. 
 
	 106	
Martín-Fontecha A, Thomsen LL, Brett S, Gerard C, Lipp M, Lanzavecchia A, Sallusto F. 
Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 
priming. Nat Immunol. 2004;5(12):1260-1265.  
 
Mathew R, Seiler MP, Scanlon ST, Mao AP, Constantinides MG, Bertozzi-Villa C, Singer 
JD, Bendelac A. BTB-ZF factors recruit the E3 ligase cullin 3 to regulate lymphoid 
effector programs. Nature. 2012;491(7425):618-21.  
 
Mavilio D, Lombardo G, Benjamin J, Kim D, Follman D, Marcenaro E, O'Shea MA, Kinter 
A, Kovacs C, Moretta A, Fauci AS. Characterization of CD56-/CD16+ natural killer 
(NK) cells: a highly dysfunctional NK subset expanded in HIV-infected viremic 
individuals. Proc Natl Acad Sci U S A 2005;102(8):2886-91.  
 
McNerney ME, Lee KM, Kumar V.	2B4 (CD244) is a non-MHC binding receptor with 
multiple functions on natural killer cells and CD8+ T cells.	 Mol 
Immunol. 2005;42(4):489-94.  
 
Ménager MM, Menasche G, Romao M, Knapnougel P, Ho CH, Garfa M, Raposo G, 
Feldmann J, Fischer A, de Saint Basile G: Secretory cytotoxic granule maturation and 
exocytosis require the effector protein hMunc13-4. Nat Immunol 2007; 8:257-267. 
	
Metes D, Galatiuc C, Moldovan I, Morel PA, Chambers WH, DeLeo AB, Rabinowich 
H, Schall R, Whiteside TL, Sulica A, et al. Expression and function of Fcgamma RII on 
human natural killer cells. Nat Immun. 1994;13(6):289-300. 
 
Metes D, Ernst LK, Chambers WH, Sulica A, Herberman RB, Morel PA. Expression of 
functional CD32 molecules on human NK cells is determined by an allelic 
polymorphism of the FcgammaRIIC gene. Blood. 1998;91(7):2369-80. 
 
Metes D, Manciulea M, Pretrusca D, Rabinowich H, Ernst LK, Popescu I, Calugaru A, 
Sulica A, Chambers WH, Herberman RB, Morel PA.	Ligand binding specificities and 
signal transduction pathways of Fc gamma receptor IIc isoforms: the CD32 isoforms 
expressed by human NK cells.	Eur J Immunol. 1999;29(9):2842-52. 
 
Mishima Y, Terui Y, Takeuchi K, Matsumoto-Mishima Y, Matsusaka S, Utsubo-
Kuniyoshi R, Hatake K. The identification of irreversible rituximab-resistant 
lymphoma caused by CD20 gene mutations. Blood Cancer J. 2011;1(4):e15.   
 
Mitroviç Z, Aurer I, Radman I, Ajdukoviç R, Sertiç J, Labar B. FCgammaRIIIA and 
FCgammaRIIA polymorphisms are not associated with response to rituximab and 
CHOP in patients with diffuse large B-cell lymphoma. Haematologica. 
2007;92(7):998-9. 
 
	 107	
Mizushima T, Yagi H, Takemoto E, Shibata-Koyama M, Isoda Y, Iida S, Masuda K, Satoh 
M, Kato K. Structural basis for improved efficacy of therapeutic antibodies on 
defucosylation of their Fc glycans. Genes Cells. 2011;16(11):1071-80.   
 
Mocikat R, Braumüller H, Gumy A, Egeter O, Ziegler H, Reusch U, Bubeck A, Louis 
J, Mailhammer R, Riethmüller G, Koszinowski U, Röcken M. Natural Killer cells 
activated by MHC class I (low) targets prime dendritic cells to induce protective CD8 
T cell responses. Immunity 2003; 19: 561-569. 
 
Molfetta R, Quatrini L, Gasparrini F, Zitti B, Santoni A, Paolini R. Regulation of fc 
receptor endocytic trafficking by ubiquitination. Front Immunol. 2014; 5:449.  
 
Montalvao F, Garcia Z, Celli S, Breart B, Deguine J, Van Rooijen N, Bousso P. 
The mechanism of anti-CD20-mediated B 
cell depletion revealed by intravital imaging. J Clin Invest 2013; 123(12):5098-103.  
 
Morel PA, Ernst LK, Metes D.	Functional CD32 molecules on human NK cells.	Leuk 
Lymphoma.	1999;35(1-2):47-56.  
 
Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari MC, Biassoni R, Moretta L: 
Activating receptors and coreceptors involved in human natural killer cell-mediated 
cytolysis. Annu Rev Immunol 2001; 19:197-223. 
 
Moretta L, Ciccone E, Mingari MC, Biassoni R, Moretta A. Human natural killer cells: 
origin, specificity, and receptors. Adv Immunol 1994; 55:341-80. 
 
Mössner E, Brünker P, Moser S, Püntener U, Schmidt C, Herter S, Grau R, Gerdes C, 
Nopora A, van Puijenbroek E, Ferrara C, Sondermann P, Jäger C, Strein P, Fertig G, Friess 
T, Schüll C, Bauer S, Dal Porto J, Del Nagro C, Dabbagh K, Dyer MJ, Poppema S, Klein 
C, Umaña P. Increasing the efficacy of CD20 antibody therapy through the 
engineering of a new type II anti-CD20 antibody with enhanced direct and immune 
effector cell-mediated B-cell cytotoxicity. Blood. 2010;115(22):4393-402.   
 
Mukhopadhyay D & Riezman H. Proteasome-independent functions of ubiquitinin 
endocytosis and signaling. Science. 2007; 315:201–5. 
 
Natarajan K, Dimasi N, Wang J, Mariuzza RA, Margulies DH: Structure and function of 
natural killer cell receptors: multiple molecular solutions to self, nonself 
discrimination. Annu Rev Immunol 2002; 20:853-885. 
 
Newman KC, Riley EM. Whatever turns you on: accessory-cell-dependent activation 
of NK cells by pathogens. Nat Rev Immunol 2007; 7(4):279-91. 
 
 
	 108	
Niederfellner G, Lammens A, Mundigl O, Georges GJ, Schaefer W, Schwaiger M, Franke 
A, Wiechmann K, Jenewein S, Slootstra JW, Timmerman P, Brännström A, Lindstrom F, 
Mössner E, Umana P, Hopfner KP, Klein C. Epitope characterization and crystal 
structure of GA101 provide insights into the molecular basis for type I/II distinction 
of CD20 antibodies. Blood. 2011;118(2):358-67.   
 
Nimmerjahn F, Ravetch JV. Antibodies, Fc receptors and cancer. Curr Opin 
Immunol.2007; 19(2):239–245.  
 
O'Brien S, Osterborg A. Ofatumumab: a new CD20 monoclonal 
antibody therapy for B-cell chronic lymphocytic leukemia. Clin Lymphoma Myeloma 
Leuk 2010;10(5):361-8. 
 
Oikawa Y, Matsuda E, Nishii T, Ishida Y, Kawaichi M. Down-regulation of CIBZ, a 
novel substrate of caspase-3, induces apoptosis. J Biol Chem. 2008;283(21):14242-7.  
 
Orange JS. Formation and function of the lytic NK-cell immunological synapse. Nat 
Rev Immunol 2008; 8(9):713-725. 
 
Okazaki A, Shoji-Hosaka E, Nakamura K, Wakitani M, Uchida K, Kakita S, Tsumoto K, 
Kumagai I, Shitara K. Fucose depletion from human IgG1 oligosaccharide enhances 
binding enthalpy and association rate between IgG1 and FcgammaRIIIa. J Mol Biol. 
2004;336(5):1239-49. 
 
Paolini R, Serra A, Molfetta R, Piccoli M, Frati L, Santoni A. Tyrosine kinase-dependent 
ubiquitination of CD16zeta subunit in human NK cells following receptor 
engagement. Eur J Immunol. 1999; 29:3179–87.  
 
Paolini R, Molfetta R, Piccoli M, Frati L, Santoni A. Ubiquitination and degradation of 
Syk and ZAP-70 protein tyrosine kinases in human NK cells upon CD16 engagement. 
Proc Natl Acad Sci U S A. 2001;98(17):9611-9616. 
 
Persky DO, Dornan D, Goldman BH, Braziel RM, Fisher RI, Leblanc M, Maloney DG, 
Press OW, Miller TP, Rimsza LM. Fc gamma receptor 3a genotype predicts overall 
survival in follicular lymphoma patients treated on SWOG trials with combined 
monoclonal antibody plus chemotherapy but not chemotherapy alone. 
Haematologica. 2012;97(6):937-42.  
 
Perussia B, Trinchieri G. Antibody 3G8, specific for the human neutrophil Fc receptor, 
reacts with natural killer cells. J Immunol 1984; 132(3):1410–1415. 
 
Perussia B, Trinchieri G, Jackson A, Warner NL, Faust J, Rumpold H, Kraft D, Lanier LL. 
The Fc receptor for IgG on human natural killer cells: phenotypic, functional, and 
comparative studies with monoclonal antibodies. J Immunol 1984; 133(1):180–189. 
 
	 109	
Perussia B. Fc receptors on natural killer cells. Curr Top Microbiol Immunol 1998; 
230:63-88. 
 
Peters PJ, Borst J, Oorschot V, Fukuda M, Krahenbuhl O, Tschopp J, Slot JW, Geuze HJ: 
Cytotoxic T lymphocyte granules are secretory lysosomes, containing both perforin 
and granzymes. J Exp Med 1991; 173:1099-1109. 
 
Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill 
D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, 
Lehtinen T, López-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford 
M, Kuhnt E, Loeffler M; MabThera International Trial Group. CHOP-like chemotherapy 
plus rituximab versus CHOP-like chemotherapy alone in young patients with good-
prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the 
MabThera International Trial (MInT) Group. Lancet Oncol. 2006 May;7(5):379-91. 
 
Pfreundschuh M, Kuhnt E, Trümper L, Osterborg A, Trneny M, Shepherd L, Gill DS, 
Walewski J, Pettengell R, Jaeger U, Zinzani PL, Shpilberg O, Kvaloy S, de Nully Brown 
P, Stahel R, Milpied N, López-Guillermo A, Poeschel V, Grass S, Loeffler M, Murawski 
N; MabThera International Trial (MInT) Group. CHOP-like chemotherapy with or 
without rituximab in young patients with good-prognosis diffuse large-B-cell 
lymphoma: 6-year results of an open-label randomised study of the MabThera 
International Trial (MInT) Group. Lancet Oncol. 2011;12(11):1013-22.   
 
Pickart CM & FushmanD. Polyubiquitin chains: polymeric protein signals. Curr Opin 
Chem Biol. 2004; 8:610–6. 
 
Pincetic A, Bournazos S, DiLillo DJ, Maamary J, Wang TT, Dahan R, Fiebiger BM, 
Ravetch JV. Type I and type II Fc receptors regulate innate and adaptive immunity. 
Nat Immunol. 2014;15(8):707-716.   
 
Piper RC, Lehner PJ. Endosomal transport via ubiquitination. Trends Cell Biol. 2011; 
21:647–55. 
 
Pipkin ME, Lieberman J: Delivering the kiss of death: progress on understanding how 
perforin works. Curr Opin Immunol 2007; 19:301-308. 
 
Poli A, Michel T, Thérésine M, Andrès E, Hentges F, Zimmer J. CD56bright natural 
killer (NK) cells: an important NK cell subset. Immunology 2009, 126(4):458-65  
 
Polyak MJ, Tailor SH, Deans JP. Identification of a cytoplasmic region of CD20 
required for its redistribution to a detergent-insoluble membrane compartment. J 
Immunol. 1998;161(7):3242-8. 
 
 
	 110	
Prochazka V, Papajik T, Gazdova J, Divoka M, Rozmanova S, Faber E, Raida L, Kucerova 
L, Langova K, Jarosova M, Indrak K. FcγRIIIA receptor genotype does not influence 
an outcome in patients with follicular lymphoma treated with risk-adapted 
immunochemotherapy. Neoplasma. 2011;58(3):263-70. 
 
Puszyk W, Down T, Grimwade D, Chomienne C, Oakey RJ, Solomon E, Guidez F.	The 
epigenetic regulator PLZF represses L1 retrotransposition in germ and progenitor 
cells.	EMBO J. 2013;32(13):1941-52.  
 
Quartuccio L, Fabris M, Pontarini E, Salvin S, Zabotti A et al. The 158 VV Fcgamma 
receptor 3° genotype is associated with response to rituximab in rheumatoid arthritis: 
results of an Italian multicentre study. Ann Rheum Dis. 2014;73(4):716-721.  
 
Quatrini L, Molfetta R, Zitti B, Peruzzi G, Fionda C, Capuano C, Galandrini R, Cippitelli 
M, Santoni A, Paolini R. Ubiquitin-dependent endocytosis of NKG2D-DAP10 receptor 
complexes activates signaling and functions in human NK cells. Sci Signal. 
2015;8(400):ra108.   
 
Raiborg C, Stenmark H. The ESCRT machinery in endosomal sorting of ubiquitylated 
membrane proteins. Nature. 2009. 458:445–52. 
 
Rajasekaran K, Kumar P, Schuldt KM, Peterson EJ, Vanhaesebroeck B, Dixit V, Thakar 
MS, Malarkannan S. Signaling by Fyn-ADAP via the Carma1-Bcl-10-MAP3K7 
signalosome exclusively regulates inflammatory cytokine production in NK cells. Nat 
Immunol. 2013;14(11):1127-1136.    
 
Rascu A, Repp R, Westerdaal NA, Kalden JR, van de Winkel JG. Clinical relevance of 
Fc gamma receptor polymorphisms. Ann N Y Acad Sci. 1997; 815:282-295.  
 
Raulet DH. Roles of NKG2D immunoreceptor and its ligands. Nat Rev Immunol 2003; 
3:781-90. 
 
Raulet DH. Interplay of natural killer cells and their receptors with the adaptive 
immune response. Nat Immunol 2004, 5:996-1002  
 
Raulet DH, Vance RE. Self-tolerance of natural killer cells. Nat Rev Immunol 2006; 
6(7):520-31. 
 
Ravetch JV, Kinet JP. Fc receptors. Annu Rev Immunol. 1991; 9:457-92.  
 
Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna 
N, Anderson DR. Depletion of B cells in vivo by a chimeric mouse human monoclonal 
antibody to CD20. Blood 1994; 83:435–445. 
 
Reth M. Antigen receptor tail clue. Nature 1989; 338:383-384. 
	 111	
Riteau B, Barber DF, Long EO. Vav1 phosphorylation is induced by beta2 integrin 
engagement on natural killer cells upstream of actin cytoskeleton and lipid raft 
reorganization. J Exp Med 2003; 198(3):469-74.  
 
Robak T. GA-101, a third-generation, humanized and glyco-engineered anti-CD20 
mAb for the treatment of B-cell lymphoid malignancies. Curr Opin Investig Drugs 
2009; 10:588-96. 
 
Robertson MJ, Ritz J: Biology and clinical relevance of human natural killer cells. 
Blood 1990;76:2421-2438. 
 
Romee R, Foley B, Lenvik T, Wang Y, Zhang B, Ankarlo D, Luo X, Cooley S, Verneris 
M, Walcheck B, et al. NK cell CD16 surface expression and function is regulated by a 
disintegrin and metalloprotease-17 (ADAM17). Blood. 2013;121(18):3599-608.  
 
Roncagalli R, Taylor JE, Zhang S, Shi X, Chen R, Cruz-Munoz ME, Yin L, Latour S, 
Veillette A. Negative regulation of natural killer cell function by EAT-2, a SAP-related 
adaptor. Nat Immunol. 2005; 6:1002–1010. 
 
Rosen D, Li JH, Keidar S, Markon I, Orda R, Berke G. Tumor immunity in 
perforindeficient mice: a role for CD95 Fas/APO-1. J Immunol 2000, 164:3229–3235.  
 
Rosental B, Brusilovsky M, Hadad U, Oz D, Appel MY, Afergan F, Yossef R, Rosenberg 
LA, Aharoni A, Cerwenka A, Campbell KS, Braiman A, Porgador A. Proliferating cell 
nuclear antigen is a novel inhibitory ligand for the natural cytotoxicity receptor 
NKp44. J Immunol 2011; 187(11):5693-702. 
 
Sabahi R, Anolik JH. B-cell-targeted therapy for systemic lupus erythematosus. Drugs 
2006; 66:1933– 1948.  
 
Salmena L & Pandolfi PP. Changing venues for tumour suppression: balancing 
destruction and localization by monoubiquitylation. Nat Rev Cancer. 2007; 7:409–13. 
 
Schlums H, Cichocki F, Tesi B, Theorell J, Beziat V, Holmes TD, Han H, Chiang SC, 
Foley B, Mattsson K, et al. Cytomegalovirus infection drives adaptive epigenetic 
diversification of NK cells with altered signaling and effector function. Immunity. 
2015;42(3):443-456.  
 
Schulz H, Bohlius J, Skoetz N, Trelle S, Kober T, Reiser M, Dreyling M, Herold M, 
Schwarzer G, Hallek M, Engert A. Chemotherapy plus Rituximab versus 
chemotherapy alone for B-cell non-Hodgkin's lymphoma. Cochrane Database Syst 
Rev. 2007 Oct 17;(4):CD003805.  
 
Screpanti V, Wallin RP, Grandien A, Ljunggren HG: Impact of FASL-induced apoptosis 
in the elimination of tumor cells by NK cells. Mol Immunol 2005; 42:495-499. 
	 112	
Sehn LH, Chua N, Mayer J, Dueck G, Trněný M, Bouabdallah K, Fowler N, Delwail V, 
Press O, Salles G, Gribben J, Lennard A, Lugtenburg PJ, Dimier N, Wassner-Fritsch E, 
Fingerle-Rowson G, Cheson BD. Obinutuzumab plus bendamustine versus 
bendamustine monotherapy in patients with rituximab-refractory indolent non-
Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, 
phase 3 trial. Lancet Oncol. 2016;17(8):1081-93. 
 
Shibata-Koyama M, Iida S, Okazaki A, Mori K, Kitajima-Miyama K, Saitou S, Kakita S, 
Kanda Y, Shitara K, Kato K, Satoh M. The N-linked oligosaccharide at Fc gamma RIIIa 
Asn-45: an inhibitory element for high Fc gamma RIIIa binding affinity to IgG 
glycoforms lacking core fucosylation. Glycobiology. 2009;19(2):126-34.   
 
Shibuya A, Lanier LL, Phillips JH. Protein kinase C is involved in the regulation of both 
signaling and adhesion mediated by DNAX accessory molecule-1 receptor. J Immunol 
1998; 161:1671-76. 
 
Shibuya K, Lanier LL, Phillips JH, Ochs HD, Shimizu K, Nakayama E, Nakauchi 
H, Shibuya A. Physical and functional association of LFA-1 with DNAM-1 adhesion 
molecule. Immunity 1999; 11(5):615-23. 
 
Shields SB, Piper RC. How ubiquitin functions with ESCRTs. Traffic. 2011; 12:1306–
17. 
 
Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, Xie D, Lai J, Stadlen A, 
Li B, Fox JA, Presta LG. High resolution mapping of the binding site on human IgG1 
for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 
variants with improved binding to the Fc gamma R. J Biol Chem. 2001;276(9):6591-
604. 
 
Shields RL, Lai J, Keck R, O'Connell LY, Hong K, Meng YG, Weikert SH, Presta LG. 
Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human 
Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem. 
2002;277(30):26733-40. 
 
Shih SC, Sloper-Mould KE, Hicke L. Monoubiquitin carries a novel internalization 
signal that is appended to activated receptors. EMBO J. 2000;19(2):187-98. 
 
Sivori S, Pende D, Bottino C, Marcenaro E, Pessino A, Biassoni R, Moretta L, Moretta A.	
NKp46 is the major triggering receptor involved in the natural cytotoxicity of fresh 
or cultured human NK cells. Correlation between surface density of NKp46 and 
natural cytotoxicity against autologous, allogeneic or xenogeneic target cells. Eur J 
Immunol. 1999;29(5):1656-66. 
 
 
	 113	
Sivori S, Falco M, Marcenaro E, Parolini S, Biassoni R, Bottino C, Moretta L, Moretta A. 
Early expression of triggering receptors and regulatory role of 2B4 in human natural 
killer cell precursors undergoing in vitro differentiation. Proc Natl Acad Sci USA. 
2002; 99:4526–4531. 
 
Small GW, McLeod HL, Richards KL. Analysis of innate and acquired resistance to 
anti-CD20 antibodies in malignant and nonmalignant B cells. PeerJ. 2013;1:e31.  
 
Smith KG, Clatworthy MR.	 FcgammaRIIB in autoimmunity and infection: 
evolutionary and therapeutic implications.	Nat Rev Immunol. 2010;10(5):328-43.  
 
Stinchcombe JC, Griffiths GM. Secretory mechanisms in cell-mediated cytotoxicity. 
Annu Rev Cell Dev Biol 2007, 23:495-517 
 
Tamm A, Schmidt R. The binding epitopes of human CD16 (Fc gamma RIII) 
monoclonal antibodies. Implications for ligand binding. J Immunol 1996; 157 (4): 
1576-1581.  
 
Tassi I, Klesney-Tait J, Colonna M. Dissecting natural killer cell activation pathways 
through analysis of genetic mutations in human and mouse. Immunol Rev 2006; 
214:92-105.  
 
Taylor RP, Lindorfer MA. On the mechanism of action of rituximab in autoimmune 
disease: the immune complex decoy hypothesis. Nat Clin Pract Rheumatol 2007; 3:86–
95. 
 
Taylor RP, Lindorfer MA. Immunotherapeutic mechanisms of anti-CD20 monoclonal 
antibodies. Curr Opin Immunol 2008; 20:444–449. 
 
Taylor RP, Lindorfer MA. Antigenic modulation and rituximab resistance. Semin 
Hematol 2010; 47(2):124-132. 
 
Taylor RP, Lindorfer MA. Analyses of CD20 Monoclonal Antibody-Mediated Tumor 
Cell Killing Mechanisms: Rational Design of Dosing Strategies. Mol Pharmacol. 2014; 
86(5):485-91. 
 
Tedder TF, Streuli M, Schlossmann SF, Saito H. Isolation and structure of a cDNA 
encoding the B1 (CD20)cell-surface antigen oh human B lymphocytes. Proc Natl Acad 
Sci U S A 1988; 85:208-12. 
 
Teeling JL, French RR, Cragg MS, van den Brakel J, Pluyter M, Huang H, Chan C, Parren 
PW,  Hack CE, Dechant M, Valerius T, van de Winkel JG, Glennie MJ. Characterization 
of new human CD20 monoclonal antibodies with potent cytolytic activity against non-
Hodgkin lymphomas. Blood 2004; 104(6):1793-800.  
 
	 114	
Teeling JL, Mackus WJ, Wiegman LJ, van den Brakel JH, Beers SA, French RR, van 
Meerten T, Ebeling S, Vink T, Slootstra JW, Parren PW, Glennie MJ, van de Winkel JG. 
The biological activity of human CD20 monoclonal antibodies is linked to unique 
epitopes on CD20. J Immunol 2006; 177:362–71.  
 
Terszowski G, Klein C, Stern M. KIR/HLA interactions negatively affect rituximab- 
but not GA101 (obinutuzumab)-induced antibody-dependent cellular cytotoxicity. J 
Immunol. 2014;192(12):5618-24.   
 
Thomas DA, Du C, Xu M, Wang X, Ley TJ: DFF45/ICAD can be directly processed by 
granzyme B during the induction of apoptosis. Immunity 2000; 12:621-632. 
 
Thrower JS, Hoffman L, Rechteiner M, Pickart CM. Recognition of the polyubiquitin 
proteolytic signal. EMBO J. 2000; 19 (1):94–102.  
 
Ting AT, Karnitz LM, Schoon RA, Abraham RT, Leibson PJ: Fc gamma receptor 
activation induces the tyrosine phosphorylation of both phospholipase C (PLC)-
gamma 1 and PLCgamma 2 in natural killer cells. J Exp Med 1992; 176:1751-1755. 
 
Tobinai K, Ogura M, Kobayashi Y, Uchida T, Watanabe T, Oyama T, Maruyama D, 
Suzuki T, Mori M, Kasai M, Cronier D, Wooldridge JE, Koshiji M. Phase I study of 
LY2469298, an Fc-engineered humanized anti-CD20 antibody, in patients with 
relapsed or refractory follicular lymphoma. Cancer Sci. 2011;102(2):432-8.   
 
Traub LM, Lukacs GL. Decoding ubiquitin sorting signals for clathrin-dependent 
endocytosis by CLASPs. J Cell Sci. 2007; 120:543–53.  
	
Treon SP, Mitsiades C, Mitsiades N, Young G, Doss D, Schlossman R, Anderson KC. 
Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in 
patients with B-cell malignancies. J Immunother. 2001; 24(3):263-71. 
 
Trinchieri G. Biology of natural killer cells. Adv Immunol 1989; 47:187-376. 
 
Trinchieri G, Valiante N: Receptors for the Fc fragment of IgG on natural killer cells. 
Nat Immun 1993; 12:218-234. 
 
Trinchieri G. The choices of a natural killer. Nat Immunol 2003; 4:509-510. 
 
Uchida J, Hamaguchi Y, Oliver JA, Ravetch JV, Poe JC, Haas KM, Tedder TF. The innate 
mononuclear phagocyte network depletes B lymphocytes through Fc receptor-
dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 2004; 
199:1659–1669. 
 
 
 
	 115	
Umana P, Moessner E, Bruenker P, Unsin G, Puentener U, Suter T, Grau R, Schmidt C, 
Gerdes C, Nopora A, Patre M, Moser S, Sondermann P, Wheat L, Dyer M J.S., Poppema 
S, Bauer S, Strein P, Friess T, Klein C. Novel 3rd Generation Humanized Type II CD20 
Antibody with Glycoengineered Fc and Modified Elbow Hinge for Enhanced ADCC 
and Superior Apoptosis Induction. Blood.2006;108(11):72a-a.  
 
Upshaw JL, Arneson LN, Schoon RA, Dick CJ, Billadeau DD, Leibson PJ. NKG2D-
mediated signaling requires DAP10-bound Grb2-Vav1 intermediate and 
phosphatidylinositol 3-kinase in human natural killer cells. Nat Immunol 2006; 7:524-
532. 
 
van de Winkel JG, Capel PJ.	Human IgG Fc receptor heterogeneity: molecular aspects 
and clinical implications.	Immunol Today. 1993;14(5):215-21.  
 
van Meerten T, van Rijn RS, Hol S, Hagenbeek A, Ebeling SB. Complement-induced cell 
death by rituximab depends on CD20 expression level and acts complementary to 
antibody-dependent cellular cytotoxicity. Clin Cancer Res. 2006; 12:4027–35. 
 
van Meerten T, Hagenbeek A. CD20-Targeted Therapy: The Next Generation of 
Antibodies. Semin Hematol 2010; 47:199–210.   
 
Vance BA, Huizinga TW, Wardwell K, Guyre PM. Binding of monomeric human IgG 
defines an expression polymorphism of FcRIII on large granular lymphocyte/natural 
killer cells. J Immunol 1993; 151:6429-6439. 
 
Váróczy L, Zilahi E, Gyetvai A, Kajtár B, Gergely L, Sipka S, Illés A. Fc-gamma-
receptor IIIa polymorphism and gene expression profile do not predict the prognosis 
in diffuse large B-cell lymphoma treated with R-CHOP protocol. Pathol Oncol Res. 
2012;18(1):43-8.  
 
Veeramani S, Wang SY, Dahle C, Blackwell S, Jacobus L, Knutson T, Button A, Link 
BK, Weiner GJ. Rituximab infusion induces NK activation in lymphoma patients with 
the high-affinity CD16 polymorphism. Blood 2011; 118(12):3347-9. 
 
Veillette A. NK cell regulation by SLAM family receptors and SAP-related adapters. 
Immunol Rev. 2006; 214:22–34.  
 
Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. 
Nat Immunol 2008; 9(5):503-10.  
 
Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, Yokoyama WM, 
Ugolini S. Innate or Adaptive Immunity? The Example of Natural Killer Cells.   
Science 2011, 331(6013): 44-9.  
 
	 116	
von Bubnoff D, Andrès E, Hentges F, Bieber T, Michel T, Zimmer J. Natural killer cells 
in atopic and autoimmune diseases of the skin. J Allergy Clin Immunol. 2010; 
125(1):60-8.  
 
Vyas YM, Maniar H, Dupont B. Cutting edge: differential segregation of the SRC 
homology 2-containing protein tyrosine phosphatase-1 within the early NK cell 
immune synapse distinguishes noncytolytic from cytolytic interactions. J 
Immunol. 2002; 168(7):3150-4. 
 
Vyas YM, Maniar H, Dupont B. Visualization of signaling pathways and cortical 
cytoskeleton in cytolytic and noncytolytic natural killer cell immune synapses. 
Immunol Rev 2002; 189:161-178. 
 
Walport MJ. Complement. N Engl J Med 2001; 344: 1058–1066. 
 
Walzer T, Dalod M, Robbins SH, Zitvogel L, Vivier E. Natural-killer cells and dendritic 
cells: "l'union fait la force". Blood. 2005;106(7):2252-8.   
 
Wang SY, Racila E, Taylor RP, Weiner GJ. NK-cell activation and antibody-dependent 
cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b 
component of complement. Blood 2008; 111(3):1456-1463. 
 
Wang SY, Veeramani S, Racila E, Cagley J, Fritzinger DC, Vogel CW, St John W, Weiner 
GJ. Depletion of the C3 component of complement enhances the ability of rituximab-
coated target cells to activate human NK cells and improves the efficacy of 
monoclonal antibody therapy in an in vivo model. Blood 2009 10.1182. 
 
Waterhouse NJ, Sedelies KA, Browne KA, Wowk ME, Newbold A, Sutton VR, Clarke 
CJ, Oliaro J, Lindemann RK, Bird PI, Johnstone RW, Trapani JA: A central role for Bid 
in granzyme B-induced apoptosis. J Biol Chem 2005; 280:4476-4482. 
 
Watzl C & Long EO. Signal transduction during activation and inhibition of natural 
killer cells. Curr Protoc Immunol. 2010;Chapter 11:Unit 11.9B.  
 
Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer 
immunotherapy. Nat Rev Immunol 2010; 10 (5): 317-327. 
 
Weiner GJ. Rituximab: mechanism of action. Semin Hematol. 2010;47(2):115-23.  
 
Weissman A M. Regulating protein degradation by ubiquitination. Immunol 
Today. 1997; 18:189–198.   
 
Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms 
independently predict response to rituximab in patients with follicular lymphoma. J 
Clin Oncol 2003; 21 (21):3940-7. 
	 117	
Whiteside TL, Heberman RB. Role of human Natural Killer cells in Health and Disease. 
Clin Diagn. Lab Immunol 1994; 1:125-133. 
 
Wierda WG, Padmanabhan S, Chan GW, Gupta IV, Lisby S, Osterborg A; Hx-CD20-406 
Study Investigators. Ofatumumab is active in patients with fludarabine-refractory 
CLL irrespective of prior rituximab: results from the phase 2 international study. 
Blood 2011; 118(19):5126-5129.  
 
Woelk T, Sigismund S, Penengo L, Polo S.	 The ubiquitination code: a signalling 
problem.	Cell Div. 2007;2:11. 
 
Wu L, Adams M, Carter T, Chen R, Muller G, Stirling D, Schafer P, Bartlett JB. 
lenalidomide enhances natural killer cell and monocyte-mediated antibody-
dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer 
Res 2008; 14(14):4650-7.  
 
Wu J, Edberg JC, Redecha PB, Bansal V, Guyre PM, Coleman K, Salmon JE, Kimberly 
RP. A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and 
predisposes to autoimmune disease. J Clin Invest 1997; 100:1059–70. 
 
Zamai L, Ahmad M, Bennett IM, Azzoni L, Alnemri ES, Perussia B: Natural killer (NK) 
cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and 
mature primary human NK cells. J Exp Med 1998; 188:2375-2380. 
 
Zelenetz AD. A clinical and scientific overview of tositumomab and iodine I-131 
tositumomab. Semin Oncol 2003; 30: Suppl 4:22-30. 
 
Zent CS, Taylor RP, Lindorfer MA, Beum PV, LaPlant B, Wu W, Call TG, Bowen DA, 
Conte MJ, Frederick LA, Link BK, Blackwell SE, Veeramani S, Baig NA, Viswanatha DS, 
Weiner GJ, Witzig TE. Chemoimmunotherapy for relapsed/refractory and progressive 
17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, 
alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of 
CD20 expression by circulating CLL cells. Am J Hematol 2014; 89(7):757-65.  
 
Zhang T, Scott JM, Hwang I, Kim S. Cutting edge: antibody-dependent memory-like 
NK cells distinguished by FcRγ deficiency. J Immunol. 2013;190(4):1402-1406.  
 
Zhang W, Wang X, Li J, Duan MH, Zhou DB. Fcgamma receptor IIIA polymorphisms 
and efficacy of rituximab therapy on Chinese diffuse large B-cell lymphoma. Chin 
Med J (Engl). 2010;123(2):198-202. 
 
Zhou J, Amran FS, Kramski M, Angelovich TA, Elliott J, Hearps AC, Price P, Jaworowski 
A. An NK Cell Population Lacking FcRγ Is Expanded in Chronically Infected HIV 
Patients. J Immunol. 2015;194(10):4688-97. 
	 118	
Acknowledgments  
 
I would like to thank my supervisor Prof. Ricciarda Galandrini for giving me the 
opportunity to perform this research project. Her precious scientific and intellectual 
support, teachings, great trust and availability allowed me to improve my scientific 
background and my work.  
Thanks to Dr. Cristina Capuano for guiding me in these years and for her precious support 
and advices. She made my stay in the lab very pleasant, for which I will be forever grateful.  
Thanks to Prof. Gabriella Palmieri and Dr. Simone Battella for their cultural suggestions 
and technological support.  
Thanks to my chief of lab and PhD program coordinator Prof. Angela Santoni for her 
cultural support and for this enriching educational experience. 
 
 
 
 
 
 
 
 
 
 
